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The ovarian reserve represents the absolute number of primordial follicles with the 
potential to release a fertilizable oocyte. A reduction of follicles occurs naturally with aging until 
the reserve is depleted and induces menopause. However, there is a growing population of post 
pubertal women who experience aberrant reproductive function prior to the onset of menopause, 
classified as premature ovarian failure (POF). A subset of POF cases directly result from surgical 
or chemical procedures used to ameliorate cancer or other ovarian-associated pathologies. The 
current gold standard used to treat iatrogenic POF is the transplantation of cryopreserved ovarian 
tissues, which has led to greater than 130 reported live-births to-date. This strategy has shown 
clinical success, but there remain risks of malignant cell transmission and complications due to 
surgery. We hypothesized that an ovarian-specific hydrogel could provide a minimally-invasive 
platform to facilitate the intraovarian delivery, engraftment and survival of isolated immature 
ovarian follicles.   
The first aim of this study was to prepare a hydrogel from ovarian tissues that retained 
ovarian specificity. Porcine ovaries were decellularized using a series of enzymes and detergents 
to remove immunogenic components from the tissues. Decellularization significantly reduced 
dsDNA, while preserving ovarian tissue morphology, extracellular matrix (ECM) proteins and 
proteoglycans. Additionally, ovarian-specific hormones, such as anti-Müllerian hormone, estradiol 
and progesterone, were detected within decellularized ovaries. Ovarian ECM (OECM) hydrogels 
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formed via physical crosslinking when exposed to physiological conditions.  Hydrogel viscoelastic 
and ultrastructural properties were sensitive to changes in ECM concentration, while gelation time 
remained constant. Successful in vitro follicle maturation using OECM hydrogels demonstrated 
follicle compatibility.   
The second aim of this study was to examine the efficacy of an OECM hydrogel as a 
vehicle to support intraovarian follicle delivery and graft survival within chemotherapy-induced 
POF (ciPOF) mice. Immature ovarian follicles from young DBA-GFP/nu female mice were 
enzymatically isolated and microinjected into the ovaries of ciPOF nude mice within the OECM 
hydrogel. Mating studies resulted in multiple litters containing pups derived from transplanted 
donor follicles. Transplanted ovarian tissues contained developing donor follicles suggesting 
hydrogel-facilitated intraovarian microinjection could offer a low-risk, minimally-invasive 
alternative for fertility preservation.  
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The focus of this dissertation is to develop novel methods with the potential to restore 
fertility for female patients diagnosed with iatrogenic premature ovarian failure (POF). To 
accomplish this goal, it is important to understand normal female reproductive biology and how 
invasive mechanical or cytotoxic chemical treatments can impair the ovarian microenvironment. 
Therefore, the following section will provide an overview of female reproductive biology, causes 
and consequences of POF and current strategies for fertility preservation.   
1.1 Female Reproductive Biology 
 Female reproductive biology is the study of the cells and tissues that make up the female 
reproductive system. The major organs of this system include the ovaries, fallopian tubes, uterus, 
and vagina, which work in concert to support fertility (1). The ovaries provide a permissible 
environment for the development of the female gametes, or oocytes (2). During embryonic 
development, primordial germ cells (PGCs) aggregate within the cortex of the ovary and acquire 
a single layer of granulosa cells forming primordial follicles (3, 4). This population of primordial 
follicles represents the ovarian reserve, which is an indicator of potential conception for women 
of reproductive age (5-8). Upon puberty, the hypothalamus and pituitary increase gonadotropin 
levels (9, 10). In response to gonadotropin production, a small number of primordial follicles are 
recruited and activated into a growing pool (11). This activation is accompanied by granulosa and 
theca cell proliferation, which amplifies the secretion of sex steroids that stimulate the growth and 
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maturation of the recruited follicles (12). Ovarian steroid production actively contributes to an 
essential feedback loop known as the hypothalamus-pituitary-gonadal (HPG) axis (10, 13-15). The 
HPG axis establishes the female sexual cycle, which repeats each month to support the release of 
a single mature oocyte and prepares the uterus for embryo implantation and pregnancy (13). 
The following sub-sections of Section 1.1 provide more details on selected subject matter 
within female reproductive biology that are relevant to the present study. The primary focus will 
be on the following topics: (1) the development and composition of the ovary, (2) ovarian cell 
types and function, (3) reproductive differences between mammals and (4) normal ovarian aging.   
1.1.1 Ovarian Development 
During early embryonic development, undifferentiated sexual organs begin their assembly 
within the gonadal ridge, which develops from proliferating gonadal ridge epithelial-like (GREL) 
cells from the coelomic epithelium of the mesonephros (Figure 1) (16, 17). Around five weeks 
post-coitum, bipotential gonads begin to form out of the expanding gonadal ridge. Meanwhile, 
primordial germ cells (PGCs), which are the precursor cells to gametes (oocyte and sperm), 
migrate from the embryonic yolk sac along the gut to the gonadal ridge. During migration, PGCs 
proliferate substantially, which increases their population from about 100 in the yolk sac to 1,700 
upon arrival at the gonadal ridge (18). A breakdown of the basal lamina lying beneath the coelomic 
epithelium during gonadal ridge formation facilitates the invasion of mesenchymal and stromal 
cells of the mesonephros into the developing gonads (16).  
Once the PGCs enter the gonadal ridge, they undergo sexual differentiation upon which 
they exclusively develop into either oogonia or spermatogonia. Sex determination is predicated 
upon the composition of the chromosomes present within the growing embryo (19). Humans are 
 3 
made up of diploid cells, which contain two sets of chromosomes (23 pairs). Of the 23 pairs, one 
pair is composed of the genes that determine the sex of the embryo. Male and female gametes are 
haploid germ cells, which contain one set of chromosomes. Male sperm carry the 22 autosomal 
chromosomes and either an x or y sex chromosome. Similarly, female oocytes contain the 22 
autosomal chromosomes, but only provide an x sex chromosome. Upon fertilization, genetic 
recombination of the haploid germ cells yields a diploid embryo with 44 autosomal chromosomes 
and two sex-determining chromosomes: XY (male) or XX (female) (20). The sex of developing 
human embryos is indicated by the presence of the sexual determining region of the Y (SRY) gene 
(21). Without the SRY gene, the ovary forms in response to the upregulated expression of the 
female gonad-specific WNT4/β-catenin signaling, which inhibits the male gonad-specific 
SOX9/FGF pathway (Figure 2) (22). 
At the conclusion of female sex determination, around 9 weeks post-coitum, PGCs begin 
to differentiate into oogonia, which are distinguished by their increased rate of mitosis (23). This 
increase  in cell division directly contributes to the formation of oogonial nests (23). 
Simultaneously, the gonadal ridge undergoes significant expansion, as the migration of 
mesonephric cells, including stroma and blood vessels, begin to occupy and surround the rapidly 
dividing germ cell nests, forming the ovigerous cords. The appearance of the sex cords signals the 
beginning of a compartmentalization of the ovary, as the stromal cells are preferentially separated 
from the GREL cells and oogonia by a basal lamina (16, 24, 25). The ovary is subsequently divided 
into two main regions, which are composed of an outer cortex and an inner medulla. The cortex 
primarily contains proliferating oogonia while the medulla is comprised of connective tissue, large 
blood and lymphatic vessels (26). Around 11 weeks, oogonia, residing along the interface of the 
cortex and medulla, enter meiosis I (27). As this process continues, oogonia and oocytes within 
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the germ cell nests undergo apoptosis, which dramatically reduces the total number of germ cells 
available for maturation (5). The oocytes that remain acquire a peripheral layer of pre-granulosa 
cells surrounded by a basal lamina forming the primordial follicles (16). The total number of 














Figure 1 Ovarian Development 
 (A) The development of the ovary commences at the mesonephric surface epithelium (yellow cells) in the location 
of the future gonadal ridge. (B) Some mesonephric surface epithelial cells change phenotype into GREL cells 
(yellow-blue cells). (C) The GREL cells proliferate and the basal lamina underlying the mesonephric surface 
epithelium breaks down allowing stromal cells (green) to penetrate into the gonadal ridge. (D) GREL cells continue 
to proliferate and PGCs (grey) migrate into the ridge between the GREL cells. Mesonephric stroma including 
vasculature (red) continues to penetrate and expand in the ovary. (E) Oogonia proliferate and stroma penetrates 
further towards the ovarian surface enclosing oogonia and GREL cells into ovigerous cords. (F) 
Compartmentalization of oogonia occurs surrounded by the basal lamina, which is also forms below GREL cells at 
the surface. The cortex is characterised by alternating areas of ovigerous cords and stroma, whereas the medulla is 
formed by stromal cells, vasculature and tubules originating from the mesonephros (rete ovarii). (G) Ovigerous 
cords are partitioned into smaller cords and eventually into follicles. These contain GREL cells that form granulosa 
cells (blue cells) and oogonia that form oocytes. The first primordial follicles appear in the inner cortex-medulla 
region, surrounded by a basal lamina. A now fully intact basal lamina underlies multiple layers of surface epithelial 
cells. (H) At the final stage the surface epithelium becomes mostly single-layered and a tunica albuginea, densely 
packed with fibres, develops from the stroma below the surface epithelial basal lamina.  
[Figure and text reproduced from (16). Open-access - Creative Commons Attribution License.] 
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Figure 2 Sexual Differention and Gonadal Development 
Diagram illustrating differentiation of indifferent gonads into testes or ovaries: (A) Bipotential gonads from a six-
week-old em- bryo; (B) At seven weeks, showing testes developing under the influence of SRY;  (C) At 12 weeks, 
showing ovaries developing in the absence  of SRY; (D) Testis at 20 weeks, showing the rete testis and seminiferous 
tubules derived from medullary cords; (E) Ovary at 20 weeks, showing primordial follicles; (F) Section of a 
seminiferous tubule from a 20-week fetus; and (G) Section from the ovarian cortex of a 20-week fetus, showing two 
primordial follicles.  
[Figure and text reproduced from (18). License obtained from Elsevier- No. 4797171375381] 
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1.1.1.1 Oogenesis 
To produce genetically distinct progeny, gametes must only contain half of the 
chromosomes prior to their fusion at fertilization, with half of the genes coming from the male and 
half from the female. Oogenesis begins during the early stages of embryonic development with 
the differentiation of PGCs to oogonia after female sex determination (28, 29). Oogonia undergo 
rapid mitotic proliferation and form germ cell nests or clusters from 2-7 months in utero (23). 
Oogonia give rise to individual primordial follicles that contain a primary oocyte arrested in 
prophase I of meiosis (30). 
Meiosis is the process that forms haploid daughter cells or sex cells within the female and 
male gametes (Figure 3) (31). Like mitosis, meiosis undergoes DNA replication and cell division; 
however, a major difference is that mitosis converts one diploid cell (2N) to two exact replicate 
diploid cells, which contain the same genetic signature (32). Conversely, meiosis converts a single 
diploid germ cell into four unique haploid (N) gametes (33). One mature ovum in females and one 
sperm in males, that fuse during fertilization, give rise to a single genetically distinct diploid cell 
or embryo, which contains half of the genes from the mother and the other half from the father. 
Meiosis begins identically to mitosis through the entrance into the first stage of the cell 
cycle or G1, where the cells start to prepare for replication and division (34). During G1, the cells 
begin to produce more organelles and proteins to support the functions of an additional cell. After 
G1, the cells enter the S1 or synthesis phase, where the DNA will undergo replication to double 
the genetic material (34). After DNA replication in S1, the cell enters the G2 phase. In G2, the cell 
prepares for division by producing more cytoplasm to grow the total volume of the cell (34). These 
first three stages together are called interphase. Interphase repeats for all germ cells prior to meiotic 
division. After interphase, germ cells undergo two cycles of meiotic division, referred to as meiosis 
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I and meiosis II (31). During each cycle of meiosis, the cells undergo prophase, metaphase, 
anaphase and telophase. In meiosis I, prophase I starts by breaking down the nuclear envelope and 
condensing the chromatin into chromosomes that are identified by the presence of a centromere. 
Maternal and paternal chromosomes approach one another and form homologous pairs, which 
undergo phenomenon known as crossing over. Crossing over is a process in which a small segment 
of the maternal and paternal alleles, that code for the same genomic region, swap places and attach 
to the opposing chromosome (28). This event is one of many that helps to diversify the genes 
present within the resulting embryo. After forming homologous pairs and randomly crossing over, 
the cells move into metaphase I. In metaphase I, the chromosomes are centered at the midline of 
the cell (32). This is facilitated by microtubules that extend from the centrosomes that have 
relocated to the opposite or polar ends of the cell. Microtubules adhere to the kinetochores on the 
opposing ends of the centromere of each chromosome (31). During anaphase I, microtubules begin 
to separate the homologous pairs toward the opposite poles. Once the chromosomes have arrived 
at their respective poles, the cell enters telophase I, where the cell undergoes cytokinesis and each 
of the separated chromosomes are surrounded by their own nuclear envelope (35). Normally, 
cytokinesis divides the cells equally, but this is not the case for oocytes. The first meiotic division 
of oocytes yields one larger oocyte and a smaller polar body (36). Meiosis II resumes with 
prophase II, where the chromatin condenses into chromosomes and the nuclear envelope degrades 
the two haploid cells that resulted from the first meiotic division (31). Metaphase II aligns the 
chromosomes at the middle of the cells and anaphase II begins to separate the sister chromatids, 
pulling them towards their respective poles. Finally, in telophase II the two haploid cells from the 




Figure 3 Process of Meiosis 
Meiosis is a unique form of nuclear division that results in haploid gametes. In preparation for the first meiotic 
division, homologous chromosomes come together in synapsis, forming a tetrad of two replicated chromosomes, 
each with two sister chromatids. As the tetrads line up on the metaphase plate, those from maternal and paternal 
origin orient (assort) randomly. Crossing-over may occur, in which a piece of a chromatid is physically exchanged 
with a homol- ogous chromatid, forming new allele combinations. In the meiosis I division, homologs separate, and 
thus each secondary oocyte is haploid, though each chromosome has two sister chromatids. The meiosis II division 
separates sister chromatids. Crossing-over and random assortment create new combinations of maternal and paternal 
genes, resulting in gametes that are genetically unique.  
[Figure and text reproduced from (1). License obtained from Elsevier - No. 4842610641195] 
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In oogenesis, meiosis begins during embryonic development with the formation of oocytes 
from oogonia in the gonadal ridge (37, 38). Primordial follicles, containing primary oocytes that 
are arrested in prophase I of the first meiotic division, remain in this developmental phase until 
puberty (39). Upon activation of primordial follicles, oocytes enlarge to accommodate the 
maturation of the cytoplasm, but they remain meiotically static until the formation of an antrum 
appears within the follicle (36). During this pre-antral stage, oocytes undergo dramatic changes 
which facilitate successful downstream meiotic division and fertilization. For example, the oocyte 
cytoplasm acquires maternal effect genes, such as zygotic arrest-1 (Zar1) and NOD-like receptor 
family pyrin domain containing 5 (Nlrp5), which aid in embryonic development (40, 41). 
Additionally, the stage-dependent positioning and function of organelles can impact the 
effectiveness of oocyte maturation. Specifically, mitochondria supply the oocyte with adenosine 
triphosphate (ATP) and preferentially relocate around the poles the become more accessible during 
meiosis (42-44). Similarly, the endoplasmic reticulum acts as a catalyst upon fertilization by 
releasing calcium that inhibits polyspermy and concludes oocyte maturation (45, 46). Regulation 
of oocyte growth is dependent upon the relationship between the oocyte and the surrounding 
granulosa cells of the follicle compartment. Growth differentiation factor 9 (GDF9) and bone 
morphogenic factor 15 (BMP15) are produced by the oocyte to induce granulosa cell proliferation 
and modulate oocyte hypertrophy during meiotic quiescence (47, 48).  
Oocytes resume meiosis in response to rising levels of luteinizing hormone (LH), which is 
augmented by an upregulation of LH receptors presented by granulosa cells(49). This interaction 
sets off a signaling cascade that effectively removes intraoocyte cyclic adenosine monophosphate 
(cAMP). The presence of cAMP inhibits oocytes from continuing meiotic cell division and 
regulates follicle growth (36). The pre-ovulatory LH surge causes cumulus cells to detach from 
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the oocyte and reduces the translocation of cAMP to the oocyte (50). In addition, residual oocyte 
cAMP is enzymatically degraded by phosphodiesterase (PDE), which is induced by mitogen-
activated protein kinase (MAPK) expression from cumulus cells(51, 52). The loss of cAMP 
reduces protein kinase A (PKA), which phosphorylates and inhibits the phosphatase, cell division 
cycle 25 (CDC25) (53). Once CDC25 is activated, it dephosphorylates and activates cyclin-
dependent kinase 1 (CDK1), which together with cyclin B (CYB) forms a protein complex known 
as maturation promoting factor (MPF) that directly facilitates the resumption of meiosis (54-56). 
This event transforms the oocytes from a germinal vesicle (GV) stage, identified by an intact 
nuclear membrane to germinal vesicle breakdown (GVBD) stage, classified by an absence of the 
nuclear membrane. Upon ovulation, meiosis is once again interrupted and arrests at metaphase II 
(MII) by the degradation of CYB and inactivation of CDK1 (57, 58). At this step of maturation, 
the MII, or secondary oocyte, has completed the first meiotic division and extrudes a polar body, 
which will degenerate. Oogenesis concludes after the sperm fertilizes the MII oocyte, resuming 
meiosis II, as the haploid cells form a genetically distinct embryo.  
1.1.1.2 Folliculogenesis 
Oogenesis is made possible through the maturation of the ovarian follicles, which 
synergistically secrete hormones that regulate primary oocyte growth and trigger secondary oocyte 
ovulation. Folliculogenesis, like oogenesis, undergoes a series of developmental stages, which 
occurs cyclically for each follicle throughout the female reproductive lifespan (59).  Primordial 
follicles are the initial stage of development that make up the ovarian reserve, or the finite number 
of oocytes with the potential for maturation and fertilization (5, 7, 8). At this stage, the follicles 
are tightly clustered within the ovarian cortex and are composed of a central primary oocyte 
surrounded by a single layer of squamous granulosa cells (3). 
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In humans, there are approximately one million primordial follicles that make up the 
ovarian reserve at birth; however, most of these follicles will undergo atresia, which reduces the 
absolute follicle number by 70% at puberty (7, 60). This drastic reduction has been attributed to a 
stringent selection process that prematurely removes imperfect follicles, containing genetic errors, 
poor cytoplasmic composition or low granulosa cell numbers (61, 62). Further, DNA damage 
incurred by primordial follicles can be recognized by the transactivation domain of tumor protein 
p63 (TAp63), which can trigger premeditated cell death through the p53 upregulated modulator of 
apoptosis (PUMA) (63-65). The remaining primordial follicles that make up the reserve are 
recruited to the growing pool by environmental stimuli. For example, granulosa cell production of 
growth factors, such as KIT ligand, can be induced through mechanistic target of rapamycin 
complex 1 (mTORC1) signaling, directly initiating the phosphatidylinositol 3-kinase (PI3K) 
pathway upon KIT ligand binding of KIT at the oocyte membrane (66, 67). Alternatively, follicle 
activation can be inhibited by anti-Mullerian hormone (AMH) and activin produced by small pre-
antral follicles (68, 69). 
Recruited primordial follicles undergo distinct morphological changes as their surrounding 
granulosa cells begin their transition from a flattened to cuboidal appearance (12). The formation 
of a full layer of cuboidal granulosa cells surrounding the oocyte represents primary follicles (70). 
Additionally, the oocytes of primary follicles begin to display a zona pellucida, which is a rich 
extracellular matrix glycoprotein that facilitate fertilization (70). The proliferation of granulosa 
cells continues toward the development of secondary follicles, represented by multiple layers of 
granulosa cells as well as the presence of a theca cell layer. Within pre-antral follicles, the central 
oocyte is meiotically static; however, it does increase in size to accommodate the maturation of 
the cytoplasm (70). The transition from pre-antral to antral follicles is distinguished by the 
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presence of antral fluid surrounding the oocyte. The antral follicles are the final stage development 
prior to ovulation, when the meiotically competent, MII oocyte is released for fertilization. Upon 
ovulation, the granulosa cells will differentiate into luteal cells to form a structure known as the 
corpus luteum (71). The corpus luteum secretes progesterone to maintain pregnancy after 
successful embryo implantation into the uterine wall.            
1.1.2 Ovarian Anatomy and Physiology 
The ovary is the female reproductive organ that is responsible for both the maintenance 
and maturation of oocytes (1). At puberty, the ovary has fully matured and contains active, 
hormone-producing follicles. Granulosa and theca cells surround oocytes to compose the ovarian 
follicles, which are the functional subunit of the ovary. The somatic cells are intimately connected 
with the oocyte and operate as part of a dynamic feedback loop to regulate follicle growth and 
maturation (72). The predominant cell type within the ovary are stromal cells, which actively 
remodel the ovarian microenvironment to support the proliferation and migration of follicles 
throughout reproductive development (73). Transient corpora lutea form a glandular structure from 
differentiated granulosa cells to facilitate the production of progesterone to sustain pregnancy after 
ovulation (74). Endocrine function is promoted by an extensive vasculature network that provides 
the ovary with direct access to essential nutrients from the blood (75). It is essential that each of 





Figure 4 Cross-Section of The Human Ovary 
The ovary is a female reproductive organ composed of an outer cortex and inner medulla. The cortex contains 
primordial follicles, which undergo cyclic activation to support the ovulation of a mature oocyte, wheras the medulla 
is primarilly made up of large blood vessels and lymphatics. Growing follicles and corpora lutea produce hormones 
to regulate endocrine function and maintain pregnancy.  
[Figure reproduced from (1). License obtained from Elsevier - No. 4842610641195] 
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1.1.2.1 Tissue Organization and Cell Types 
The ovary is made up of two main regions: the peripheral cortex and the central medulla 
(Figure 4) (76). The mechanically rigid cortex is primarily comprised of immature primordial and 
small growing follicles, whereas the more compliant medulla is home to the bulk of mesenchymal 
tissue with large blood and lymphatic vessels (75, 77). A diverse extracellular matrix (ECM) is 
interspersed throughout the stroma, interstitial tissues and follicle compartments. The ECM 
undergoes rapid changes during folliculogenesis to provide a permissible environment for follicle 
maturation. The parenchyma is composed of somatic cells, granulosa and theca cells, which 
surround the oocyte, and form the functional unit of the ovary, known as the ovarian follicle (76). 
The cells and tissues of the ovary are highly responsive and regulated by the hypothalamus-
pituitary signals (13). Active production of hormones and growth factors by ovarian cells ensure 
tight control over changes within the ovarian microenvironment and sustain endocrine function.     
1.1.2.1.1 Ovarian Extracellular Matrix 
The ovarian ECM plays a critical role in the maintenance of ovarian follicles. Ovarian 
ECM is synthesized during the early stages of embryonic gonadal development (78). The first 
expression of ECM deposition is observed within the genital ridge during the formation of a 
basement membrane, which surrounds the germ cells nests. The basement membrane is primarily 
composed of laminin, collagens, fibronectin and proteoglycans (78). Primitive ovarian ECM 
undergoes significant remodeling by matrix metalloproteinases (MMPs), which actively degrade 
ECM components (78, 79). MMPs are also active throughout folliculogenesis to accommodate the 
exponential growth of follicles and release of MII oocytes upon maturation (79). 
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 Throughout the initial stages of ovarian development, ECM production is primarily 
mediated by three cell types: somatic cells, stromal cells and germ cells (78). Each of these cells 
express a distinct transcriptional profile of ECM-specific genes that are present during sexual 
differentiation of mouse gonads (78). However, stromal cells are the most active participant in 
ECM synthesis, as they account for about 94% of the total ECM genes detected within the 
immature XX gonads (78). The genes expressed by the stroma are well represented across each 
major type of ECM, including, collagens, glycoproteins, proteoglycans and matricellular proteins 
(78). Somatic cells and germ cells only contribute to the expression of 11 and 7 ECM-associated 
genes respectively, which primarily code for non-collagen ECM components (78). 
The ovarian ECM plays a critical role in folliculogenesis, acting as a structural framework 
for the cells and sequestering essential hormones and growth factors that facilitate cell signaling 
and proliferation(80, 81). Ovarian-specific ECM components primarily consist of collagen I, 
collagen IV, laminin and fibronectin and are well conserved across species(82-86). Localization 
of these specific ECM components varies throughout the ovary and changes depending on the 
stage of follicle development. 
1.1.2.1.2 Ovarian Follicles 
The ovarian follicles are the functional subunit of the ovary that produces hormones to 
regulate oocyte maturation (70). Follicle assembly begins with primordial germ cell migration 
infiltrating the gonadal ridge and differentiating into oogonia (87). Oogonia cell cysts breakdown 
to form oocytes that arrested in prophase I of meiosis (88). GREL cells differentiate into pre-
granulosa cells that encapsulate the oocyte to form primordial follicles (16). This population of 
primordial follicles make up the ovarian reserve, which is an indicator of potential fertility (7, 8). 
 17 
Primordial follicles are activated into the growing pool and acquire numerous layers of granulosa 
cells that play an essential role in oocyte maintenance (12, 89). Secondary follicles continue 
granulosa cell proliferation and recruit theca cells to facilitate the production of sex steroids, 
estradiol and progesterone (59, 90). A single dominant follicle, characterized by a pocket of 
accumulated antral fluid surrounding a meiotically competent oocyte arrested in metaphase II, will 
be selected for ovulation (91). Upon ovulation, granulosa cells will differentiate to form a corpus 
luteum, which is a transient endocrine gland that produces high levels of progesterone to sustain 
pregnancy (71).  
1.1.2.1.3 Granulosa Cells 
Granulosa cells are the most abundant cell type within growing ovarian follicles. These 
cells derive from the GREL cells that are sequestered inside of the ovigerous cords adjacent to the 
proliferating oogonia (92). Squamous pre-granulosa cells form a loose layer around immature 
oocytes forming primordial follicles (93). Once the primordial follicles are activated from the 
resting stage, granulosa cells rapidly proliferate to support the oocyte. Multiple layers of granulosa 
cells accumulate as they transition from secondary to antral follicles.  Granulosa cells directly 
surrounding the oocyte of antral follicles differentiate into cumulus cells, which expand prior to 
ovulation (70). 
1.1.2.1.4 Theca Cells 
Theca cells form the outermost layer of ovarian follicles and produce androgens, which are 
subsequently converted into estrogens by the granulosa cells(70). These somatic cells are derived 
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from two distinct populations of theca progenitor cells (94). The predominant theca progenitor 
population is derived from the fetal ovary and expresses Wilms’ tumor 1 (Wt1), which is required 
for gonad development (95, 96). The other theca progenitor cells originate in the mesonephros and 
differentiate into glioma-associated oncogene homolog 1 (Gli1) positive cells regulated by growth 
differentiation factor 9 (GDF9) and hedgehog (Hh) signaling, coordinated through the oocyte and 
granulosa cells (94).       
1.1.2.1.5 Luteal Cells 
Luteal cells are the primary cell type of the corpus luteum, which is formed from follicles 
that have released a mature oocyte (74). Prior to ovulation, granulosa cells begin to differentiate 
into luteal cells through the acquisition of LH receptors (1). Unlike granulosa or theca cells, luteal 
cells have all the enzymes needed to directly convert cholesterol into progesterone and estradiol. 
During the luteal phase of the menstrual cycle, luteal cells are transiently expressed to produce 
progesterone and estradiol to aid in the preparation of the uterus for pregnancy and will degenerate 
in the absence of a fertilized oocyte (1). However, if fertilization and pregnancy occur, the 
menstrual cycle is delayed, and the luteal cells continue to produce high levels of progesterone to 
sustain pregnancy. 
1.1.2.1.6 Stromal Cells 
Stromal cells are one of the most prevalent cell types within ovarian tissue. They are 
primarily responsible for maintaining tissue homeostasis through the production and remodeling 
of the extracellular matrix(78). These cells are also capable of producing essential growth factors 
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such as bone morphogenic proteins (BMPs) to support follicle development. Specifically, the 
release of BMP-4 and BMP-7 has been shown to play a role in the transition from primordial to 
primary follicles(97, 98). Stromal cells may also differentiate into theca cells, transitioning from a 
mesenchymal to parenchymal cell type through the acquisition of Gli1 or Wt1. 
1.1.2.1.7 Endothelial Cells 
Endothelial cells present within the ovary are critical for providing functional blood vessels 
to the ovarian follicles and corpus luteum (75, 99). Ovarian mediated endocrine function is also 
highly dependent upon the secretion of steroids into the blood vessels. The ovarian vasculature is 
primarily found within the stroma; however, as follicles mature, endothelial cells embed 
themselves within the theca compartment surrounding the granulosa cells (75). Endothelial cells 
are most prevalent within the developing corpus luteum. Specifically, the peripheral vasculature 
of the ovarian follicles is transformed into the highly vascularized gland, primarily composed of 
steroid-producing luteal cells (1).     
1.1.2.1.8 Ovarian Surface Epithelial Cells 
Ovarian surface epithelial (OSE) cells are derived from the GREL progenitors, which also 
give rise to granulosa cells, during embryonic development (16). OSE cells make up the outermost 
layer of the ovary and play a critical role in facilitating ovulatory rupture and repair (Figure 5) 
(100). More recently, characterization of OSE cells generated data suggesting that they may retain 
inherent plasticity or stemness, which may play a role in ovarian tissue homeostasis as well as 
ovarian cancer (101). As ovulatory follicles approach the ovarian surface, proteolytic enzymes 
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degrade OSE cells as well as the basal lamina and follicular wall components allowing the follicle 
to rupture, releasing an oocyte (102). After the oocyte has been released, OSE cells proliferate and 
migrate toward the ruptured surface and facilitate the remodeling of the ovary (103, 104).     
 
 
Figure 5 Ovarian Surface Epithelium and Ovulation 
Cyclic ovarian surface epithelium (OSE) rupture and repair can be broadly divided into three phases: (a) an 
ovulatory phase; (b) a rupture phase; and (c) a repair phase.  
[Figure and text reproduced from (101). License obtained from Springer Nature – No. 4842620174150] 
1.1.2.2 The Menstrual Cycle 
The menstrual cycle is a highly regulated process by which the female reproductive tissues 
prepare to establish pregnancy (Figure 6) (14). This process reoccurs monthly in reproductive aged 
women until their ovarian reserve is exhausted and initiates menopause. The first stage of the cycle 
is the menstrual phase, which can last from one to seven days. During the menstrual phase, low 
estradiol and progesterone levels, reduced from a degenerating corpus luteum, trigger the ischemic 
death of endometrial lining, which begins to shed (105). The uterine lining is evacuated along with 
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blood and mucus. This tissue slowly redevelops as the menstrual cycle progresses and fully 
matures in time for potential embryo implantation. 
The second stage of the menstrual cycle, known as the follicular phase, coincides with the 
start of the menstrual phase and occurs from one to fourteen days (106). The follicular phase is 
responsive to gonadotropin secretion from the pituitary gland, specifically follicle stimulating 
hormone (FSH) and luteinizing hormone (LH). These hormones are regulated by the 
hypothalamus, which directly produces gonadotropin-releasing hormone (GnRH) (15).  The rising 
FSH levels initiate the cyclic recruitment of a cohort of small antral follicles that are selected to 
grow (93). The granulosa cells of the follicles produce increased levels of estradiol, which 
influences the production of de novo endometrial tissue in preparation of embryo implantation 
(105). Within a few days after estradiol levels peak, a rapid increase of LH stimulates the 
resumption of meiosis and triggers the ovulation of a metaphase II oocyte (93). 
The final stage of the menstrual cycle is referred to as the luteal phase, which occurs from 
days fourteen to twenty-eight, and is characterized by the formation of a corpus luteal gland and 
the maturation of the endometrial tissue lining the uterus (9). Within the ovary, granulosa cells 
from the ovulated follicle differentiate into luteal cells, forming a corpus luteum that secretes 
estradiol and progesterone (105). These ovarian hormones work together to inhibit the production 
of gonadotropins. If fertilization of the oocyte occurs, the corpus luteum will continue hormone 
production; however, if the egg is not fertilized, the corpus luteum will degenerate and trigger the 
recurrence of the menstrual cycle (105).  
 22 
 
Figure 6 The Menstrual Cycle and Hormone Regulation 
Average blood levels of hormones during a 28-day menstrual cycle, along with changes in the ovaries and uterine endometrium. Note that an 
estradiol peak precedes the LH surge. The ratio of estradiol to progesterone is high during the follicular phase and lower during the luteal phase. 
The ovaries also secrete small amounts of another estrogen (estrone), androgens, and 17-hydroxyprogesterone (not shown). Levels of 
progesterone are in nanograms (one thousandth of a milligram) and of estradiol in picograms (one thousandth of a nanogram). Levels of FSH and 
LH are in milli-international units (one thousandth of an international unit). An international unit is an amount of a hormone that produces a given 
biological response in a target tissue. Although average FSH and LH blood amounts are shown, the levels of these hormones and GnRH exhibit 
hourly pulses.  
[Figure and text reproduced from (105). License obstained from Elsevier – No. 4842611244985] 
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1.1.2.3 Role of Hormones and Growth Factors 
A critical function of the ovary is the production and regulation of reproductive hormones. 
The ovary is part of an intricate feedback loop known as the hypothalamus-pituitary-gonadal 
(HPG) axis (13). The hypothalamus releases gonadotropin releasing hormone (GnRH), which then 
stimulates the gonadotropes of the anterior pituitary gland to produce gonadotropins, follicle 
stimulating hormone (FSH) and luteinizing hormone (LH). These gonadotropins directly mediate 
the production of estradiol and progesterone from the somatic cells of the ovarian follicles. The 
presence of the ovarian hormones can provide feedback to control the secretion of FSH and LH. 
In addition, ovarian accessory molecules can assist with the regulation of the menstrual cycle.     
1.1.2.3.1 Gonadotropin Releasing Hormone 
Gonadotropin releasing hormone (GnRH) is produced within the hypothalamus and 
initiates the HPG axis through the stimulation of gonadotrope cells of the anterior pituitary gland 
(15, 107). GnRH expression varies over time, with limited production in infants and upregulated 
to normal levels around puberty (108, 109).  Once active, GnRH binding to GnRH receptor 
(GnRHR) takes place in the pituitary and releases follicle stimulating hormone (FSH) and 
luteinizing hormone (LH), which can regulate the production of ovarian hormones that are critical 
for follicle maturation, ovulation and pregnancy. GnRHR is also present within the ovarian tissues; 
however, binding within the ovary can influence cell proliferation (15). GnRH pulses can be 
modulated by fluctuating estradiol concentrations, with average levels of estradiol producing an 
inhibitory effect, whereas high levels of estradiol stimulate GnRH production (105). This feedback 
loop has major implications in the production of FSH and LH throughout the menstrual cycle.    
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1.1.2.3.2 Follicle Stimulating Hormone 
Follicle stimulating hormone (FSH) is one of two hormones secreted by the gonadotropes 
of the anterior pituitary gland (105). The presence of FSH can triggers the proliferation of 
granulosa cells and follicular growth. This is made possible through the FSH receptor (FSHR) 
found on granulosa cells of growing follicles (110). Further, FSH-FSHR binding upregulates 
aromatase activity, which facilitates the conversion of testosterone to estradiol. As a result of these 
qualities, the level of FSHR on granulosa cells has been suggested as a differentiating factor in the 
selection of the dominant follicle (111). FSH can be inhibited due to high estrogen levels further 
dampening the growth of competing antral follicles and triggering atresia.   
1.1.2.3.3 Luteinizing Hormone 
Luteinizing hormone (LH) is also produced in response to GnRH pulses from the 
hypothalamus, which stimulates the pituitary to secrete LH (15). Upon activation, LH can bind to 
LH receptors (LHR) found on theca cells and can trigger the synthesis of androstenedione, as 
follicles transition from preantral to antral stage (112). As dominant follicles prepare for ovulation, 
the granulosa cells start to display LHR to facilitate the production of enzymes to directly produce 
progesterone (1). Toward the end of the follicular phase, there is a surge of LH production, where 
high levels of LH promote oocytes to resume meiotic maturation and leads to ovulation. The luteal 
cells, which differentiate from follicular granulosa cells, make up the highly vascularized corpus 
luteum (113). Since luteal cells express LHR, LH is necessary to facilitate the synthesis of 
progesterone and estradiol within the corpus luteum. 
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1.1.2.3.4 Ovarian Steroidogenesis 
Steroidogenesis is the process by which hormones are synthesized (Figure 7) (114). In the 
ovary, steroid hormones are critical for maintaining reproductive homeostasis. In preparation for 
steroidogenesis, cholesterol is collected from the blood and taken up by either theca or luteal cells. 
Cholesterol is a necessary component for all steroid hormone production within the ovary. Further, 
steroidogenesis is catalyzed by enzymes, which are primarily from the cytochrome P450 (CYP) 
family (115). To initiate steroidogenesis, enzymes convert cholesterol into pregnenolone, which is 
a precursor steroid hormone that can follow two distinct pathways. Within ovarian follicles, 
pregnenolone is converted into 17-hydroxypregnenolone, then into dehydroepiandrosterone 
(DHEA) and finally, androstenedione (1). Within corpora lutea, pregnenolone is directly converted 
into progesterone, then into 17-hydroxyprogesterone and finally, androstenedione (1). In both 
pathways, androstenedione can then be converted into either estrone or testosterone, both of which 
can give rise to estradiol (1). For follicles to synthesize estradiol, the theca and granulosa cells 
must work together since neither of the cells alone have the enzymes needed for estradiol synthesis. 
This phenomenon is known as the two-cell model, where theca cells convert cholesterol to 
androstenedione and granulosa cells synthesize estradiol, which can then diffuse back into the 
theca cells and into the blood (112). However, the luteal cells of the corpus luteum can directly 









Figure 7 Steroidogenesis in the Ovary 
Steroidogenesis in the tertiary and preovulatory follicle and in the corpus luteum after ovulation. Note that the 
tertiary follicle follows the Δ5 pathway, producing mostly estradiol in the blood. In contrast, the preovulatory 
follicle (i.e. a Graafian follicle after the LH surge but before ovulation) and the corpus luteum produce a large 
amount of progesterone and some estradiol, and thus follow the Δ4 pathway of steroidogenesis.  




Estradiol, also known as 17β-estradiol, is a steroid hormone produced by granulosa cells 
of growing follicles as well as the luteal cells of the corpus luteum (1). The presence of estradiol 
promotes the thickening of the uterine lining at the conclusion of the menstrual phase as well as 
the maturation of the uterus prior to embryo implantation (105). Estradiol levels rise primarily 
during the follicular phase and peak just before the LH surge, which triggers ovulation. Oocyte 
release from the dominant follicle during ovulation is facilitated by estradiol, which can lead to 
the production of collagenase that assists in the breakdown of the connective tissues within the 
follicle.  Another critical function of estradiol is the regulation of the HPG axis through negative 
and positive feedback. Specifically, intermediate levels of estradiol can elicit negative feedback to 
GnRH and dampens the production of LH and FSH (15). However, high levels of estradiol can 
stimulate GnRH, which leads to a spike in the gonadotropins. Although these fluctuations in 
estradiol concentrations are known to influence GnRH pulse frequency and amplitude, GnRH-
specific neurons lack estrogen receptors. Therefore, estradiol must signal through intermediary 
neurotransmitters that can directly mediate GnRH production. Estradiol-receptive kisspeptin-
producing neurons, that directly synapse with GnRH neurons, are believed to facilitate this 
response(116).  
1.1.2.3.6 Progesterone 
Progesterone is a steroid hormone from the progestin family that is synthesized by the theca 
cells of growing follicles and luteal cells of corpus luteum (1). Progesterone plays a significant 
role in the regulation of reproductive function, specifically targeting the mammary glands and the 
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uterus to maintain pregnancy (105). During the luteal phase, the luteal cells are activated by LH to 
synthesize progesterone, which diffuses into the blood vessels embedded within the corpus luteum. 
A reduction of progesterone concentration in the blood triggers the end of the luteal phase and the 
endometrial tissue rapidly degenerates (105).  Like estradiol, progesterone can also regulate the 
HPG axis through negative feedback of GnRH production and subsequent loss of gonadotropin 
secretion.  
1.1.2.3.7 Other Accessory Molecules 
A significant portion of reproductive function is regulated by GnRH, FSH, LH, estradiol 
and progesterone; however, there are also several other accessory molecules that can influence 
ovarian function. Several of these molecules belong to the transforming growth factor β (TGF-β) 
superfamily, which includes anti-Müllerian hormone (AMH), inhibins, activins, bone 
morphogenic proteins (BMPs), and growth differentiation factors (GDFs)(4, 72, 117, 118). Anti-
Müllerian hormone (AMH), which is a glycoprotein produced by the granulosa cells of small 
growing follicles, can inhibit the premature recruitment of primordial follicles(68, 119, 120). 
Inhibin and activin can form dimers, which specifically impact the production of FSH. Inhibin, as 
the name suggests, inhibits FSH production, whereas activin acts in opposition to inhibin and 
stimulates FSH secretion (105). Similar to activin, follistatin can bind directly to inhibin and 
reverse FSH inhibition (105). A number of BMPs have been suggested to play a role in within the 
ovary, including BMP2, 4, 6, 7 and 15 (121). BMP2 is a regulator of primordial follicle activation 
and FSH production (121-124). BMP4 is expressed by both granulosa and theca cells and acts as 
an inhibitor to progesterone synthesis (125-127). Oocytes and granulosa cells express BMP6, 
which can regulate proliferation and FSHR expression to induce steroidogenesis (125, 128-131). 
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Theca cells primarily produce BMP7 and has been shown to contribute toward the proliferation of 
granulosa cells as well as mediate steroid production (125, 126, 132, 133). Like BMP6, BMP15 is 
also expressed by the oocytes and is upregulated gradually throughout the early stages of follicle 
development (134-137). A significant presence of BMP15 has been suggested to improve fertility 
outcomes (128, 138). GDF3 and GDF9 are also present within the oocytes at early primordial 
follicle stages; however, GDF3 promotes, while GDF9 inhibits the expression of LHR (139, 140). 
Another key molecule in ovarian physiology is insulin-like growth factor 1 (IGF-1), which can 
trigger both the proliferation and differentiation of granulosa cells as well as promote gonadotropin 
function (141). Finally, one of the most critical hormones for ovarian endocrine function is 
vascular endothelial growth factor (VEGF), which assists in the formation of blood vessels within 
large antral follicles and corpus luteum (142). 
1.1.2.4 Reproductive Differences in Female Mammalian Species  
In this study, we were interested in testing a novel method for supporting the delivery and 
engraftment of ovarian follicles that would lead to a potential therapy for human patients. 
However, different mammalian species were used to evaluate our approach. We prepared an 
ovarian ECM hydrogel from porcine ovaries due to tissue volume and availability. We used mice 
for all follicle transplants, mating and histological assessment. Although there are many 
reproductive similarities between these mammalian species, there are definitive differences. This 
raises significant questions regarding how this technology would translate to human patients in the 
clinic. To compare these differences, the reproductive characteristics in the context of humans, 
pigs and mice will be examined. 
The female mammalian reproductive anatomy of humans, pigs and mice is similar, as all 
these species include ovaries, fallopian tubes, uterus and vagina; however, they vary slightly in 
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organization and location (Figure 8 and Figure 9). One of the primary differences, in contrast to 
the human uterus, is that pigs and mice have a bilateral uterus or uterine horns (143). The uterine 
horns of pigs are much larger than the human uterus, whereas the mouse uterine horns are 
significantly smaller. The porcine cervix is also anatomically distinct from the human, as it 
contains pulvini cervicales, which are undulating mucosa layers that span the total length of the 
cervix (143). Unlike the separate orifices for the urethra and vagina in humans, pigs share a 
urogenital opening. Another anatomical difference in pigs and mice is the presence of the ovarian 
bursa, which is a sack surrounding the ovary and is lacking in humans (101). The ovarian ligament 
in humans and mice are anatomically dissimilar, where the fimbriae of the fallopian tube is directly 
in contact with the ovary in humans, the ovarian ligament in placed in a way that brings the ovary 
close to the fimbria of the fallopian tubes (101).     
Female mammalian species also differ in their reproductive cycles (Figure 10 and Figure 
11). Humans reach sexual maturity at 12.9 years of age on average (143). In contrast, mice become 
sexually mature the earliest, between 6-8 weeks, followed by pigs at 4-6 months of age (144-146). 
Once sexually mature, all these mammals continuously cycle until their ovarian follicle reserve 
has been depleted. In each of these mammalian species, their cyclicity is maintained by the 
hypothalamus-pituitary-gonadal (HPG) axis. The human menstrual cycle, pig and mouse estrous 
cycles all respond to gonadotropin feedback, which stimulates the production of ovarian endocrine 
hormones, estradiol and progesterone. One of the main differences is the type of cycle, 
classification and length. Humans have a menstrual cycle, which is indicative of changes within 
the ovary and endometrial lining, whereas pigs and mice do not menstruate, but instead both have 
characteristic estrous cycles that are dependent upon sexual receptiveness (143). The menstrual 
cycle in humans is about four weeks long, whereas the estrous cycle in mice lasts 3-5 days and 
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occurs every 19-21 days in pigs (143). Estrous is made up of four main stages: proestrus, estrus, 
metestrus and diestrus (145, 147). Proestrus is the first stage of the estrous cycle, during which 
follicles as well as the endometrial tissue begin developing. Proestrus is followed by estrus, which 
indicates the sexual receptivity of the animal. The third step in the estrous cycle is metestrus that 
signals the development of the corpus luteum and is followed by diestrus that stimulates the 
production of progesterone. Although these species share different types of reproductive cycles 
they all maintain a follicular phase and luteal phase; however, their durations vary between 
mammals (143). The follicular phase in humans lasts approximately 14 days followed by the luteal 
phase, which is an additional 12-15 days (105). In contrast pigs, have a shorter follicular phase (5-
6 days) with a longer luteal phase (15-17 days) (147). Finally, due to their relatively quick 4-5 day 
estrous cycles, mice have the shortest follicular (2 days) and luteal (2-3 days) phase (145). 
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Figure 8 Human vs. Pig Reproductive Anatomy 
The porcine uterus differs macroscopically from the human simplex uterus by having bilateral horns (bicornuate). 
The porcine cervix displays a characteristic feature, not found in women; the cervical pulvini (red arrow). 
Furthermore, the porcine urethra opens on the ventral surface of the vagina (purple arrow) creating an urogenital 
sinus that opens to the outside through the common urogenital orifice. In women, the urethra and vagina have its 
own separate openings to the outside. Otherwise the porcine vagina is similar to the human one.  




Figure 9 Human vs Mouse Reproductive Anatomy 
The diagrams show the organization and anatomy of the adult human and mouse ovary; the fallopian tube (also 
known as the oviduct), including finger-like fimbria; the ovary ligament; and the uterus. A thin bursa membrane 
encapsulates the mouse ovary but is absent in humans. The placement of the ovary ligament differs between humans 
and mice. In humans, the ovary and the fimbria are anatomically contiguous at the ovarian fimbriae, whereas the 
ovary ligament abridges the ovary–fimbria connection in mice. A single-layered epithelium lines the ovary, fimbria 
and ovary ligament.  







Table 1 Differences in Reproductive Cycle of Mammals 




Figure 10 Porcine Estrous Cycle 
The estrous cycle in pigs begins and ends with ovulation/ estrous. The menstrual cycle in women begins and ends 
with the start of menses, with the ovulation in the middle of the cycle. Otherwise, the length of the cycle and the 
hormonal fluctuations are very similar. 





Figure 11 Rodent Estrous Cycle 
Schematic pattern of the 4-day estrous cycle in the rat depicting serum estradiol and progesterone concentrations as 
they relate in time to the surge of luteinizing hormone (LH). Ovulation will typically occur during the early morning 
hours of estrus, approximately 10–12 hours after the rise in LH. Shaded blocks at the base of the figure indicate the 
dark portion of a 14:10 hr light:dark photoperiod.  









1.2 Female Fertility Preservation 
Fertility preservation is primarily dedicated to conserving the reproductive function of 
female and male cancer patients (148-151). A growing number of patients are surviving metastatic 
disease, which has also increased the clinical need for methods of fertility preservation. Cancer 
treatments, such as chemotherapy, radiation and gynecologic surgery can directly cause iatrogenic 
premature ovarian failure (POF), which lead to a loss of fertility (149). As a proactive effort to 
preserve fertility in women, oocytes and embryos are collected and cryopreserved prior to 
treatment using hormone stimulation. After these patients are cleared of cancer, their 
cryopreserved cells may be used for in vitro fertilization (IVF) and embryo transfer to induce 
pregnancy. However, there is another population of young girls and women, who cannot afford to 
delay cancer treatments and therefore are unable to undergo hormone stimulation for egg 
collection. As an alternative, ovarian cortical tissues are cryopreserved, which can be used for 
autotransplantation (152). This procedure is the primary method for fertility preservation; 
however, there remain risks associated with this approach including malignant cell transmission 
and surgical complications (153). A number of experimental cell and tissue engineering 
approaches have been developed to address these issues including in vitro/in vivo follicle 
maturation, an artificial ovary and the future potential for ovarian stem cell therapy (154). The 
following sub-sections will review the causes of infertility, specifically the effects of cancer 
treatments that can induce iatrogenic POF, and the progress of next generation therapies for female 
fertility preservation.                
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1.2.1 Female Infertility 
Approximately 9% of world is infertile, which amounts to roughly 50 to 80 million people 
(155, 156). Infertility can be caused by several confounding factors including age, diet, genetic 
defects, and exposure to environmental hazards (157). Ovarian-associated pathologies, such as 
ovarian cancer, premature ovarian failure (POF), polycystic ovarian syndrome (PCOS) and 
endometriosis can also contribute to a loss of fertility (157). In each case, infertile patients looking 
to restore fertility may now have options due to improvements in assisted reproductive 
technologies, such as hormone stimulation, in vitro fertilization and embryo transfer. However, 
patients that do not have viable eggs of their own may turn to a surrogate or adoption.    
1.2.2 Premature Ovarian Failure 
Premature ovarian failure (POF), or primary ovarian insufficiency (POI) is the sudden or 
gradual loss of reproductive function and fertility prior to normal menopause (158-160). POF is 
generally caused by a loss or dysfunction of ovarian follicles, which can be attributed to genetic 
disorders or a malfunction within the HPG axis. Further, iatrogenic damage to the gonadal cells 
through surgical or chemical intervention can also result in POF. Specifically, cancer treatments, 
such as chemotherapy and radiotherapy are cytotoxic, which can rapidly induce follicle apoptosis 
and impair fertility. Female patients with abnormally high levels of follicle stimulating hormone 
(FSH) can be used as an indicator of POI (161). In the presence of healthy growing follicles, 
ovarian hormones provide a negative feedback to the GnRH neurons, which reduce the 
concentrations of FSH, however, with a lack of follicles, FSH remains constitutively active. 
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Additionally, anti-Müllerian hormone (AMH) can be predictive of the remaining ovarian reserve 
as it is expressed by small growing follicles. 
1.2.3 Causes of Iatrogenic POF 
Iatrogenic premature ovarian failure (POF) can be defined as any form of physical or 
chemical procedure that directly causes a significant loss or dysfunction of ovarian follicles (158). 
For example, cancer patients who are treated with chemotherapy, radiation or gynecologic surgery 
are at risk for developing POF. Chemotherapy agents and radiation are cytotoxic in moderate to 
high doses, which can depopulate the ovarian reserve, which is composed of the remaining 
immature follicles that indicate future fertility potential (162). Similarly, surgical methods to 
reduce malignant ovarian tissues can also damage the environment and trigger follicle atresia 
(151). To further elucidate these effects, the chemical agents and procedures that can induce POF 
will be reviewed in the following sub-sections.     
1.2.3.1 Chemotherapy-Induced POF 
It is estimated that 1 in 18 premenopausal women will be diagnosed with an invasive form 
of cancer (163). Chemotherapy is a common treatment for the ablation of malignant disease. 
However, there are side effects that can significantly reduce the quality of life for cancer patients. 
One of the major side effects is the disruption of normal reproductive function. Chemotherapeutic 
agents are notoriously cytotoxic and can severely damage the ovarian tissues and cells (Figure 12). 
Several studies that performed histological sampling of ovarian tissues exposed to chemotherapy, 
have provided evidence of a depreciated ovarian reserve and reduction in overall tissue volume 
(164-166). There are a number of different types of chemotherapy agents with varying mechanisms 
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of action including alkylating agents, platinum-based compounds, antimetabolites, vinca alkaloids 
and anthracycline antibiotics (162). The most significant risk of incurring infertility is caused by 
alkylating agents. This groups consists of cyclophosphamide, busulfan, mechlorethamine, 
chlorambucil, and melphalan (162). Alkylating agents primarily induce apoptosis within the 
oocytes of ovarian follicles. Specifically, guanine bases within DNA are compromised by the 
addition of an alkyl group that results in unrepairable double stranded DNA breaks that trigger cell 
death (167, 168). Further, these agents can cause disruption of developing follicles, which can 
prevent menstrual cycling. Chemotherapy exposure may also negatively impact the ovarian 
vasculature, which is critical in follicle maintenance and viability (169, 170). Additionally, 
increased fibrosis throughout the stroma can be observed within treated ovaries leading to further 
dysfunction (169, 171). 
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Figure 12 Iatrogenic Premature Ovarian Failure and Fertility Preservation 
As shown in Panel A, high-dose radiation and most chemotherapeutic agents damage the growing cells in mature 
and immature follicles and, depending on the type of drug, the dose, and the age of the patient, may result in 
depletion of many or all follicles. This depletion may result in a short-term loss of reproductive function and an 
inability to attain a natural pregnancy after treatment. As shown in Panel B, if fertility interventions are warranted, 
the patient can delay treatment and undergo hormonal induction for 2 to 3 weeks to stimulate follicle development 
and recover mature oocytes. The oocytes can be frozen or fertilized, depending on the wishes of the patient. If there 
is insufficient time or if there are contraindications, one ovary can be removed, and ovarian cortical strips can be 
cryopreserved for use in tissue transplantation or emerging techniques such as in vitro follicle maturation. 
[Figure and text reproduced with permission from (150), Copyright Massachusetts Medical Society.] 
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1.2.4 Current Fertility Preservation Techniques 
Over the past several years, there have been significant advancements toward improving 
female fertility preservation (Figure 13). One of the major accomplishments was the development 
of cryopreservation protocols that dramatically improved the viability of ovarian tissues and cells 
for long-term storage (172). Without reliable cryopreservation, natural pregnancy would not be an 
option for POF patients. During the early 2000s, another outstanding achievement was made as 
ovarian tissue transplantation led to live-births in multiple human patients (173-175). To this day, 
orthotopic transplantation of ovarian cortical tissue remains the standard for female patients with 
iatrogenic POF. Due to the diversity of clinical outcomes and reporting, it has been difficult to 
gauge the effectiveness of ovarian tissue transplantation; however, it is anticipated that this 
procedure will soon be elevated from an experimental approach to the primary standard of care. 
Although this technique has shown undeniable clinical success, there remain concerns for patients 
with aggressive forms of cancer, which could lead to the transmission of malignant cells upon 
transplantation. Further, ovarian transplantation requires an invasive surgical procedure that could 
lead to complications. As a result, researchers have been working to develop new methods to 
reduce the potential for cancer transmission by isolating immature follicles from the surrounding 
stroma. In vitro and in vivo follicle maturation has been used with biomaterials to recapitulate 
folliculogenesis to obtain mature oocyte for downstream assisted-reproductive technologies 
(ARTs). Several of these techniques have directly resulted in live-births in mice; however, further 
research must be conducted to better replicate the highly dynamic conditions observed within the 





Figure 13 Fertility Preservation Options for Female Cancer Patients 
Fertility-preserving options for young women with cancer include hormonal stimulation with cryopreservation of 
oocytes or embryos and laparoscopic oophorectomy with tissue storage and later use in transplantation or in vitro 
follicle maturation. At the time of tissue harvest, mature follicles may exist and cumulus–oocyte complexes may be 
harvested and matured in vitro to provide another source of mature eggs for storage. Depending on the patient’s 
uterine status, a gestational surrogate may be required. Tissue cryopreservation is the only option for girls who are 
not candidates for hormone stimulation. 
[Figure and text reproduced with permission from (150), Copyright Massachusetts Medical Society.] 
1.2.4.1 Cryopreservation 
One of the most critical parts of fertility preservation is the capacity to store and retain the 
viability of ovarian tissues and cells. To accomplish this, cryopreservation techniques have been 
developed for ovarian tissues and follicles over the past 60 years (176, 177). The success of this 
process is now generally recognized internationally as the standard of care for female cancer 
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patients (178). The initial  cryopreservation approach was to use slow-freezing with 
cryoprotectants, such as glycerol, dimethyl sulfoxide (DMSO), 1,2-propanediol (PROH) and 
sucrose (179-182). However, these methods led to poor cell viability and fertility outcomes after 
ovarian tissue transplantation. More recently, the use of vitrification, or rapid freezing after 
dehydration, has become the preferred method for cryopreservation (183, 184). Briefly, ovarian 
tissues are sequentially placed in graded concentrations of ethylene glycol and DMSO, 
supplemented with handling medium (HEPES-buffered TCM-199 solution with 20% synthetic 
serum substitute) in the primary incubation and sucrose in the secondary incubation. Tissues are 
subsequently added directly to liquid nitrogen and stored until further use. Just as tissues are 
rapidly frozen, the tissues are also rapidly warmed to 37°C in handling medium with decreasing 
concentrations of sucrose solution. This procedure demonstrates excellent oocyte viability and 
represents a feasible method for long-term storage of ovarian tissues and cells that offer patients 
an opportunity to restore fertility(184).    
1.2.4.2 Ovarian Tissue Transplantation 
The most common treatment for restoring fertility in female cancer patients is the use of 
ovarian cortical strip transplantation. This method has generated greater than 130 live-births 
worldwide (149). The decision to use ovarian tissue transplantation is generally predicated by a 
severe cancer diagnosis that requires immediate treatment. Therefore, prior to treatment, the 
patient undergoes a laparoscopic procedure to remove a small piece of the ovarian cortex, which 
is then cryopreserved until patients are ready for autotransplantation. Patients that can afford to 
delay potentially gonadotoxic treatments are able to use normal ARTs, such as hormone 
stimulation, to collect and cryopreserve oocytes and embryos prior to treatment. The primary form 
of this procedure is orthotopic transplantation, where ovarian cortical tissues are introduced into 
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the pelvic region, preferably onto the ovary, to promote natural conception; however, heterotopic 
procedures, with subcutaneous transplantation within the forearm and abdomen, are also used for 
in vivo follicle maturation and restoring endocrine function (185). Although this treatment has 
been successful, there are some considerable limitations including, follicle ischemia, malignant 
cell transmission and surgical complications. Overall, this method is a promising form of restoring 
both fertility and endocrine function for POF patients.  
1.2.4.3 Biomaterial-Facilitated Approaches 
A concern for using intact ovarian cortical tissues is the potential presence of residual 
malignant cells. For this reason, many researchers have begun testing the efficacy of using isolated 
follicles to reduce the reintroduction of cancer cells back to the patient upon transplantation. 
Several experimental techniques, such as in vitro and in vivo follicle maturation and artificial 
ovarian transplantation, are now being tested to support oocyte maturation from early-stage 
ovarian follicles that may be used to restore fertility.  In order to promote follicle survival and 
maturation, a variety of biomaterials have been used to mimic the ovarian microenvironment. The 
following sub-sections will document the current research and outlook for these experimental 
therapies.   
1.2.4.3.1 In Vitro Follicle Maturation 
In vitro follicle maturation (IVM) is a popular experimental approach used for the support 
of follicle development to obtain meiotically competent oocytes for IVF. Follicles are isolated 
from the surrounding stroma and cultured in media supplemented with specific ovarian hormones 
and growth factors. Ideally, immature follicles will be activated under the influence of follicle 
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stimulating hormone and granulosa cells will start to proliferate. After substantial follicle growth 
over the course of several days to weeks, human chorionic gonadotropin (hCG) is used to stimulate 
the resumption of meiosis and the release of metaphase II (MII) oocytes. MII oocytes are then 
artificially inseminated to form an embryo for implantation and pregnancy.  
The concept of IVM was initially examined by Eppig and O’Brien, who implemented a 
two-step culture system to develop mouse primary oocytes into meiotically-competent MII 
oocytes, which were used to generate live-births (186, 187). To improve maturation efficiency of 
two dimensional follicle culture (188), biomaterials have been used to provide a supportive three-
dimensional culture environment and better mimic the conditions observed in vivo (Figure 14)  
(111, 189). Xu et al. 2006 used an alginate matrix to encapsulate mouse secondary follicles, which 
were cultured for eight days in growth medium (190). Upon enzymatic extraction from the alginate 
bead, follicles were placed in maturation medium, consisting of hCG and epidermal growth factor 
(EGF), to simulate ovulation. Results from this study indicated that a 3D culture environment 
could retain normal follicle morphology and yield a high percentage (70.9%) MII oocytes. Further, 
the fertilization rate of MII oocytes, which developed into a zygote, was 68.2%, which only 
differed by approximately 13% from in vivo superovulated control oocytes. Pseudopregnant 
female rats that received an embryo transfer, derived from in vitro culture, gave birth to health 
offspring. This study gave the impetus for an increased focus on advancing the field of female 





Figure 14 Hydrogel-facilitiated Follicle Encapsulation for 3D Culture 
With 2-D growth granulosa cell migration away from the oocyte is evident with time in culture, leaving the oocyte 
vulnerable for premature extrusion. Pre-antral follicles embedded in hydrogel maintain their 3-D architecture. 
Granulosa cell expansion occurs in all directions resulting in less stress on gap junctions. 
[Figure and text reproduced from (191). Open-access - Creative Commons Attribution License.] 
  
To date, alginate has been the primary biomaterial studied and used for 3D encapsulation 
of ovarian follicles for IVM across several species, including mouse (189, 190, 192-195), goat 
(196, 197), dog (198), cow (199), primate (200) and human (201). However, other popular 
biomaterials have emerged in an attempt to demonstrate in vitro folliculogenesis, such as collagen 
(202-207), fibrin (208-210), Matrigel (211), hyaluronic acid (212) and poly-ethylene glycol (PEG) 
(213). Adjustments in material properties and composition, as well as culture conditions, have led 
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to improved outcomes, which has made IVM a common practice for obtaining mature oocytes in 
lower species. However, efficiency for the maturation of immature human follicles remains poor 
and must be significantly improved for clinical translation.      
1.2.4.3.2 In Vivo Follicle Maturation 
In vivo follicle maturation is an experimental strategy using the body’s natural environment 
to improve developmental outcomes after follicle isolation. Additionally, this technique would 
offer a protective barrier to prevent the transmission of malignant cells. The study by Xu et al. 
2006 demonstrated that it was possible to recover encapsulated follicles from alginate hydrogels 
and continue with oocyte maturation(190). Therefore, Rios et al. 2019 examined the potential of 
using alginate encapsulation to create a retrievable implant to assess follicle maturity for 
fertilization(214). Primordial, primary, and secondary follicles were mechanically isolated and 
encapsulated within a 0.5% alginate bead. Encapsulated follicles were transplanted into 
ovariectomized mice at both orthotopic (subcutaneous) and heterotopic (ovarian bursa) sites. 
Alginate hydrogels were retrieved after seven days and upon follicle release, the antral follicles 
were exposed to hCG and EGF for 16 hours to induce ovulation. Among the recovered follicles, 
survival rates were low with the smallest number of follicles transplanted leading to the great 
recovery (76%). The subcutaneous transplants appeared to dramatically improve follicle survival 
in comparison to the transplants from the ovarian bursa. Although the survival rates were low, of 
the antral follicles recovered from subcutaneous implants, 63% achieve MII stage. Follicles 
obtained from the ovarian bursa yielded only 20% MII oocytes. After intracytoplasmic sperm 
injection (ICSI), 36% of the oocytes developed into 2-cell and 7% into 4-cell embryos. Standard 
IVF resulted in 40% of oocytes becoming 2-cell embryos. Finally, cancer cell transmission was 
 49 
evaluated using luciferase-expressing malignant cells and detection via in vivo imaging. After 
removal of the alginate implant, there was no indication of neoplastic cells within the recipient 
mice. This strategy could be an effective way to promote improved follicle development while 
limiting the potential for cancer recurrence.         
1.2.4.3.3 Artificial Ovary 
The artificial ovary is a concept that uses biomaterials to facilitate the transplantation of 
isolated follicles to restore reproductive function and fertility. Recently, there have been several 
groups that have incorporated different strategies and biomaterials to prepare a supportive material 
to enhance follicle survival upon transplantation. Shikanov et al. 2011 introduced a combination 
system consisting of a fibrin gel supplemented with vascular endothelial growth factor (VEGF) to 
stimulate angiogenesis and promote graft survival. Transplanted mouse ovarian tissues supported 
by the fibrin/VEGF material improved follicle survival when compared to no biomaterial control. 
The transplanted material was also able to give rise to a litter of pups (215). Similarly, Smith et al. 
2014 characterized the use of a fibrin gel for the transplantation of ovarian follicles. Early-stage 
follicles were enzymatically isolated, encapsulated within fibrin gels and transplanted into an 
ovariectomized mouse. Fibrin graft explants were performed at 0, 3, 9 and 21 days with follicles 
populations being significantly reduced by day 9 (216).  Kniazeva et al. 2015 tested multiple 
biomaterials combinations, including variable concentration of fibrin, alginate and collagen, to 
improve follicle survival upon in vivo transplantation in an ovariectomized mouse model. 
Successful litters resulted solely from follicles encapsulated within fibrin gels that were 
supplemented with VEGF (217). Laronda et al. 2015 detailed a procedure for the decellularization 
of both human and bovine ovaries. Primary ovarian cells were seeded onto decellularized grafts, 
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which were then transplanted into ovariectomized mice. Post-transplantation, recipient mice 
showed evidence of initiating puberty(218).  Paulini et al. 2016 tested an artificial ovary using a 
fibrin gel showing the efficacy of xenografting isolated preantral follicles within the peritoneum. 
Results showed that follicles had survived and were proliferating up to 7 days post-transplantation 
(219). Kim et al. 2016 implemented a poly-ethylene glycol vinyl sulfone (PEG-VS) hydrogel to 
support the transplantation of immature follicles and showed a restoration of endocrine function 
for up to 60 days post-transplantation (220). Laronda et al. 2017 established a bioprosthetic 3D 
printed ovary composed of gelatin to restore ovarian function in sterilized mice. As a result of the 
transplanted scaffold, GFP pups were born from the exogenous follicle transplant (221). These 
strategies have delivered exceptional results in a short time, which bodes well for the field of 
female fertility preservation. The next step for the development of artificial ovarian tissues is to 
test these materials in higher order mammalian species that could better evaluate their efficacy for 
human use.   
1.2.4.4 Ovarian Stem Cells 
The testis contains mitotically active spermatogonia that can produce sperm indefinitely 
throughout the course of a man’s life. However, in contrast, oogonia complete mitosis and enter 
meiosis during prenatal development, which produces a finite number of oocytes in the ovary at 
birth. Within the past two decades, there have been several claims suggesting that a population of 
mitotically-active, female germline stem cells (FGSCs) may exist within the ovary (222). 
However, there have also been conflicting studies that oppose these findings (223). Nevertheless, 
multiple studies have shown that the intraovarian microinjection of FGSCs can support the birth 
of healthy pups post-chemotherapy (224-226). Although the mechanism behind this technique is 
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not well understood, the results suggest that ovarian stem cell populations may be a valuable tool 
to study the development of human oocytes and could offer a potential therapy to treat infertility.  
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2.0  Overview of Decellularized ECM Biomaterials 
The field of tissue engineering and regenerative medicine uses various biomaterials to 
create a microenvironment that promotes a desired cell function. One of the most promising types 
of biomaterials are decellularized extracellular matrices (dECM) and their derivatives (ie. 
hydrogels, etc.). The benefit of using dECM materials is their tissue-specific molecular and 
biochemical composition, which has been shown to promote cellular infiltration and tissue 
remodeling. These materials are prepared using the process of decellularization that removes 
immunogenic material to avoid rejection upon transplantation in vivo. A diverse portfolio of 
decellularization agents have been used in combination to remove cells, while retaining tissue 
specificity. However, tissues are inherently different and thus, materials and method selection, 
along with significant optimization, are required to obtain a tissue-specific bioactive dECM 
scaffold. Recently, an increasing number of decellularization protocols and resultant dECM 
materials have been developed for ovarian tissues with potential for restoring fertility in female 
patients. Although great strides have been made in this area, there are several challenges and 




2.1 The Extracellular Matrix 
The extracellular matrix (ECM) is a critical component of the cell microenvironment and 
is essential to maintaining homeostasis. The ECM is a diverse, tissue-specific network of proteins, 
proteoglycans and glycoproteins that are secreted by cells to provide structural support and act as 
a reservoir of small molecules to facilitate cell signaling. ECM composition varies based upon 
desired organization and functions of local cells.  In the following section, we will look at some of 











Figure 15 Extracellular Matrix Composition 
ECMs are classified into two major types, the interstitial and pericellular matrices. Basement membrane, a type of 
pericellular matrix, is found between epithelial cells and connective tissue. This layer is composed of a collagen IV 
network that associates with ECM components including nidogen, laminin, perlecan, and minor collagens like 
collagen XV and XVIII. Epithelial cells are anchored to basement membranes by hemidesmosomes formed via 
interactions of integrins with laminins. Interstitial matrices are composed of collagen fibrils, elastin, secreted PGs 
and HA, and matricellular proteins. They interact with each other creating a dynamic and complex three-
dimensional network. Cells bind to ECM components by specific cell surface receptors, such as integrins; cell 
surface PGs; syndecans and glypicans; the HA receptor CD44; and DDRs. They transduce signals into cells that 
regulate various cellular functions.  




2.1.1 ECM Components 
The extracellular matrix (ECM) is composed of a diverse set of biomolecules, such as 
proteins, glycoproteins, and proteoglycans that provide a structural framework to accommodate 
the function of resident cells (Figure 15) (228-231). A large portion of the ECM is made up of 
fibrous collagen proteins and are primarily recognized by their distinct triple helix configuration, 
which help to build supramolecular structures that are essential for establishing mechanical 
strength of a tissue (232, 233). Elastin fibers, composed of crosslinked tropoelastin molecules, and 
microfibrils provide elasticity within tissues (234). Glycoproteins are another class of ECM 
molecules that act as structural bridges between the ECM and their cellular inhabitants. The major 
glycoproteins of the ECM are laminins, fibronectin, and tenascins. Laminins are generally found 
within the basement membrane of tissues and can directly interact with cellular surface molecules 
(235). Fibronectin is a large molecule that can associate and bind to other ECM molecules, cell 
adhesion molecules and growth factors depending on its diverse and dynamic conformation (236). 
Similar to other glycoproteins, tenascin-C can also interact with ECM molecules and assist with 
cell migration through binding with cell adhesion molecules (237). A sub-class of glycoproteins 
are proteoglycans, which are distinguished by multiple chains of repeating, unbranched 
disaccharides referred to as glycosaminoglycans (GAGs). Proteoglycans containing GAGs, such 
as heparin, heparan sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, and hyaluronic 
acid play a significant role in water retention, growth factor and cytokine binding, as well as cell 
adhesion   (238-242). The ECM communicates with the cells via cell surface molecules, such as 
integrins and syndecans, which facilitates adhesion and cell migration (243-246). Recently, it was 
demonstrated that fibrillar components of the ECM can sequester proteins, microRNA and lipids 
within matrix-bound nanovesicles (MBVs), which can influence immune cell phenotype and stem 
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cell differentiation (247-249). Matrix metalloproteinases (MMPs), along with other proteolytic 
enzymes, can actively degrade ECM components to remodel the extracellular niche and facilitate 
the release of angiogenic, chemotactic, mitogenic and anti-inflammatory factors to influence 
resident cells (250-259). 
2.1.2 Role of the ECM 
The biochemical profile of the ECM can change dynamically within certain organs or can 
remain relatively static in others depending on their function. In general, the ECM plays a 
significant role in mediating homeostasis as it can provide mechanical and biochemical cues that 
trigger cell proliferation and differentiation. This process is facilitated by a phenomenon referred 
to as dynamic reciprocity, which is the continuous feedback between cells and the ECM to support 
the spatiotemporal functions of a given tissue (260-262). As a result, environmental stimuli may 
trigger the cells to generate a diverse milieu of proteins and soluble factors, which can then 
influence downstream processes, such as gene expression and protein synthesis (263). The ECM 
also is known to play a regulatory role in facilitating normal biological functions, such as stem cell 
differentiation, angiogenesis, innervation and healing response due to injury or disease (264-270). 
Due to these intrinsic properties, the ECM has become a desirable biomaterial, which has several 
applications for tissue engineering and regenerative medicine. 
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2.2 Decellularization 
To obtain acellular ECM scaffolds, tissues must first undergo the process of 
decellularization. Decellularization is a procedure that disrupts and removes the cellular 
components of a tissue of interest using physical and/or chemical treatments. A critical factor of 
decellularization is the ability to obtain a non-immunogenic scaffold while retaining tissue-specific 
components, such as prominent ECM proteins and growth factors. In addition, it is important to 
consider the impact of the decellularization treatments on tissue morphology, especially if acellular 
ECM scaffolds will be re-seeded with cells. To achieve these outcomes, the materials and tissue 
processing must be carefully selected based upon tissue type to effectively remove endogenous 
cellular content while preserving the desired tissue-specific characteristics. To date, a wide range 
of tissues and organs have been decellularized using a diverse combination of materials and 
processing methods. The use of decellularization has grown dramatically due to successful 
application for tissue engineering and regenerative medicine. This technique has recently been 
demonstrated for use within female reproductive tissue engineering to mimic the ovarian 
microenvironment to support both follicle culture and in vivo transplantation. The following 
section will provide a general overview on the materials, methods and processing for successful 
decellularization to prepare dECM biomaterials for fertility preservation.  
2.2.1 Methods 
As mentioned above, there have been a significant number of decellularization approaches 
designed to obtain dECM scaffolds from almost every tissue and organ in the body (271). These 
approaches generally include treatments that fall into three main categories: (1) physical 
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treatments, (2) chemical treatments, and (3) enzymatic treatments (271-280). Tissues may only 
require one or a combination of these treatments in order to remove cellular content and preserve 
the integrity of the ECM. Processing methods, as well as incubation times, wash steps, and 
temperature, can dramatically alter the decellularization outcomes and dECM biomaterial efficacy. 
To improve the effectiveness of decellularization, tissues may be perfused or diced to increase 
surface area exposure to chemical or enzymatic reagents. Perfusion uses the existing vasculature 
of an organ to penetrate deep within the tissues and allows the organ to remain intact. This is 
beneficial for whole organ recellularization. However, if intact dECM scaffolds are not required, 
then dicing is also an option to enhance the quality of the decellularization. Ultimately, the 
selection of decellularization methods creates a tradeoff between the cell removal and preservation 
of bioactive components, which makes it critical to optimize protocols for non-standardized 
tissues. The following sub-sections will look at the most common types of treatments and their use 
for decellularization. 
2.2.1.1 Physical Treatments 
A variety of physical treatments are used to aid in the removal of cells including freeze-
thaw cycles, mechanical delamination and hydrostatic pressure. Freeze-thaw cycles enhance the 
decellularization effects of detergents and enzymes when compared to chemical treatments alone 
(281). This process helps to loosen the cells within the tissues making it easier for their removal. 
Mechanical delamination is used to remove unwanted cellular layers to leave behind an acellular 
matrix. This strategy has been implemented in the preparation of ECM grafts and sheets, such as 
small intestinal submucosa (SIS) and urinary bladder matrix (UBM) (282-285). Hydrostatic 
pressure is another technique used to avoid the negative effects of detergents and reduce the total 
time of decellularization (286, 287). This process uses high-hydrostatic pressure, induced by a 
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pressurized and temperature-controlled chamber, to uniformly disrupt the cellular membranes of 
a tissues without compromising the structural components of the ECM.    
2.2.1.2 Chemical Treatments 
A common strategy for decellularization is to use chemical treatments, which includes 
detergents, acid and bases, hypo- and hypertonic solutions, solvents and chelators (288). 
Detergents are highly effective decellularization agents and are grouped based upon the net charge 
of the molecule. Many times, more than one type of detergent is used to improve both cell removal 
and clearance of residual chemicals (289, 290). Ionic detergents, such as sodium dodecyl sulfate 
(SDS) and sodium deoxycholate (SDC), are popular decellularization agents that are proficient at 
lysing cell and nuclear membranes (286, 287, 291-329). However, there are some negative 
consequences of using these detergents as they can also disrupt native ECM ultrastructure and can 
significantly reduce the presence of GAGs and tissue-specific growth factors (295, 302-304). Non-
ionic detergents, such as Triton X-100, have been shown to be less aggressive than SDS, which 
can result in residual cellular content in thicker tissues, but it is more favorable for GAG and 
growth factor preservation (286, 287, 289, 291, 292, 294, 295, 299-301, 303-307, 311, 315, 319-
324, 326, 328, 330-335). Finally, zwitterionic detergents such as, CHAPS (3-((3-cholamidopropyl) 
dimethylammonio)-1-propanesulfonate) and sulfobetaine-10,16 are primarily used for 
preservation of proteins and can also be used for the ablation of cells but are less effective cellular 
removal agents than ionic and non-ionic detergents (293, 299, 313, 323). Acids and bases are 
frequently used in decellularization to facilitate hydrolysis within the tissues. Acetic acid has been 
used to delipidize and increase porosity of acellular scaffolds, directly attributed to a loosening of 
collagen structural proteins, which promotes greater cell infiltration (331). Peracetic acid is 
commonly used a disinfectant of animal tissues and can further dissociate remnant nucleic acids 
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without compromising the ECM (336-338). Bases can also be used in the pre-processing of tissues, 
but they can have a detrimental impact on mechanical properties, which is caused by a dissociation 
of collagen networks (295, 339, 340). Hypo- and hypertonic solutions are used generally to rinse 
and remove cells and detergents from a tissue (288). Generally, phosphate buffered saline (PBS) 
is used in high concentrations (hypertonic) to remove water from a cell and lower concentrations 
(hypotonic) to cause swelling of cell and can purify proteins through nucleic separation (341). 
Alternating washes of hypo- and hypertonic solutions can also lyse cells due to increasing osmotic 
pressure, which can directly aid in decellularization without observable depreciation of tissue-
specific components within the ECM (342). Solvents, such as alcohols (ie. ethanol, methanol, etc.), 
acetone and tributyl phosphate, can also be utilized for decellularization by similar mechanisms of 
dehydration and cell lysis (339). These chemicals can also be used for lipid removal in some 
decellularization protocols; however, solvents are known fixatives that can have irreversible 
effects on the structural integrity of the acellular scaffolds (330, 340, 343-346). Chelators are 
commonly paired with enzymes to help disrupt cell-ECM adhesions due to their ability to sequester 
essential ions (347, 348). Specifically, EDTA (ethylenediaminetetraacetic acid), a calcium (Ca2+) 
chelator, and trypsin, an enzyme used for the cleavage of peptides associated with cell adhesion 
molecules, are used in tandem to free cells from a given substrate (287, 301, 308, 321, 333, 349). 
2.2.2 Enzymatic Treatments 
The last category of decellularization agents involves the use of enzymes, specifically 
nucleases and proteases (288). Nucleases, like DNase and RNase, are used to augment 
decellularization after cell permeabilization by cleaving nucleotides, which make up DNA and 
RNA strands within cells (287, 293, 297, 301). Proteases, such as trypsin, can also be used to 
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cleave naturally occurring peptides within cell adhesion molecules, with enhanced effects in the 
presence of a chelating agent (288). Although trypsin is useful for cell removal, it has off-target 
effects, which can reduce the integrity of ECM molecules, such as collagen and elastin (289, 304, 
324, 332). Overall, the use of nucleases and proteases alone is not ideal for complete 
decellularization of a tissue; however, their use may improve the initial detachment of cells as well 
as the breakdown of large DNA/RNA fragments for a more thorough removal of immunogenic 
components. Other less common enzymes used for decellularization are collagenase, to reduce 
collagen fibers, and lipase, for improved lipid removal (330, 350).    
2.2.3 dECM Derivatives 
The immediate end-product of decellularization is an dECM scaffold that can be used for 
a number of potential tissue engineering applications. Acellular dECM scaffold materials can be 
used as a substrate for 3D cell-culture, recellularized for in vitro cell differentiation or as an 
acellular graft to promote healing and remodeling at the site of injury. Further, acellular tissues 
may be enzymatically digested, using pepsin and hydrochloric acid, to solubilize the tissue. 
Solubilized dECM is temperature-sensitive and once neutralized will form a hydrogel, which is 
primarily the product of a physical crosslinking of collagen molecules. dECM hydrogels provide 
a versatile biomaterial with several advantageous properties including tissue-specific bioactivity 
(diverse ECM composition, growth factors, hormones, etc.), injectability and degradability. 
Further, solubilized dECM components may be isolated and enriched to create highly concentrated 
forms of the tissue-specific ECM bioactive components. 
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2.2.4 Current Decellularization Approaches for Fertility Preservation 
Decellularization has recently been used to generate ovarian-specific dECM biomaterials 
for fertility preservation applications. Ovarian tissues were first decellularized by Laronda et al. 
2015 to restore puberty within an ovariectomized mouse (218). Human and bovine ovaries were 
decellularized in 500 micron slices then incubated in a 0.1% sodium dodecyl sulfate (SDS) solution 
on a rotator at room temperature for 24 hours. Whole bovine ovaries were immersed in 0.1% SDS 
at 4°C for 3 weeks to keep ovaries intact. Primary ovarian cells were isolated from CD1 female 
mice and seeded onto the acellular bovine ovarian scaffold then cultured for 2 days. Two weeks 
following ovariectomy of young CD1 female mice, recellularized ovarian scaffolds, were 
transplanted underneath the kidney capsule. Ovarian grafts showed no significant difference in 
circulating estradiol and inhibin A levels, which indicated that the decellularized graft supported 
ovarian cell function. Additionally, ovariectomized mice, that did not undergo ovarian graft 
transplantation, retained a hymen, whereas the vaginal orifices of graft recipients opened 4 weeks 
post-surgery, similar to non-ovariectomized control mice. Similar methods were used by Jakus et 
al. 2017, to prepare ovarian tissue paper (OTP) composites, using small pieces of decellularized 
bovine ovaries and poly-lactic-co-glycolic acid (PLGA) (351). OTP was used to culture both 
secondary mouse follicles as well as human and bovine ovarian cortical strips. Secondary follicles 
cultured on OTP maintained normal spherical morphology after 4 days. In addition, ovarian 
cortical strips, cultured for up to 8 weeks on OTP demonstrated healthy primordial and primary 
follicles and increasing estradiol production from 1 to 6 weeks. In another study, Hassanpour et 
al. 2018 used sodium lauryl ester sulfate (SLES) to decellularize human ovaries and evaluated 
efficacy for primary ovarian cell transplantation (352). Slices (2 mm thick) of human ovarian 
cortex were decellularized for 48 hours within a 1% SLES solution and agitated on a magnetic stir 
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plate at room temperature. Ovarian tissues were then treated with 500 units/mL of DNase I for 24 
hours at 36°C. Halved ovaries were also decellularized with the 1% SLES with longer incubation 
times (30-40 days). Upon decellularization, scaffolds were reseeded with isolated primary ovarian 
cells from 8-day old female rats and cultured for 24 hours. Reseeded ovarian grafts were 
transplanted into the renal fat pad of 4-week old ovariectomized female rats. Ovariectomized 
female rats receiving the ovarian transplant showed evidence of somatic cells as well as significant 
differences in estradiol and progesterone within the serum when compared to non-grafted controls. 
Alshaikh et al. 2019 compared three different protocols for the decellularization of mouse ovaries 
(353). Three decellularization agents were examined including 0.5% SDS, 2% SDC and 1% Triton 
X-100. The results showed that SDS was superior for cellular removal but did not retain ECM 
components as well as SDC. Additionally, it was determined that decellularization with Triton X-
100 was incomplete; however, this is to be expected at lower concentrations. Eivazkhani et al. 
2019 compared the effects of SDS and sodium hydroxide (NaOH) for the decellularization of 
mouse, sheep and human ovaries (354). Acellular human ovarian scaffolds were reseeded with 
mouse ovarian cells and transplanted into ovariectomized mice. Ovarian cells transplanted onto 
scaffolds decellularized using NaOH showed improved metabolic activity and follicle structure 
reorganization in comparison to SDS treated scaffolds. Pors et al. 2019 used a decellularized 
human ovarian scaffold to examine recellularization of isolated human and murine stromal cells 
and pre-antral follicles (355). Ovarian scaffolds were prepared using 0.1% SDS for 18-24 hours 
with an additional 24-hour wash in 1 mg/mL DNase. Successful reseeding and transplantation of 
the ovarian scaffold resulted in follicle growth toward antral stage with follicle recovery rates 
ranging from 21-25% for murine and human cells respectively. Finally, Pennarossa et al. 2020 
generated a multi-step protocol for the decellularization of whole porcine ovaries (356). Porcine 
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ovaries were frozen for at least 24 hours at -80°C and thawed at 37°C for 30 minutes. Thawed 
tissues were transferred to a solution of 0.5% SDS for 3 hours then washed in 1% Triton X-100 
overnight, with each step occurring on an orbital shaker at 200 rpm. After a 9-hour washing step 
in deionized water (dIH2O), the ovaries were moved to a 2% SDC solution for 12 hours. The 
tissues were then subjected to three final washes in dIH2O for 2 hours each. Decellularized ovarian 
tissues displayed >98% reduction in comparison to native tissues with preservation of ECM 
components, such as collagen, elastin and GAGs. Acellular scaffolds reseeded with fibroblasts 
were shown to be non-cytotoxic and cytocompatible after 7-day culture. In summary, 
decellularization for ovarian tissues has shown promise for follicle culture and transplantation, 
which may lead to improved clinical outcomes for fertility preservation.                      
2.2.5 Regulatory Pathways for dECM Clinical Translation 
[Section adapted from Buckenmeyer et al. 2020 (357)] 
In general, any new biomedical therapy must be evaluated during pre-clinical animal 
studies prior to conducting clinical trials in human patients. Several dECM-based materials have 
been successfully commercialized and therefore may be used as a template to simplify the 
regulatory process (358). Historically, most dECM products declare as 510(k) medical devices or 
biologics with the Food and Drug Administration (FDA). Products classified as medical devices 
or biologics must satisfy several pre-clinical and clinical requirements that unequivocally 
demonstrates safety and efficacy. After the pre-clinical studies have occurred, either an 
Investigational Device Exemption (IDE), for medical devices, or an Investigational New Drug 
(IND) application, for biologics, must be approved by the FDA before proceeding into clinical 
studies, which can occur in several phases.  
 65 
Each phase level is designed to carefully examine specific effects of the product after 
treating a set of eligible patients. Phase I generally consists of a small cohort of test subjects and 
is primarily focused on evaluating material safety and identifying any potential side effects. In 
Phase II, the number of test subjects increases and further examines the safety and efficacy. Phase 
III is used to directly compare the experimental material to similar products with a much larger 
test population to determine its effectiveness and compile safe-use information. The data obtained 
from the varying phase levels are then used to support a Biological Product License (BLA) or a 
Premarket Approval (PMA) application. Once the application is approved, the product can be 
marketed, as it is considered to have satisfied the FDA requirements. 
2.2.6 Future Considerations for dECM Biomaterial Development 
[Sections adapted from Buckenmeyer et al. 2020 (357)] 
Pre-clinical and clinical success of dECM materials in various disease models have made 
them an intriguing option for applications within tissue engineering and regenerative medicine. 
Although they appear to have many advantages, there are still several challenges remaining for the 
appropriate design and implementation of these materials. Some of the major limiting factors that 
must be considered to maximize the effectiveness of this emerging approach are highlighted 
below.  
Tissue selection, based upon both source and age, can have a significant impact on dECM 
materials (359). Site-specific tissues or organs harvested from exclusive regions are inherently 
different, as their microenvironments are designed to promote a specific cell function. Therefore, 
these native tissues have unique mechanical, biochemical and topographical properties that can 
illicit vastly different cellular responses. The age of the source tissue has been implicated in 
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temporal changes to ECM composition, molecular profiles and mechanical properties, such as an 
increase in fibrosis, tissue stiffening and inflammation with aging (359). Furthermore, if tissues 
are non-human, there are additional concerns related to species-specific differences that could 
negatively impact dECM material integration. For example, xenogeneic transplantation poses a 
risk of host immune rejection and incompatible homology (360). The ECM composition of sourced 
tissues must also be factored into the selection process. Specifically, the ECM proteins and 
proteoglycans that comprise healthy native tissues. Organs throughout the body have vastly 
different ECM contents and therefore, may require matching the appropriate ECM constituents to 
improve remodeling outcomes within a tissue-specific disease model. Another related element to 
ECM organization is the material stiffness, porosity and fiber orientation, which have all been 
shown to impact cell fate (361). 
Once the ideal source of tissue has been selected, the decellularization method, reagents 
and post-decellularization treatments can further enhance or deplete critical biological signatures, 
such as tissue-specific growth factors and hormones. The use of enzymatic digestion to form 
hydrogel-based dECM materials can additionally alter the ultrastructural and mechanical 
properties. Particularly, stiffness and local ECM fiber organization within a hydrogel can change 
dramatically in comparison to native tissues. After dECM materials are implanted, they undergo a 
natural degradation process, with degradation times varying as a function of concentration and 
material composition. Therefore, dECM products must be carefully designed to optimize 
degradation times to promote regeneration of the damaged site. 
Next generation dECM materials will require an in depth understanding of the diseased 
tissue and the ideal conditions that will initiate robust tissue remodeling. The goal is to create 
biomimetic materials to support the physiological profile observed within healthy tissues. To 
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accomplish this, researchers must consider testing a range of decellularization methods and 
techniques that preserve both the structural and functional components of the tissues. Tissue 
selection and processing should be carefully determined as well as the effects of dECM 
supplementation with growth factors and stem cells. Isolation and enrichment of the soluble 
fraction from decellularized nervous system tissues may also help stimulate functional 
regeneration. Finally, the addition of crosslinking agents and advancements in 3D printing may 
allow for improved tunability of the mechanical, topographical and structural properties of dECM 
materials with user-specified micropatterning and porosity to help support normal cell function 
and development. 
 68 




Fertility preservation is an effort to restore fertility in young girls and women with cancer. 
Cytotoxic cancer treatments, such as chemotherapy, can significantly reduce the number of healthy 
follicles within the ovarian reserve, which may result in an impairment of fertility. Orthotopic 
transplantation of cryopreserved ovarian tissues have led to greater than 130 live-births worldwide; 
however, there remain risks associated with this procedure, including surgery-induced 
complications and potential transmission of residual malignant cells upon transplantation (149). 
To address the concern of malignant cells transmission, several groups have attempted to isolate 
ovarian follicles from the stromal cells to significantly reduce the chances for cancer recurrence. 
In vitro follicle maturation (IVM) has been recapitulated successfully from pre-antral follicles with 
the use of a variety of biomaterials, the most common being alginate. However, there has been 
limited success using IVM for human follicles with low rates of meiotically competent oocytes 
from immature follicles. Since it is difficult to accurately mimic the highly regulated ovarian 
environment that is necessary during folliculogenesis, several groups have turned to in vivo follicle 
maturation. In vivo follicle transplantation has led to live births in ovariectomized mice and has 
also showed efficacy for follicle maturation after subcutaneous implantation. Although these 
methods have shown the ability to restore fertility within ovariectomized mice, they have not been 
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tested within a chemotherapy model of infertility. Further, transplantation of follicles sequestered 
within a fibrin clot, would be infeasible in human patients due to the absence of a bursa within 
higher order mammals. Additionally, these approaches do not address the potential surgical 
complications that may result from follicle transplantation. Extracellular matrix-based 
biomaterials may have the potential to support the in vitro development and in vivo delivery of 
isolated follicles to restore fertility. Previously, decellularized ovarian ECM (dECM) scaffolds 
have been demonstrated to support short-term culture and transplantation of ovarian cells to 
effectively restore reproductive cycling in mice. Although these studies have resulted in functional 
hormone-producing ovarian follicles, they have not examined the use of dECM biomaterials to 
treat iatrogenic infertility. Therefore, we aim to develop methods to prepare ovarian-specific ECM 
hydrogels that can facilitate intraovarian follicle microinjection and support in vivo follicle 
development within chemotherapy-treated mice. 
3.1.2 Innovation 
The primary innovation of this work is the development of a decellularization protocol for 
the preparation of an ovarian-specific ECM (OECM) hydrogel. The second innovation is to 
implement the OECM hydrogel to facilitate the intraovarian microinjection of isolated follicles to 
establish an in situ ovary (ISO), which would allow the follicles to naturally integrate within the 
ovarian cortex. There are several advantages of using a hydrogel-facilitated microinjection 
approach. First, hydrogels have the ability to form in situ at physiological conditions. This would 
allow for a minimally invasive form of delivery, such as microinjection. The procedure could be 
similar to transvaginal oocyte retrieval for IVF; however, rather than collecting oocytes, follicles 
would be delivered into the ovary. This procedure is performed under ultrasound guidance and 
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could be done less-invasively than ovarian tissue transplantation. Secondly, microinjection can 
accommodate a high concentration of immature follicles within a small volume of hydrogel. 
Further, a successful in situ delivery may improve long-term follicle viability, maturation and 
natural pregnancy. This could also permanently replace the need for in vitro follicle culture, which 
has proven to be difficult for immature follicles. Primordial follicles, which reside within the 
ovarian cortex, are the most abundant follicle type within cryopreserved tissues. Therefore, it is 
imperative to implement methods that have the potential to support their maturation in vivo to 
improve fertility outcomes. The ability to inject follicles immediately upon isolation may also 
reduce the amount of time follicles are exposed to unfavorable culture conditions. This could make 
a significant difference in follicle viability upon transplantation. Finally, current biomaterial 
approaches reported in the literature have not performed ovarian follicle/tissue transplantation 
within animals treated with chemotherapy. If successful, this approach would not require patients 
to undergo an ovariectomy procedure. Instead, patients in remission could receive a minimally 
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3.1.3 Central Hypothesis and Specific Aims 
The central hypothesis for this thesis work is that ovarian tissue-derived hydrogels retain 
ovarian-specific components and provide a natural biomaterial to support the delivery of follicles 
in a chemotherapy-induced POF mouse (Figure 16). There are two main aims that were examined 
to test this central hypothesis. 
 
Figure 16 Central Hypothesis 
The graphical representation shows our hypothesis for restoring fertility in patients with chemotherapy-induced 
premature ovarian failure (ciPOF). Intraovarian microinjection of an ovarian-specific ECM (OECM) hydrogel can 
support the delivery and long-term survival of exogenous primordial follicles (green) within an in situ ovary (ISO). 
The damaged ovarian tissue primarily consists of stromal cells (yellow) and a depleted population of endogenous 
follicles (gray). 
Specific-aim 1: To decellularize porcine ovarian tissues for the derivation of an ovarian-specific 
ECM hydrogel. 
 
Specific-aim 2: To determine the efficacy of ovarian hydrogels to support intraovarian follicle 
microinjection in a chemotherapy-induced POF mouse model. 
 72 
4.0 Aim 1: Development of an Ovarian-Specific Extracellular Matrix Hydrogel 
4.1 Introduction 
Ovarian-related pathologies, such as infertility, ovarian cancer, polycystic ovarian 
syndrome and endometriosis, significantly reduce the quality of life for female patients, which 
produces a tremendous clinical and economic burden. Advancements in tissue engineering, 
specifically the development of tissue-specific extracellular matrix (ECM) biomaterials, may be 
used as both a diagnostic tool and therapeutic to help study and treat ovarian disease. One 
application for ovarian-specific ECM materials may be for female cancer patients that are 
negatively impacted by the effects of chemotherapy, radiation or gynecologic surgery. 
Specifically, alkylating agents used for chemotherapy are cytotoxic to cells and can significantly 
reduce the ovarian follicle population, which may result in either fertility impairment or a complete 
loss of fertility. This condition is classified as iatrogenic premature ovarian failure (POF) or 
primary ovarian insufficiency (POI). 
Current strategies to restore function rely upon the cryopreservation of ovarian tissues and 
autotransplantation upon remission. However, patients who are at elevated risk for malignant cell 
contamination may be advised to avoid this therapy altogether to eliminate their chance for cancer 
cell transmission and recurrence. An alternative approach to restore fertility for cancer patients is 
through the isolation of immature follicles from the surrounding stromal cells, which may contain 
residual cancer cells. Ovarian follicles contain a basement membrane that protects the growing 
follicle from malignant cell invasion; therefore, the cancer risk can be significantly reduced, 
allowing follicles to be developed and fertilized in vitro. In vitro follicle maturation (IVM) has 
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been used successfully in several species, including humans. However, although our current 
understanding of folliculogenesis has improved, it remains incomplete. Therefore, in order to 
enhance the maturation efficiency of immature follicles toward meiotically competent oocytes it 
is important to recapitulate the ovarian microenvironment. 
ECM biomaterials have been shown to improve healing through the ECM’s intrinsic 
remodeling capability. Several tissue types have shown beneficial effects after treatment with 
ECM and most recently decellularized ovarian ECM (OECM) scaffolds have been used to 
facilitate the culture and transplantation of isolated follicles. However, ECM derivatives, such as 
hydrogels have yet to be tested as a three-dimensional substrate for IVM. To test the efficacy of 
this approach, we have developed a protocol for the decellularization of porcine ovaries to obtain 
an acellular ovarian-specific scaffold. Decellularized tissues were characterized to show the 
removal of immunogenic content without significantly disrupting the native architecture and ECM 
components of the ovary. Detection of residual ovarian-specific hormones also indicated that the 
decellularization process was mild enough to preserve native biomolecules. Solubilized acellular 
ovarian scaffolds successfully formed into hydrogels at physiological conditions. In vitro follicle 
maturation was tested to determine OECM hydrogel cytocompatibility and led to meiotically 
competent oocytes that could be fertilized up to the two-cell embryo stage. This outcome 




The objectives of the first aim are: (1) to develop an effective decellularization protocol for 
porcine ovarian tissues using mild detergents to remove immunogenic material and preserve an 
ovarian-specific ECM components; (2) to characterize the acellular ovarian tissue in comparison 
to native porcine ovaries to examine the effects of decellularization including: ovarian tissue 
morphology, cell presence and distribution, double stranded DNA (dsDNA) quantification, DNA 
size, collagen and glycosaminoglycan content, ovarian-specific ECM and ovarian-specific 
hormones and growth factors; (3) to derive a hydrogel from decellularized ovarian ECM and define 
its viscoelastic properties, gelation kinetics and ultrastructure; (4) to evaluate the application of 
ovarian ECM hydrogels for both whole ovary culture and in vitro follicle maturation.   
4.3 Methods 
4.3.1 Ovarian Tissue Decellularization  
Porcine ovaries from adolescent pigs (< 1 year old) were obtained from the local abattoir 
(Thoma Meat Market, Saxonburg, PA) and immediately stored on ice and frozen at -20°C. Ovaries 
were thawed, cleared of surrounding connective and adipose tissues, diced into cubes (~0.125 cm3) 
and transferred to a flask containing cold Milli-Q water (MQ). The diced tissues were shaken 
manually with MQ until residual blood was visibly removed then replaced with fresh MQ and 
stored overnight at 4°C. The tissues were then rinsed in fresh MQ on an orbital shaker for 30 
minutes at 300 rpm. The flask containing tissue was then replaced with a pre-warmed solution of 
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0.02% trypsin and 0.05% EDTA then agitated on a magnetic stir plate for one hour at 37°C. 
Ovaries were then rinsed three times with MQ for 15 minutes each at 300 rpm. A 3% solution of 
Triton X-100 was then added to the flask and shaken for one hour at 300 rpm. A subsequent wash 
cycle was implemented to remove any residual detergents from the tissues. Each wash cycle 
consisted of several distilled water rinses with manual shaking (until no bubbles were observed), 
then alternating washes of MQ and 1X PBS to neutralize and release detergent that was bound to 
the tissues. After the wash cycle was completed, the fluid was replaced with fresh MQ and stored 
overnight at 4°C. A 4% sodium deoxycholate solution was added to the flask and agitated for 1 
hour at 300 rpm. A subsequent wash cycle was performed then the tissue was replaced with fresh 
MQ and stored overnight at 4°C. The ovarian tissues were then depyrogenated and disinfected 
with a 0.1% peracetic acid and 4% ethanol solution for two hours at 300 rpm. This step was 
followed by three rinses in MQ, 1X PBS, MQ for 15 minutes each at 300 rpm then stored in fresh 
MQ at 4°C overnight. To ensure adequate removal of detergents and other chemical reagents one 
final series of washes with MQ, 1X PBS, MQ were performed for 15 minutes each at 300 rpm. 
The decellularized tissues were then stored at -80°C prior to lyophilization. 
4.3.2 Detergent Assay 
A commercial detergent assay kit (G-Biosciences - CMC-535) was used to assess the level 
of residual detergents during the decellularization protocol for ovarian tissues. Initial attempts at 
preparing decellularized ovarian tissues yielded hydrogels with poor cytocompatibility in the 
presence of macrophages. The detergent assay was used to ensure complete detergent removal 
from the decellularization effluent washes. Briefly, effluents were collected starting after the first 
Triton X-100 wash, and each subsequent wash step (12 steps in total), throughout the remainder 
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of the decellularization process. The assay sensitivity could detect detergent concentrations as high 
as 0.1% down to as little as 0.0016%. 50 µL of standards, Triton X-100 and sodium deoxycholate 
(SDC), and samples from each effluent step were added to the a 96 well plate in duplicate. 100 uL 
of 1X CMC-535 Fluorescent Dye was added to each well and mixed for 2 minutes on a shaker 
followed by the addition of 50 uL of 1X CMC-535 Reagent 2 to each well, which was also mixed 
for 2 minutes. The plate fluorescence intensity was excited at 485 nm and read at an emission of 
535 nm. Separate standard curves for both Triton X-100 and SDC were prepared and sample 
detergent concentrations were calculated.      
4.3.3 Functional Assessment of Macrophages 
A focus of the Brown lab is to evaluate the innate immune response to biomaterials. To 
study this, protocols have been established in the lab to isolate primary macrophages from the bone 
marrow and study their phenotype and function. To this end, we used these protocols to evaluate 
the cytocompatibility of ovarian hydrogels to replicate similar results regarding macrophage 
behavior in the presence of other common tissue-specific ECM hydrogels. The following sub-
sections describe these methods.   
4.3.3.1 Isolation of Bone Marrow-Derived Macrophages 
Bone marrow-derived macrophages were harvested from 2 month or 18-20 month-old 
C57BL/6 mice as previously described (362). Briefly, femurs and tibiae were collected and were 
stripped of muscle and connective tissue. Bones were cut at either end to expose bone marrow. Sterile 
syringe and needles were used to extract bone marrow using macrophage differentiation media. Bone 
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marrow lysate was reconstituted in media and filtered through a sterile cell filter. Cells were cultured 
for 7 days in media to induce macrophage differentiation, with media changes once every 2 days. 
4.3.3.2 Macrophage Treatment  
Following 7 days of differentiation culture as described above, macrophages were treated with 
acute polarizing regimens to distinguish phenotypes over 24 hours. Naïve macrophage (M0) controls 
were treated with basal media for 24 hours. M1 (20 ng/mL IFN-γ and 100 ng/mL LPS) and M2 (20 
ng/mL IL-4) polarizing cytokines were used to create positive controls for classical pro- and anti-
inflammatory macrophages. ECM degradation products were neutralized and diluted to 250 μg/mL in 
macrophage media to isolate biochemical effects of degradation products and prevent structural 
moieties from forming. Pepsin buffer (1 mg/mL pepsin in 0.01 M HCl) diluted in macrophage media 
was used as a control. Another set of treatment groups involved 24-hour exposure of ECM degradation 
products followed by 24-hour treatment with either the M1 or M2 treatment regimen, referred to as 
ECM→M1 or ECM→M2, respectively. 
4.3.3.3 Indirect Immunolabeling for Arginase and iNOS Expression  
Cells were fixed with 2% paraformaldehyde (PFA) for 30 minutes then washed in 1XPBS. 
Cells were incubated in blocking buffer (2% donkey serum, 1% bovine serum albumin (BSA), 0.1% 
Triton X-100, 0.1% Tween-20) for 1 hour at room temperature. Primary antibodies were diluted in this 
blocking buffer as follows and incubated overnight at 4 °C: iNOS (1:100, Abcam 3523) or Arginase-
1 (1:200, Abcam 91279). iNOS is a classical M1 macrophage marker whereas Arginase-1 is a classical 
M2 macrophage marker. Cells were washed in 1XPBS then incubated in the appropriate fluorescently-
labeled secondary antibody solution in blocking buffer for 1 hour at room temperature (donkey anti-
rat Alexa Fluor 488, Invitrogen, 1:200; donkey anti-rabbit Alexa Fluor 488, Invitrogen, 1:300). Cell 
nuclei were counterstained with DAPI. Cells from 2 month old mice were imaged nine times in the 
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center of each well at 10X magnification using automated position capture function to remove bias 
from subjective image location acquisition. All imaging was performed on an Axio observer T1 
microscope. Mean fluorescence intensity of cells was analyzed using Cell Profiler software (Broad 
Institute). Briefly, DAPI images were used by the program to identify cell nuclei then FITC images 
were used to identify cell borders around the identified nuclei. The mean fluorescent intensity was 
calculated by averaging the pixel intensities (scale of 0 to 1) across the entire cell area. Mean 
fluorescence intensity values were averaged for all imaged cells in each well. 
4.3.3.4 Phagocytosis Assay  
Following treatments, cells were assayed for phagocytic ability using Vybrant Phagocytosis 
Assay Kit (Invitrogen). Cells were incubated in FITC-labeled dead E. Coli particles for 2 hours in the 
cell culture incubator. Following washing, the cells were fixed with 2% PFA for 30 minutes then 
washed with 1X PBS. Cells were counterstained with DAPI then imaged and analyzed as described 
above. 
4.3.3.5 Nitric Oxide Assay  
Following treatments, 50 μL of supernatant from macrophages were transferred into a fresh 
plate. Nitric oxide content was assayed using a Greiss Reagent system. Briefly, 50 μL of sulfanilamide 
(1% in 5% phosphoric acid) was added to supernatants for 10 minutes. Then, 50 μL of 0.1% N-1-
napthylethylenediamine in water was added to the mixture for an additional 10 minutes. The 
absorbance at 540 nm was measured using a BioTek SYNERGY HTX spectrophotometer. 
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4.3.4 Characterization of Decellularized Tissues  
Decellularized ovarian tissues were characterized using a number of qualitative and 
quantitative measures to verify the removal of genetic material and maintenance of ovarian specific 
proteins. Native and decellularized ovarian tissues were formalin-fixed, paraffin-embedded, 
sectioned and stained using several histological procedures including DAPI (4’,6-diamidino-2-
phenylindole), Hematoxylin and Eosin (H&E), and Periodic Acid-Schiff (PAS). Antibodies 
specific for ECM proteins Collagen I (Abcam, ab34710) and IV (Abcam, ab6586), Fibronectin 
(Abcam, ab23751), and Laminin (Abcam, ab11575) were evaluated using DAB (3,3′-
Diaminobenzidine) immunohistochemistry (IHC) staining to show conservation after 
decellularization. IHC tissue sections were counterstained using Hematoxylin QS (Vector Labs, 
Cat No. H-3404) to show cell nuclei in contrast with resident ECM proteins. DNA removal was 
quantified using a PicoGreen dsDNA assay kit (Invitrogen, Cat No. P11496). A 2.5% agarose gel 
was used to detect DNA fragments at a resolution between 25 and 1000 bp. Hydroxyproline (HYP) 
and sulfated glycosaminoglycans (sGAG) assays were performed to approximate collagen and 
sGAG content. Native and decellularized ovarian tissues were placed in M tubes and homogenized 
using a gentleMACS dissociator (Milltenyi) in a High Salt Buffer (pH 7.5, 50 mM Tris base, 150 
mM NaCl, 5 M CaCl2, 1% Triton-X-100, 1% Halt protease inhibitor cocktail, Pierce 
Biotechnology, Rockford, IL). After homogenization, M tubes containing samples were 
centrifuged at 4000 x g at 4°C for 5 minutes. Decellularized tissues required more starting mass 
for homogenization to have a higher concentration of total protein to more closely match native 
samples. Protein concentrations of the extracted tissues were determined using the BCA Protein 
Assay Kit (Pierce Biotechnology, Rockford, IL) and 50 µg total protein was used per sample for 
all assays. Ovarian specific growth factors including insulin growth factor (IGF-1) (R&D Systems, 
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Minneapolis, MN), 17β-estradiol (R&D Systems, Minneapolis, MN), progesterone (Abcam, 
Cambridge, MA), anti-Müllerian hormone (AMH) (R&D Systems, Minneapolis, MN), and 
vascular endothelial growth factor (VEGF) (Abcam, Cambridge, MA), were quantified using 
enzyme-linked immunosorbent assays (ELISA). 
4.3.4.1 Hematoxylin & Eosin (H&E) Staining 
Tissue sections were deparaffinized in a series of re-hydrating steps to water. Slides were 
placed in Harris Hematoxylin for 8 minutes, followed by two 30 second washes in distilled water 
(dIH20). Tissues were then placed in a solution of acid alcohol (5% glacial acetic acid and 95% 
ethanol) for 1 minutes, then washed twice in dIH20 for 30 seconds each. The next step was a 15 
second dip in Scott’s H2O and 2 washes in dIH20 for 1 minute each. The final step was a stain in 
Eosin for 2 minutes before the tissues were dehydrated in a series of graded alcohols and xylenes. 
The slides were coverslipped using Permount and allowed to dry prior to imaging. All reagents 
were prepared fresh and filtered to remove concentrated particulate. 
4.3.4.2 Periodic Acid Schiff (PAS) Staining 
Periodic acid Schiff (PAS) staining was used to identify glycogens within the extracellular 
matrix of ovarian follicles. Native and decellularized ovarian tissues were fixed in 10% formalin 
for a minimum of 24 hours then paraffin-embedded. Tissue sections were cut at 5 micron and 
deparaffinized prior to staining. Slides were dipped in 0.5% periodic acid for 5 minutes then rinsed 
in distilled water. Tissues were then transferred to Schiff reagent for 15 minutes then washed in 
lukewarm tap water for 5 minutes. Ovarian sections were then counterstained with Harris modified 
hematoxylin (4 dips), washed for 1 minute in running water and treated with acid alcohol (95% 
Ethanol and 1% HCl) for an additional minute (3 dips). Tissues were washed in running water for 
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another minute then placed in saturated lithium carbonate (15 mg/mL water) for 6 dips. Tissues 
were washed in running water then dehydrated prior to being coverslipped with Permount. The 
PAS stain will show glycogen, mucin, fungi and basement membranes in a red/purple color and 
cell nuclei in a blue color. 
4.3.4.3 Hydroxyproline (HYP) and Sulfated Glycosaminoglycans (sGAG) Assays 
Native and decellularized ovarian tissues biochemical assays were performed to assess 
hydroxyproline (HYP) and sulfated glycosaminoglycan (sGAG) content. Lyophilized native and 
decellularized ovarian tissues were digested at 10 mg/mL in a papain solution (0.125 mg/mL 
papain; 0.100 M cysteine; 0.100 M Na2HPO4; 0.010 M Na2EDTA) overnight at 50°C. HYP content 
was assessed by adding 50 μL of 2N NaOH to 50 μL of the papain digests and hydrolyzing the 
samples at 110 °C for 18 hours. Samples were neutralized with 5N HCl. After neutralization, each 
of the following reagents were added to each sample and vortexed sequentially: 100 µL of 0.01M 
copper sulfate, 2.5N NaOH and 6% H2O2. 400 µL of 3N sulfuric acid was then added to each 
sample, vortexed and incubated at 80°C for 5 minutes, then allowed to cool. Once the samples had 
cooled, 200 μL of 5% DMAB (dimethylamino benzaldehyde) solution in propanol was added to 
each tube. Samples were incubated at 70°C for 15 minutes then transferred to a 96 well plate. To 
detect HYP content, the absorbance was read at 525 nm. sGAG content was assessed by adding 
50 µL of papain digested samples (in triplicate) onto a 96 well plate. A standard curve was prepared 
using chondroitin-6-sulfate. 250 µL of dimethylmethylene blue (DMMB) reagent was added to 
each sample and standard well and the absorbance was read at 540 nm to detect sGAG content. 
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4.3.4.4 Immunohistochemistry 
Paraffin tissue sections were deparaffinized using xylenes and graded alcohols and re-
hydrated in water. Proteinase K was added to tissues and incubated in a humidity chamber for 5 
minutes at room temperature. Slides were transferred into citric acid buffer (2.1 g/L citric acid; 
500 uL Tween 20; Type I H2O up to 1 L; pH: 6.0) at 100°C for 20 minutes, then moved to ice for 
an additional 20 minutes. Tissues were washed in 1X PBS 3 times for 3 minutes each and then 
moved to a 3% hydrogen peroxide solution in 1X PBS for 30 minutes at room temperature. This 
was followed by two 1X TBST (tris-buffered saline + 0.1% Tween 20) washes for 5 minutes each. 
A 1X PBS wash was performed two times for 3 minutes each. The non-specific epitopes were 
blocked using blocking buffer (5% Donkey Serum; 2% BSA; 0.1% Tween 20; 0.1% Triton X-100; 
1X PBS) for 2 hours at room temperature, followed by the addition of primary antibodies diluted 
in the same blocking buffer and allowed to incubate overnight at 4°C in a humidified chamber. 
After overnight incubation the tissues were washed three times in 1X PBS for 3 minutes each. 
Once the unbound primary antibodies were washed away, biotinylated-secondary antibodies (in 
blocking buffer) were added for 30 minutes at room temperature in a humidified chamber. The 
unbound secondary antibodies were removed with another three washes in 1X PBS for 3 minutes 
each. Vecta-Shield ABC (avidin-biotinylated enzyme complex) Reagent (Vector Laboratories) 
was added to the tissues for 30 minutes at room temperature then washed three times in 1X PBS 
for 3 minutes each. A 4% DAB (3, 3'-diaminobenzidine) solution, acting as a substrate, produces 
a brown precipitate in the presence of ABC reagent, which is bound to the target antibody complex. 
The incubation time was variable; however, it generally did not exceed 1 minute. The DAB 
solution was quickly removed by rinsing in water for about two minutes then counterstained using 
Hematoxylin QS for about 45 seconds. The Hematoxylin was also washed immediately in water 
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to avoid overstaining. Slides were dehydrated using graded alcohols and xylenes then coverslipped 
in Permount before imaging.              
4.3.5 Ovarian ECM Digestion and Hydrogel Formation  
Lyophilized ovarian ECM powder was solubilized via enzymatic digestion. A stock ECM 
digest concentration of 10 mg/mL was prepared by adding 200 mg of ECM powder to a 20 mL 
solution of pepsin (Sigma P7012) at a concentration of 1 mg/mL (≥2,500 units/mg) dissolved in 
0.01 N hydrochloric acid (HCl). Digestion was facilitated with an overhead mixer between 700-
2000 RPM for less than 48 hours. Hydrogels were formed after neutralizing and buffering the 
solubilized ovarian ECM to physiological conditions. Two hydrogel concentrations (4 and 8 
mg/mL) were prepared for testing and experimentation. A pre-gel solution was made on ice using 
the following components: (i) 10 mg/mL OECM digest stock (volume determined by desired final 
concentration) (ii) 0.1 N NaOH (1/10th the volume of the digest), (iii) 10X PBS (1/9th the volume 
of the digest), and (iv) 1X PBS or L-15 medium (brought up to final volume). The solution was 
pulsed 3 times on a vortexer to mix then stored at 4°C until further use.       
4.3.6 Hydrogel Characterization  
Ovarian hydrogel ultrastructure was assessed using scanning electron microscopy (SEM). 
Hydrogels were fixed using 2.5% glutaraldehyde, washed with 1X PBS and post-fixed with 
osmium tetroxide (OsO4). Samples were washed again in 1X PBS to dilute the OsO4 then they 
were slowly exsiccated through a series of increasing ethanol concentrations. Complete 
dehydration was achieved using a critical point dryer. Dried hydrogels were sputter-coated with 
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gold/palladium particles and imaged at 8,000X magnification. A proprietary Matlab code was used 
to analyze SEM images to determine various hydrogel fiber network characteristics (363). Ovarian 
hydrogel bulk viscoelastic properties were determined using a dynamic parallel plate (40 mm) 
rheometer (AR-2000 TA instruments). A time sweep (5% strain, 1 rad/s) was used to demonstrate 
the effect of ECM concentration on both the storage (G’) and loss (G’’) modulus. Turbidimetric 
gelation kinetics were performed on the ovarian hydrogels as previously described (364, 365). 
4.3.7 Whole Ovary Culture 
Sohlh1-mCherry transgenic newborn mouse (Rajkovic Lab) ovaries were excised and 
cultured using ovarian ECM hydrogels at varying ECM concentrations to determine the impact on 
ovarian follicle development. Ovarian hydrogels were prepared in Millicell Cell Culture Inserts – 
PTFE, 0.4 µM pore size (Millipore Sigma) at concentrations of 2, 5 and 10 mg/mL. Similarly, 
collagen and PTFE were used as controls. Sohlh1 newborn mouse ovaries were removed and 
placed on top of the various substrates and cultured for 7 days in ovarian culture medium 
(Appendix Table 3) in a cell culture incubator at 37°C (95% air, 5% CO2). Media was changed 
every 2-3 days and ovaries were monitored carefully. After 7 days, whole ovaries were imaged 
under confocal microscopy to determine the presence of Sohlh1+ cells, which is a marker of 
primordial follicles. Sohlh1+ cells were quantified based upon the volume of the cells using 
Volocity software (Appendix Figure 20). Subsequently, ovaries were fixed in paraformaldehyde 
and embedded in paraffin wax. Ovaries were serial sectioned and stained using a variety of 
histological methods, including H&E, PAS, and IF/IHC. IHC was performed to identify cells 
expressing NOBOX, which is an oocyte-specific marker. IF was used to identify additional oocyte 
markers, Sohlh1 (oocyte cytoplasm) and Sohlh2 (oocyte nucleus), after cell culture. 
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4.3.8 In Vitro Follicle Culture 
Follicle culture media was prepared and sterile filtered prior to follicle isolation (Appendix 
Table 4). Ovaries were excised from 14-16 day old C57BL/6 or B6/D2 female mice and transferred 
into warmed Dissection Media. Note: Dissection Media containing L-15 medium is pH stable out 
of cell culture incubator and was pre-warmed to 37°C in a water bath or incubator without CO2. 
Once the ovaries were excised and the bursa was removed, ovaries were moved to a 9-well glass 
plate containing fresh Dissection Media. Secondary follicles were mechanically isolated from the 
ovaries using 27-½ gauge insulin syringes. One needle was used to secure the ovary while the 
other needle as used to gently scrape away the stromal cells and connective tissues to free the 
follicles. After 20-40 secondary follicles were isolated from each ovary, they were selected using 
an oocyte transfer pipette and placed in a 30 mm petri dish containing Maintenance Media then 
transferred to the cell culture incubator. This step was repeated until follicles had been removed 
from each ovary. Each isolation was performed at room temperature and limited to 30 minutes of 
exposure outside of the incubator to improve follicle viability. Prior to culture, follicles were 
encapsulated in 8 mg/mL ovarian hydrogels or 0.5% alginate. 8 mg/mL OECM pre-gel was 
prepared on ice, then multiple 100 µL droplets or a single 500 µL droplet were pipetted into a 35 
mm petri dish on ice. Secondary follicles were then picked up with minimal volume, 5 at a time, 
and placed on top of each OECM droplet.  A 100 µL positive displacement pipette was set to 25 
µL and picked up about half of the total volume of OECM pre-gel then the other portion of the 
volume was used to pick up the follicle in the OECM droplet. The 25 µL follicle-OECM was 
perpendicularly pipetted into sterile and warmed 1X PBS or L-15 in a 35 mm petri dish. After 10 
follicle-OECM hydrogel droplets were formed the petri dish was transferred into an incubator at 
37°C (no CO2) for an additional 20 minutes. After 20 minutes, the encapsulated follicles were 
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transferred into fresh Maintenance Media. This process was repeated until all follicles were 
encapsulated. Alginate encapsulation was performed similarly. First, 4-5 mL of calcium solution 
(50 mM CaCl2; 140 mM NaCl; 500 mL Type I H2O; pH:7.4) was pipetted into a 35 mm petri dish. 
Then, 500 µL of 0.5% alginate was placed in the center of another 35 mm petri dish. After all 
follicles were encapsulated, they were transferred to a 96-well plate containing pre-
warmed/equilibrated Growth Media (100 µL). Follicles were cultured for 11 days, with Growth 
Media changes every two days (50 µL removed and frozen for hormone analysis), adding 50 µL 
of freshly prepared Growth Media. After every media change, follicles were imaged under a bright 
field microscope (with a humidified chamber) to assess follicle morphology and growth. Follicle 
diameters were determined using ImageJ to track development throughout the culture period. At 
day 11, antral follicles that surpassed 300 µm in diameter were transferred to Maturation Media 
for 14-16 hours to induce ovulation and the resumption of meiosis. After 16 hours, follicles were 
nicked with a insulin needle to free the oocyte. Oocyte meiotic competence was evaluated 
morphologically and characterized into three categories: (1) Germinal Vesicle (GV) Stage – 
oocytes retain nuclear membrane and do not re-enter meiosis (2) Germinal Vesicle Breakdown 
(GVBD) – oocytes resume meiosis without a nuclear membrane, and (3) Metaphase II (MII) which 
extrudes the first polar body. In vitro fertilization (IVF) studies of MII oocytes produced from 
follicle cultures were conducted by Dr. Yi Sheng (Orwig Laboratory). 
4.3.9 Statistical Analysis 
All data were expressed as mean ± s.e.m and plotted using GraphPad Prism 7.02. To detect 
differences between native and decellularized tissues for dsDNA, HYP, and sGAG concentrations 
as well as changes in hydrogel fiber network characteristics, the individual means were compared 
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using an unpaired, two-tailed, t-test. To detect differences in hormone retention between native 
tissues (ovary vs. bladder) and decellularized (OECM vs. UBM), the mean ranks were compared 
using an unpaired, one-way ANOVA (Kruskal-Wallis) with adjusted P-values calculated based 
upon Dunn’s multiple comparisons test. Exact P-values resulting from the statistical analysis are 
presented within each figure.    
4.4 Results and Discussion 
4.4.1 Biomaterial Selection and Tissue Processing 
The damaging effects of chemotherapy on ovarian tissues significantly reduces a patient’s 
follicle population, which has a direct impact on fertility and endocrine function (162, 366, 367). 
In addition, chemical treatments have been implicated in microvasculature and stromal cell 
irregularities culminating in a compromised environment for cell survival (162). These 
unfavorable conditions cause a depletion of ovarian follicles and may reduce follicle viability post-
transplantation (76, 221). Therefore, to re-establish the ovarian tissue microenvironment and 
repopulate the depleted endogenous follicle pool, we have bioengineered an ISO using an OECM 
hydrogel to facilitate intraovarian follicle transplant and provide a temporary niche to aid follicle 
engraftment and survival (Figure 16).  
To prepare acellular ovarian scaffolds, porcine ovaries (Figure 17b) were diced (Figure 
17c) then processed using a series of enzymatic and detergent-based washes to remove 
immunogenic material (Figure 17d). Trypsin and EDTA were used in tandem to disrupt cell 
adhesions to the ECM prior to treatments with Triton X-100 and sodium deoxycholate, which act 
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to permeabilize cell membranes. Tissues transitioned from an initial opaque appearance to 
translucent at the conclusion of the decellularization steps (Figure 17e). Intermediate water 
washing steps proved to be critical for the complete removal of residual cells and detergent from 
the tissues. Once the tissues were completely decellularized they were frozen, lyophilized (Figure 




Figure 17 Ovarian Tissue Processing 
b, Young (< 1 year old) porcine ovaries were sourced for decellularization. c, Ovaries were diced into small cubes 
(~0.125 cm3). d, Cubed ovaries were added to a flask and decellularized using enzymes and detergents. e, 
Decellularized ovarian tissues appeared white. f, Ovaries were frozen then lyophilized to remove their water content. 




To demonstrate the effective removal of immunogenic components and preservation of 
extracellular matrix (ECM) components, we performed a set of histological stains and biochemical 
assays. Fluorescence staining with 4′,6-diamidino-2-phenylindole (DAPI) showed few, if any 
nuclei present within the decellularized tissues in comparison to native ovarian tissue controls 
(Figure 18h). H&E (Figure 18i) and PAS (Figure 18j) staining showed a clear retention of ovarian 
microarchitecture, such as structural aspects of follicles, zona pellucida and corpora lutea, while 
sparse cellular content was visible. This highlights the effectiveness of our method to successfully 
remove cellular content, while causing limited disruption of tissue-specific morphology. Scanning 
electron micrographs (SEM) further detailed the dense cellular content within native ovarian 
tissues, whereas decellularized tissues appeared to show vacated follicular compartments 
surrounded by a porous scaffold (Figure 18k).  A PicoGreen assay demonstrated greater than 98% 
reduction of dsDNA between native (9126 ± 1988 ng/mg) and decellularized (262.4 ± 59.96 
ng/mg) samples (Figure 19l). Gel electrophoresis further showed a lack of DNA (Appendix Figure 
10) within the decellularized tissues in comparison to native controls, suggesting a reduced 
potential for disease transmission and adverse immune reaction to cellular contents. Collagen and 
sulfated glycosaminoglycans (sGAG) were also examined to determine their retention post-
decellularization. A hydroxyproline (HYP) assay was used to estimate the total collagen content 
within the scaffold. Native tissues (61.95 ± 6.064 ug/mg) contained significantly less HYP as a 
percentage of dry weight than decellularized tissues (153.3 ± 8.564 ug/mg) due to the loss of 
cellular mass; however, under this assumption the total collagen content within the decellularized 
scaffold as a fraction of the dry weight of all components was enriched after decellularization 
(Figure 19m). sGAG content was also preserved with no significant difference observed between 




Figure 18 Histological and Ultrastructural Evaluation of Native and Decellularized Ovarian Tissues 
h-j, Native (top row) and decellularized (bottom row) images of DAPI (200 μm scale), H&E (100 μm scale), and 
periodic acid-Schiff (PAS) (100 μm scale) staining determined that decellularized tissues removed cellular content 
while preserving ovarian tissue morphology. k, Scanning electron micrographs (SEM) show a dense cellular 
ultrastructure in native ovaries in comparison to a porous decellularized scaffold (10 μm scale). 
 
 
Figure 19 DNA and ECM Component Quantification 
l, PicoGreen assay indicated that decellularized ovarian tissues significantly reduced the dsDNA concentration. Data 
represent mean ± s.e.m. of ng/mg dry weight. P values by unpaired, two-tailed t-test. m, Hydroxyproline (HYP) 
concentration was significantly enriched in decellularized tissues and n, sulfated-Glycosaminoglycans (sGAG) 
levels did not differ significantly between native and decellularized samples. Data represent mean ± s.e.m. of μg/mg 
dry weight. P values by unpaired, two-tailed t-test. 
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4.4.2 Ovarian Tissue Specificity Present Post-Decellularization 
The ECM is composed of a tissue-specific milieu of secreted proteins and proteoglycans 
that support the desired functions of a tissue (271, 288, 330). In the ovary, the ECM undergoes 
dynamic remodeling throughout the reproductive life span and is essential for regulating 
folliculogenesis and ovulation (2, 368). Specifically, OECM provides mechanical support, 
maintains normal cell morphology, promotes cell proliferation and steroidogenesis (2). 
Additionally, the OECM can sequester hormones and growth factors within the follicle niche to 
facilitate paracrine and endocrine signaling (2, 369). Therefore, the retention of OECM proteins 
would be ideal for supporting follicles within the ISO. To determine the effects of decellularization 
on ECM retention, we characterized a subset of the most highly expressed OECM proteins: 
Collagen I, Collagen IV, laminin and fibronectin (2, 368, 370, 371). Immunohistochemistry 
revealed that Collagen I was distributed uniformly in the native samples, with a slight enrichment 
surrounding the thecal compartments of the follicles in decellularized samples (Figure 20a). 
Collagen IV was also labeled, showing definitive staining within the basement membrane of the 
epithelial layer and the basal lamina of individual follicles in both the native and decellularized 
groups (Figure 20b). Similar to Collagen IV, laminin was predominantly found within the basal 
lamina adjacent to the theca interna surrounding follicles (Figure 20c). Finally, fibronectin 
appeared to be conserved throughout the ovarian tissues with little to no differences in distribution 




Figure 20 Characterization of Ovarian-specific ECM Proteins 
Immunohistochemistry (IHC) images of native (top row) and decellularized (bottom row) ovarian tissues shows the 
distribution of extracellular matrix proteins:  a, Collagen I was uniformly expressed throughout each of the tissues.  
b, Collagen IV appeared to concentrate in the basal lamina of the follicles and the basement membrane surround the 
epithelial layer of the ovary. c, Laminin was present within the thecal compartment and d, Fibronectin was evenly 
expressed in lower concentrations; however, antibody staining was enriched in decellularized tissues. Scale, 100 μm. 
 
 Ovarian hormones and growth factors sequestered in the OECM orchestrate both local and 
systemic endocrine function. The hypothalamic-pituitary-gonadal (HPG) axis stimulates the 
production of ovarian hormones, which act to modulate hormone production in a cyclic manner 
(13). The hypothalamus produces gonadotropin releasing hormone (GnRH), which stimulates the 
secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH) (13). FSH and LH 
trigger the production of estradiol, follicle development and ovulation. Estradiol from the 
ovulatory follicle and progesterone from the resulting corpus luteum provide feedback to either 
inhibit or stimulate hormone secretion from the hypothalamus and pituitary (13). Spatiotemporal 
production of these reproductive hormones primarily facilitates follicle development, ovulation 
and pregnancy (13).  
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For this study, we were particularly interested in hormones produced by the ovary due to 
their roles in follicle selection. Specifically, anti-Müllerian hormone (AMH), estradiol and 
progesterone. AMH is produced by granulosa cells of pre-antral and antral follicles (120). As 
AMH levels increase, it can inhibit the recruitment of primordial follicles and decrease the 
responsiveness of large pre-antral/antral follicles to FSH. AMH is one of the few hormones that 
are produced during the early stages of folliculogenesis, which are widely recognized as 
gonadotropin-independent (4). Estradiol is also produced by follicular cells and is most commonly 
known for its role in the LH surge which triggers ovulation; however, at low concentrations, 
estradiol can function as a negative regulator of FSH, which inhibits follicle growth (4, 10). The 
corpus luteum, which arises from the cells of ovulatory follicles and is present during the late luteal 
phase, produces high levels of progesterone, which is necessary for maintaining pregnancy. Like 
estradiol, progesterone can also inhibit FSH production further delaying follicle growth (4).  
We hypothesized that these ovarian hormones may be important for the survival of 
transplanted immature follicles within the ISO. Therefore, to elucidate the effects of 
decellularization on the disruption of these components, we processed a large batch of 100 ovaries 
separated into five groups (n = 20 per group) analyzed as independent samples (Appendix Figure 
1). As controls, we used both native and decellularized urinary bladder matrix (UBM), collected 
from female pigs and prepared as previously described (372), to determine if there were significant 
differences in the hormone concentrations based upon tissue source. After tissue homogenization, 
protein was extracted from each group and tested using biochemical assays for AMH, estradiol 
and progesterone.  ELISA quantification determined that decellularized OECM samples contained 
low concentrations of each of the ovarian-specific analytes: AMH (1031 ± 192.9 pg/mg), estradiol 
(113.8 ± 19.63 pg/mg) and progesterone (2697 ± 1890 pg/mg) (Figure 21e-g). Native ovaries 
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contained significantly higher levels of estradiol and progesterone when compared to native 
bladder. Furthermore, decellularized OECM had significantly higher progesterone values than 
UBM. Additional analytes associated with follicle development, insulin-growth factor (IGF-1) and 
vascular endothelial growth factor (VEGF), were also tested but were undetectable within the 




Figure 21 Quantification of Ovarian-specific Hormones after Decellularization 
Ovarian hormones secreted by follicular cells were quantified from total protein using enzyme-linked 
immunosorbent assays (ELISAs). e, Anti-Müllerian hormone (AMH) was measured at high concentrations within 
native ovarian tissues but was reduced by >50% within decellularized OECM. f, Estradiol concentrations were 
significantly higher in native ovary in comparison to native bladder and OECM was two-fold greater than UBM. g, 
Progesterone levels were significantly greater in both native ovary and OECM in comparison to native bladder and 
UBM, respectively. ELISAs were conducted using 100 ovaries batched into 5 independent samples (n = 20 ovaries). 
Data represent mean ± s.e.m. of pg/mg of total protein. P values by one-way ANOVA using Kruskal-Wallis with 
Dunn’s multiple comparisons test. Native (ovary and bladder) and decellularized groups (OECM and UBM) were 
compared separately. 
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4.4.3 Ovarian Hydrogel Properties Modified with Changes in ECM Concentration 
Once the decellularized tissues were processed and characterized, we solubilized the 
OECM then neutralized the digested material to prepare the hydrogels. Visibly transparent 
hydrogels were formed after exposure to physiological conditions for approximately 20 minutes 
(Figure 22a). We used SEM to evaluate the hydrogel ultrastructural properties at 4 and 8 mg/mL 
ECM concentrations (Figure 22b,c). Fiber network characteristics were quantified using SEM 
imaging and digital image analysis (363) with concentration dependent effects observed with a 
significant increase in fiber diameter, fiber length and bulk porosity in the 8 mg/mL OECM 
hydrogel group (Figure 23d-h). These results indicate that individual fiber and large-scale network 
properties such as the bulk porosity are dependent on ECM concentration. 
 
 
Figure 22 Ovarian ECM Hydrogel Formation and Ultrastructure 
a, Solubilized ovarian ECM (OECM) formed transparent hydrogels upon neutralization and exposure to physiologic 
conditions. b-c, Scanning electron micrographs (SEM) show a fibrous and porous architecture at both 4 and 8 




Figure 23 OECM Hydrogel Fiber Network Analysis 
d-h, Hydrogel fiber network characteristics were quantified using a Matlab algorithm with significant increases in 
fiber diameter, fiber length and porosity directly correlating with an increase in OECM concentration. Data represent 
mean ± s.e.m. for all parameters. P values by unpaired, two-tailed t-test. 
  
 
To determine the viscoelastic properties of the OECM hydrogel, we performed a 
rheological time sweep on varying ECM concentrations. An increase in ECM concentration from 
4 to 8 mg/mL appeared to correlate with an elevated storage (G’) and loss (G’’) moduli (Figure 
24i,j). However, there were no observable differences in turbidimetric gelation kinetics with a 
change in ECM concentration (Figure 24k). Gelation time varied based upon the test conditions. 
Specifically, direct conduction with the Peltier plate achieved complete gelation approximately 15 
minutes prior to the samples heated via convection during gelation kinetics testing. However, once 




Figure 24 OECM Hydrogel Viscoelastic Properties and Gelation Kinetics 
Viscoelastic material properties were quantified using a rheological time sweep. i, Storage (G’) and j, Loss (G’’) 
moduli increased dramatically with the higher 8 mg/mL OECM concentration. k, Turbidimetric gelation kinetics 
showed that gelation was conserved with a change in OECM concentration. 
4.4.4 In Vitro Applications 
4.4.4.1 Whole Ovary Culture 
Ovarian hydrogels were prepared in a sterile environment in a cell culture hood at three 
ECM concentrations: 2, 5 and 10 mg/mL. Pre-casted hydrogels were immersed in either 
Waymouth’s MB 7521 or DMEM/F12 media then moved into the incubator at 37°C (95% air; 5% 
CO2). Ovaries were microdissected from day 0 Sohlh1-mCherry (S1CF) newborn mice and placed 
in warmed 1X PBS. mCherry fluorescent protein was used to track primordial follicles indicated 
by the presence of Sohlh1+ cells in the nucleus and cytoplasm of oocytes. Extracted ovaries were 
trimmed to remove the outer membrane as well as any remaining tissues then transferred on top of 
the hydrogels at each concentration and returned to the incubator. Media was changed every 2-3 
days and follicle development was assessed after 7 days in culture. Ovaries cultured in 
Waymouth’s media were characterized after 7 days using several staining and imaging techniques. 
Ovaries were fixed in paraformaldehyde (PFA), serial-sectioned and stained. PAS staining was 
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used to validate follicle morphology and viability showing that ovaries cultured on top of the 
hydrogels maintained a normal structure and size at each concentration, however there was little 
growth evident. (Figure 25A) Primordial follicles appeared to dominate at 2 mg/mL ECM  
concentration and slightly decrease in number at 5 mg/mL concentration. This was verified 
quantitatively using confocal imaging of the whole ovary. A volumetric analysis was performed 
using Volocity software by measuring the fluorescence signal from Sohlh1+ cells indicating the 
presence of early oocytes. Volocity parameters were set to classify a minimum fluorescence 
intensity volume of 500 µm3 as a detectable viable oocyte for detection (+/- 10 micron threshold 
for oocyte diameter). No significant differences were observed between the total number of 
Sohlh1+ cells in the 2 mg/mL ovary culture compared to the wild-type mouse ovary extracted at 
day 7 suggesting that lower ECM concentration or stiffness represents similar culture conditions 
to in vivo follicle development. (Figure 25A) The decrease of detectable Sohlh1+ cells in the 5 
mg/mL hydrogel culture may indicate that an increase in stiffness could drive follicle maturation. 
As a comparative study, a second experimental group of ovaries were cultured in Dulbecco’s 
Modified Eagle Medium/F-12 Nutrient Mixture (DMEM/F-12) to determine how a change in 
culture conditions affected follicle growth. Immunohistochemistry (IHC) using a NOBOX oocyte-
specific marker was used to qualitatively diagnose oocyte viability and follicle development. 
NOBOX is a homeobox gene that is present in oocytes from early to late stage follicles throughout 
development. IHC results from these experimental groups showed little to no oocyte growth across 
all hydrogel cultured ovaries (Figure 25B). NOBOX stain in the wild-type ovary was indicative of 
follicle growth with several primary follicles migrating towards the center of the ovary and 




Figure 25 In Vitro Culture of Newborn Mouse Ovaries 
Newborn mouse ovaries were cultured on top of ovarian hydrogels for 7 days. (A) Periodic acid Schiff (PAS) 
staining shows a comparison of ovarian tissue morphology at varying hydrogel ECM concentrations in comparison 
to normal WT mouse ovary extracted at day 7. Confocal imaging of Sohlh1+-mCherry cells indicated by red 
fluorescence. Sohlh1+ cells were quantified using Volocity software. (B) Immunohistochemistry (IHC) and 
immunofluorescence (IF) staining show oocyte presence using three oocyte markers: NOBOX, Sohlh1, and Sohlh2. 






This data suggests that the ovarian hydrogels inhibit development, which contradicted the previous 
cultures immersed in Waymouth’s media. Immunofluorescence (IF) imaging was performed using 
Sohlh1 (spermatogenesis and oogenesis specific basic helix-loop-helix 1) and Sohlh2 markers, 
which appear in early primordial follicles.  Images taken at 60X magnification support the 
qualitative IHC data showing both Sohlh1+ (red) and Sohlh2+ (green) oocytes, which confirms 
the presence of early oocytes (Figure 25B). 
4.4.4.2 In Vitro Follicle Maturation 
One of the potential techniques for restoring fertility is the use of in vitro follicle maturation 
(IVM). Therefore, we hypothesized that OECM hydrogels would be a cytocompatible biomaterial 
that could support follicle maturation. To test this hypothesis, we developed methods to isolate, 
encapsulate and culture secondary mouse follicles using OECM hydrogels (Figure 26). This 
process was significantly improved over multiple trials by altering the material properties, follicle 
encapsulation methods and culture conditions. In the first trial, 2 mg/mL OECM hydrogels (100 
µL) were used to encapsulate a single or group (8) of mechanically isolated primary to secondary 
follicles. The ECM concentration was selected based upon the results from the whole ovary 
culture, which produced the several viable follicles within the ovary after 7-day culture. Once the 
follicle(s) were resuspended in the OECM hydrogel they were pipetted into a 96 well plate. 100 
µL of growth media was added to the top of the encapsulated follicles and they were cultured for 
6 days. After 6 days, all the follicles in both the single and grouped samples had atypical 
morphology and showed minimal to no growth (Appendix Figure 25 and Appendix Figure 27). In 
addition, the OECM hydrogel appeared to be shriveled and degenerating. 
We observed that the OECM hydrogels used in the whole ovary cultures led to poor 
outcomes from higher ECM concentrations, which we initially attributed to their corresponding 
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mechanical properties. However, the initial mechanical properties of the OECM hydrogels were 
not significantly different (Appendix Figure 21). This conclusion led us to test the 
cytocompatibility of the original OECM hydrogel with a non-ovarian cell type. We hypothesized 
that the initial protocol for ovarian decellularization did not clear residual detergents, which could 
lead to poor cell viability. To test this hypothesis, we cultured primary macrophages in the presence 
of our OECM hydrogel. After running several standard macrophage functional assays, we 
determined that the initial decellularization protocol did not sufficiently remove detergents and 
caused cytotoxic effects on macrophages. A revised ovarian decellularization protocol, with 
additional washes, was developed to remove residual detergents (Ovarian Tissue 
Decellularization). Upon repeating these macrophages assays, with the new OECM hydrogel, the 
results showed similar outcomes to other tissue-specific materials, such as porcine small intestine 
submucosa (SIS) and urinary bladder matrix (UBM) (Appendix Figure 5, Appendix Figure 6, 
Appendix Figure 7, Appendix Figure 8). In addition, an unintended byproduct of the revised 
decellularization protocol was a significant increase in the storage and loss modulus of the OECM 
hydrogel (Figure 24). This allowed us to better evaluate the effects of biomaterial stiffness on 
follicle cultures. 
During the second trial of IVM, we implemented the newly refined OECM hydrogel at two 
ECM concentrations (4 and 8 mg/mL) as well as a 0.5% alginate as a control material. The OECM 
hydrogels and follicles were prepared similarly to the first trial, whereas the alginate was used in 
a droplet form, floating within the growth media (Appendix Figure 30). The results of this second 
trial showed that rather than degenerating, the follicles grew slightly within the OECM hydrogel 
groups with greater growth observed in the 4 mg/mL in comparison to the 8 mg/mL OECM group 
(Appendix Figure 31 and Appendix Figure 32). Interestingly, the 0.5% alginate group did not grow 
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after 6 days in culture. After repeating these experiments under the same conditions, we saw 
similar outcomes, with modest growth after six days of culture. However, mouse follicles generally 
experience exponential growth around 6 days, which was not observed in our second trial.  
One of the main factors in follicle recruitment and growth is follicle stimulating hormone 
(FSH). Therefore, we hypothesized that using a human recombinant FSH (Gonal-F), which is a 
clinical-grade FSH used for human patients in the IVF clinics, would stimulate exponential growth 
of the follicles encapsulated in OECM hydrogels. In addition, we changed the follicle 
encapsulation method to a droplet form of OECM to improve the diffusion of nutrients into the 
follicle, which also mimics the alginate encapsulation (Appendix Figure 29). These changes were 
applied in the third trial of IVM, using an 8 mg/mL OECM hydrogel (n = 13 follicles), 8 mg/mL 
UBM hydrogel (n = 5) and 0.5% alginate hydrogel (n = 5) to encapsulate the follicles. After 
encapsulation, the follicle diameters were measured and averaged, with initial mean follicles 
diameters of the following: OECM = 104.14 µm; UBM = 97.54 µm; Alginate = 124.44. On day 8 
of follicle culture, the mean diameters, showed little to no growth across all the groups; however, 
one of the follicles from the OECM group retained normal morphology and grew exponentially 
after day 6 of culture (Figure 27 and Figure 28). By day 10, this follicle surpassed 300 µm in 
diameter and retained excellent morphological integrity, which clearly demonstrated follicle 
support. Further, this follicle successfully resumed meiosis I and released a polar body, indicative 
of a meiotically-competent MII oocyte (Figure 29). A follow up study was conducted to test the 
fertilization potential for MII oocytes derived from OECM encapsulated follicles. A group of 97 
follicles (127.72 mean starting diameter) were isolated from B6/D2 female mice and encapsulated 
within 8 mg/mL OECM hydrogels then cultured for 12 days. By day 12, 20 of the follicles reached 
antral stage (20.6%), but only 14 of the oocytes were able to be released for in vitro fertilization 
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(IVF). Of the 14 oocytes undergoing IVF, only one was successfully fertilized and developed into 
a two-cell embryo (Figure 30). These results suggest that OECM hydrogels are a suitable substrate 
for in vitro follicle maturation. Although, further improvements in follicle isolation and 


















Figure 29 Cumulus Oocyte Complex (COC) and MII Oocyte 
 
 




In aim 1, we developed a decellularization method to obtain an acellular porcine ovarian 
scaffold. We demonstrated that a protocol combining physical agitation with a series of enzymes, 
detergent, acids and alcohols was an effective strategy to remove cells while preserving ovarian-
specific components. Specifically, histological comparisons between native and decellularized 
ovarian tissues showed cellular ablation in decellularized samples with evidence of evacuated 
follicle structures. A quantitative decellularization assessment resulted in >98% reduction of 
dsDNA as well as a severe fragmentation of DNA. In addition, hydroxyproline and 
glycosaminoglycan content was not significantly different native samples. Ovarian-specific ECM 
proteins were also evaluated using immunohistochemical staining and clearly showed the presence 
of collagen I, collagen IV, laminin and fibronectin within decellularized samples. Additionally, 
decellularized tissues retained detectable levels of ovarian-specific hormones, such as anti-
Müllerian hormone, progesterone and estradiol. Acellular ovarian-specific ECM scaffolds were 
enzymatically digested and successful formed into hydrogels. SEM image analysis showed 
significant differences between 4 and 8 mg/mL OECM hydrogel concentration changes in 
hydrogel fiber network properties, including fiber diameter, length and porosity. Hydrogel 
viscoelastic properties were assessed and showed that increased ECM concentration can result in 
a direct increase of both the storage and loss modulus. However, gelation kinetics determined that 
there was no difference in the rate of turbidity between changing ECM hydrogel concentrations. 
Finally, OECM hydrogels were tested for compatibility for both whole newborn mouse ovary 
culture and in vitro follicle maturation (IVM). Newborn mouse ovaries cultured on top of 2mg/mL 
OECM hydrogels showed no significant difference in Sohlh1-positive oocytes in comparison to 
native tissues. Further, 8 mg/mL OECM hydrogel droplets were used to encapsulate pre-antral 
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follicles for IVM. This platform led to the maturation of meiotically-competent MII oocytes after 
12 days of culture. In addition, in vitro fertilization of MII oocytes obtained from OECM hydrogel 
-mediated IVM resulted in a two-cell embryo.         
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5.0 Aim 2: Ovarian ECM Hydrogel-Facilitated Intraovarian Follicle Microinjection 
5.1 Introduction 
Ovarian follicles are the major functional component of the ovary that produce hormones 
(e.g., estrogen) and mature eggs for ovulation (13, 373). Chemotherapy or radiation treatments for 
cancer or other conditions can deplete the ovarian follicle pool, which can result in premature 
ovarian failure (POF), compromising ovarian hormone production and fecundity (162, 366, 367). 
Ovarian tissue cryopreservation is an experimental option used to preserve the fertility of patients 
who cannot afford to delay gonadotoxic treatment. Upon remission, the ovarian cortex, which is 
rich in primordial follicles, can be transplanted back into patient survivors and ovulate eggs to 
establish natural pregnancies or be stimulated to produce eggs for in vitro fertilization (IVF) (172-
175, 219, 374-377). However, ovarian tissue transplantation remains an invasive surgical 
procedure and may not be appropriate in cases where there are concerns that ovarian tissues may 
harbor malignant cells (e.g., leukemia). To address these concerns, other experimental alternatives, 
such as in vitro follicle maturation (IVM) and artificial ovaries, use isolated immature follicles 
from the stroma to reduce the potential for co-transplantation of cancer cells. These methods have 
been used to achieve complete folliculogenesis and have led to live-births in mouse models of 
infertility, but several challenges must be addressed prior to their clinical translation for human 
patients. 
A major obstacle for restoring reproductive function and fertility has been the inability to 
accurately mimic the dynamic environment of the human ovary. While our understanding of the 
spatiotemporal biochemical and mechanical signaling cues is improving, it remains poorly defined. 
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However, a potential solution may be to simply use the ovary as a transplantation site for isolated 
immature follicles. Intraovarian transplantation has successfully been used to generate live-births 
from infertile mice after the delivery of female germline stem cells (224-226). However, the 
existence and characterization of ovarian stem cells in the human adult ovary remains controversial 
(223, 378). Alternatively, intraovarian transplantation of isolated primordial follicles may have 
potential to replenish the ovarian reserve of cancer patients post-chemotherapy. A previous attempt 
to restore fertility after chemotherapy using this approach resulted in follicle apoptosis (379). 
However, we hypothesized that immature follicles may benefit from the additional support of a 
biomaterial to facilitate integration within the ovary to promote long-term survival and function.    
One option to improve the effectiveness of intraovarian follicle transplantation, integration 
and survival could be the use of a tissue-specific extracellular matrix (ECM) hydrogel. ECM 
hydrogels have been used to treat a spectrum of diseases due to their intrinsic ability to promote 
tissue remodeling (359). To obtain ECM hydrogels, tissues must be first be decellularized to 
remove immunogenic components. This process can be used to preserve an ovarian-specific 
acellular scaffold, which is composed of a unique profile of ECM proteins, proteoglycans, 
glycoproteins and sequestered biomolecules (ie. growth factors) (380, 381). Recently, bovine 
ovaries were decellularized using sodium dodecyl sulfate (SDS) to obtain a tissue-specific 
scaffold, which was re-seeded with healthy follicles and transplanted to restore cycling in an 
ovariectomized mouse (218). Similarly, porcine and bovine ovaries were decellularized then 
processed into ECM composite “tissue papers”, demonstrating a versatile approach for short-term 
in vitro culture of nonhuman primate and human ovarian cortical strips (351). Another group has 
cited the use of SDS to decellularize human ovarian medulla and cortical tissues, but observed low 
follicle recovery rates upon recellularization and xenotransplantation after three weeks (382).  
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Although SDS is highly proficient at cellular ablation, acellular scaffolds prepared with SDS have 
led to adverse cytocompatibility, which has been directly linked to the disruption of matrix 
composition (330, 383-386). Therefore, we aimed to develop a new decellularization method using 
less abrasive detergents to obtain acellular scaffolds that can be processed into an ovarian-specific 
ECM (OECM) hydrogel to facilitate intraovarian follicle transplant.   
5.2 Objectives 
Here, we report a strategy to enhance intraovarian microinjection of isolated immature 
follicles using an OECM hydrogel. Porcine ovaries were decellularized then characterized to 
evaluate the effects on ovarian tissue-specificity. Solubilized acellular ovaries were formed into 
OECM hydrogels to facilitate the delivery of primordial follicles and establish an in situ ovary 
(ISO). Chemotherapy-induced POF (ciPOF) mice were prepared using busulfan and 
cyclophosphamide to observe the impact on follicle populations. Intraovarian microinjection of 
immature follicles resuspended in OECM hydrogels were performed using ciPOF mice to examine 
the efficacy of this approach for donor follicle survival and reproductive outcomes. Transplanted 
ciPOF female mice were bred to fertile males and produced donor follicle (GFP+)-derived 
progeny. In human patients, the OECM/follicle suspension could be injected non-invasively under 
the ovarian cortex using a transvaginal ultrasound-guided approach similar to how eggs are 
retrieved from the ovary for in vitro fertilization (IVF). Therefore, this approach may offer a 
minimally-invasive method to support and enhance the transplantation of immature follicles to 




5.3.1 Chemotherapy-Induced POF Model  
Busulfan (Sigma) and cyclophosphamide (MP BioMedicals LLC) were combined to 
induce POF in 6-week old female mice (NCR nu/nu). Recipient mice were given a single 
intraperitoneal injection (IP) and allowed to recover up to 3 weeks prior to treatment. To initially 
identify the most appropriate chemotherapy regimen, four doses of busulfan/cyclophosphamide 
(mg/kg) were tested: (1) 12-100 (2) 12-200 (3) 24-100 (4) 24-200. Ovaries were excised, fixed in 
4% paraformaldehyde (PFA), paraffin embedded and serial sectioned.  
5.3.2 Weigert’s Hematoxylin Picric Methyl Blue Staining 
To evaluate the effects of chemotherapy on ovarian follicle populations, ovarian tissues 
were stained using Weigert’s hematoxylin picric acid methyl blue. Tissues were deparaffinized to 
water and then placed in Weigert’s Iron Hematoxylin for 10 minutes. Weigert’s Iron Hematoxylin 
was prepared by making a 1:1 mixture of Solution A (1 gram of Hematoxylin in 95% ethanol in 
100 mL) and Solution B (Ferric Chloride – 29% aqueous 4 mL; dIH2O 95 mL; HCl 1 mL). Slides 
were washed in running tap water for 2 minutes until a blue-purple color is visible. The tissues 
were counterstained with Picric Acid Methyl Blue (Picric acid saturated (aqueous)  250 mL; 
Methyl Blue 100 mg) for 6 minutes and washed three times in 95% ethanol for 3-5 minutes each. 
The stained tissues were dehydrate in a series of graded alcohols and xylenes then coverslipped 
using Permount. After staining, the tissues were imaged under an upright bright field microscope. 
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5.3.3 Ovarian Follicle Classification and Quantification 
Ovarian tissue sections stained with Weigert’s Hematoxylin Picric Methyl Blue were 
evaluated based on the reduction of follicle populations due to chemotherapy dosing. Every 10 
sections were examined for total follicle number and classified by stage and quantified. The 
following criteria was used to count the follicles: (1) each follicle contains a visible oocyte (2) 
Primordial follicles have a single layer of squamous granulosa cells (3) Primary follicles have 
single layer of cuboidal granulosa cells (4) Secondary follicles contain two to four layers of 
granulosa cells without the development of an antrum (5) Antral follicles have greater than four 
layers of granulosa cells as well as definitive antrum. The total number of follicles were quantified 
then the sum was multiplied by 10 to provide an estimate of the entire follicle population of each 
ovary. 
5.3.4 Enzymatic Follicle Isolation 
Ovarian donor follicles were prepared using a physical and enzymatic isolation procedure 
adapted from Kim et al. (220). First, ovaries were excised from 6-14 day old female (DBA GFP/nu) 
mice and placed into pre-warmed L-15 (Leibovitz’s) medium. The ovaries were freed from the 
bursa using a pair of forceps and an insulin needle. Ovaries were then minced using insulin needles 
into small fragments to aid in digestion. The ovarian fragments were then added to 1.5 mL 
microcentrifuge tube containing 500 μL of pre-warmed L-15 medium and 50 μL of Liberase TM 
(13 Wünsch units/mL). The tubes were then placed on an orbital shaker and agitated at 200 rpm 
for 5 minutes at 37°C. After incubation, the mixture was then pipetted gently for one minute to 
help free the ovarian follicles from connective tissue. This process was repeated once more until 
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the ovaries had been completely dissociated. After digestion, 10% fetal bovine serum was added 
to the mixture to halt enzyme activity. The tubes were placed in an upright position for 15 minutes 
at 37°C to allow follicles to sediment. After 15 minutes, 200 μL of the mixture was carefully 
pipetted off the top to remove singular ovarian cells. The samples were centrifuged at 100g for 5 
minutes to loosely concentrate the follicles. A syringe needle was used to gently remove the 
medium from the tube without disturbing the follicle pellet. Finally, the pellet was resuspended in 
a chilled 4 mg/mL OECM pre-gel and kept on ice in preparation for follicle microinjection. 
5.3.5 Ovarian Tissue Decellularization  
Porcine ovaries from adolescent pigs (< 1 year old) were obtained from the local abattoir 
(Thoma Meat Market, Saxonburg, PA) and immediately stored on ice and frozen at -20°C. Ovaries 
were thawed, cleared of surrounding connective and adipose tissues, diced into cubes (~0.125 cm3) 
and transferred to a flask containing cold Milli-Q water (MQ). The diced tissues were shaken 
manually with MQ until residual blood was visibly removed then replaced with fresh MQ and 
stored overnight at 4°C. The tissues were then rinsed in fresh MQ on an orbital shaker for 30 
minutes at 300 rpm. The flask containing tissue was then replaced with a pre-warmed solution of 
0.02% trypsin and 0.05% EDTA then agitated on a magnetic stir plate for one hour at 37°C. 
Ovaries were then rinsed three times with MQ for 15 minutes each at 300 rpm. A 3% solution of 
Triton X-100 was then added to the flask and shaken for one hour at 300 rpm. A subsequent wash 
cycle was implemented to remove any residual detergents from the tissues. Each wash cycle 
consisted of several distilled water rinses with manual shaking (until no bubbles were observed), 
then alternating washes of MQ and 1X PBS to neutralize and release detergent that was bound to 
the tissues. After the wash cycle was completed, the fluid was replaced with fresh MQ and stored 
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overnight at 4°C. A 4% sodium deoxycholate solution was added to the flask and agitated for 1 
hour at 300 rpm. A subsequent wash cycle was performed then the tissue was replaced with fresh 
MQ and stored overnight at 4°C. The ovarian tissues were then depyrogenated and disinfected 
with a 0.1% peracetic acid and 4% ethanol solution for two hours at 300 rpm. This step was 
followed by three rinses in MQ, 1X PBS, MQ for 15 minutes each at 300 rpm then stored in fresh 
MQ at 4°C overnight. To ensure adequate removal of detergents and other chemical reagents one 
final series of washes with MQ, 1X PBS, MQ were performed for 15 minutes each at 300 rpm. 
The decellularized tissues were then stored at -80°C prior to lyophilization. 
5.3.6 Ovarian ECM Digestion and Hydrogel Formation  
Lyophilized ovarian ECM powder was solubilized via enzymatic digestion. A stock ECM 
digest concentration of 10 mg/mL was prepared by adding 200 mg of ECM powder to a 20 mL 
solution of pepsin (Sigma P7012) at a concentration of 1 mg/mL (≥2,500 units/mg) dissolved in 
0.01 N hydrochloric acid (HCl). Digestion was facilitated with an overhead mixer between 700-
2000 RPM for less than 48 hours. Hydrogels were formed after neutralizing and buffering the 
solubilized ovarian ECM to physiological conditions. Two hydrogel concentrations (4 and 8 
mg/mL) were prepared for testing and experimentation. A pre-gel solution was made on ice using 
the following components: (i) 10 mg/mL OECM digest stock (volume determined by desired final 
concentration) (ii) 0.1 N NaOH (1/10th the volume of the digest), (iii) 10X PBS (1/9th the volume 
of the digest), and (iv) 1X PBS or L-15 medium (brought up to final volume). The solution was 
pulsed 3 times on a vortexer to mix then stored at 4°C until further use.       
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5.3.7 Fluorescent-Labeling of Ovarian ECM Hydrogels 
A fluorescently-tagged TRITC-labeled ovarian ECM hydrogel was prepared to track the 
gel post-injection and determine whether the gel localized within the site of injection (Appendix 
Figure 35). To prepare the labeled gel, 40 µL tetramethylrhodamine isothiocyanate (TRITC) stock 
solution was added to 160 uL of dimethylformamide (DMF) and vortexed to solubilize the TRITC. 
The TRITC solution was added to 5 mL of 10 mg/mL ovarian digest within a 25 mL flask. The 
pH was adjusted to 10 through the addition of 0.1 N NaOH, approximately 4.8 mL. The TRITC 
and OECM were mixed on a magnetic stir plate overnight at 4°C to allow TRITC conjugation to 
the free amines within the OECM digest. The pH was then re-adjusted to 2 to halt the reaction. 
The TRITC-OECM hydrogel was dialyzed for one week to remove unbound TRITC from the 
OECM digest. TRITC-OECM was then frozen and lyophilized for long-term storage. Lyophilized 
TRITC-OECM was resuspended in water and evaluated at various dilutions. To prepare a TRITC-
labeled gel, 1:20 of the total hydrogel volume was replaced with the TRITC-OECM stock, which 
provided a strong signal under a TRITC fluorescent filter to track the OECM hydrogel. 
5.3.8 In Vivo Follicle Microinjection 
The experimental design and rationale for animal use (described in IACUC Protocol #: 
18103002) were reviewed and approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee (IACUC). Eight-week old ciPOF female mice (NCR nu/nu) mice were 
anesthetized and placed on the operating table with their back exposed. A single midline dorsal 
incision (0.5 cm) was made using small scissors. Subcutaneous connective tissue was then freed 
from the underlying muscle on each side using blunt forceps. Once the ovary was located under 
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the thin muscle layer, a small incision (<1 cm) was made to gain entry to the peritoneal cavity. The 
edge of the incision was held with tooth forceps, while the ovarian fat pad was removed to expose 
the ovary and surrounding bursa. A small volume (<10 μL) of chilled follicle-OECM pre-gel was 
transferred to a glass needle (filament Cat#: FB245B and borosilicate glass micro pipette Cat#: 
B100-75-10) then secured to a pressurized microinjection system. Eppendorf microinjection 
system (TransferMan NK2 and FemtoJet) was used for follicle delivery and surgical manipulation 
observed under a Nikon SMZ stereomicroscope. The loaded needle was positioned perpendicular 
to the ovary and guided into the ovarian cortex, where the follicle-OECM mixture was slowly 
injected at a constant pressure ranging from 50-250 hPa. For each injection, approximately 1.0x103 
follicles were transplanted. The same surgical and injection procedures were performed 
contralaterally. The follicle-injected ovaries were placed back into the abdominal cavity, the 
muscle layers were sutured, and the skin incision was stapled. 
5.3.9 Mating Study  
Two weeks after injection both the follicle recipient and non-injected control ciPOF nude 
female mice were bred to male nude mice (NCR nu/nu, Taconic). The breeding was conducted for 
three cycles, which concluded at 106 days on average. Pups born were fostered within 1 day with 
NCR nu/+ (Taconic) females due to the lack of developed mammary glands in the nude mouse 
strain used for recipients, then they were weaned at 3-4 weeks old. Pups (DBA-GFP/nu-, Orwig 
Lab) inherited from the follicle injected recipients were selected based on physical traits consisting 
of fur, dark eyes or GFP expression. Genotyping was performed using mouse tail DNA and 
standard PCR with the following primers: GFP forward primer sequence (GAA CGG CAT CAA 
GGT GAA CT); GFP reverse primer sequence (TGC TCA GGT AGT GGT TGT CG); β-actin 
 117 
forward primer sequence (CGG TTC CGA TGC CCT GAG GCT CTT); β-actin reverse primer 
sequence (CGT CAC ACT TCA TGA TGG AAT TGA) (primers prepared by Integrated DNA 
Technologies, inc.). PCR products were run on a 2.5% agarose gel and imaged under UV light. 
The resulting pups were grown to 8 weeks and bred for fertility status. Second generation breeding 
pairs consisted of a GFP/nu- experimental female and DBA/2 control male (Jackson), a GFP/nu- 
experimental female and GFP/nu- experimental male, and a DBA/2 control female and GFP/nu- 
experimental male. Breeding pairs were separated after two weeks. 
5.3.10 Immunofluorescence Staining and Imaging of Microinjected Ovaries 
Ovaries were excised at the conclusion of the third breeding cycle and fixed in 4% PFA 
overnight then embedded in paraffin. Tissues were serial sectioned and stained with DAPI and α-
GFP antibody to evaluate the presence of endogenous and transplanted (GFP+) cells/follicles. 
Sectioned tissues were deparaffinized and placed in citric acid buffer (2.1g/L citric acid; 500 µL 
of Tween 20; 1L of dIH2O at pH: 6.0) at 100°C for 20 minutes and then on ice for an additional 
20 minutes. The slides were removed and washed twice in dIH2O for two minutes each the twice 
in 1X PBS for 2 minutes each. The tissue sections were then placed in a solution of copper sulfate 
(10 mM) and ammonium acetate (50 mM) in 1 L of dIH2O for 20 minutes in a water bath at 37°C. 
Following this step, the tissues were washed twice in 1X TBST (tris-buffered saline and 0.1% 
Tween 20) for 3 minutes each and repeated using 1X PBS for two washes of 2 minutes each. The 
tissue sections were circles with a PAP pen and then covered with blocking buffer (5% Donkey 
Serum; 2% BSA; 0.1% Tween 20; 0.1% Triton X-100; 1X PBS) for 2 hours at room temperature, 
followed by the addition of primary antibodies diluted in the same blocking buffer and allowed to 
incubate overnight at 4°C in a humidified chamber. The primary antibodies were removed and 
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tissues were washed five times in 1X PBS for 2 minutes each. Fluorescently-tagged secondary 
antibodies (diluted in blocking buffer) were added to the tissues and incubated for 30 minutes at 
room temperature protected from light. The tissues were washed five times in 1X PBS for 2 
minutes, mounted in FluoroGel plus DAPI and coverslipped prior to imaging. Four ovaries were 
evaluated per treatment group. Nikon Eclipse Ti-U inverted microscope and NIS Elements 
software was used to capture representative images of GFP-positive structures within each tissue 
section. DAPI and FITC channels were taken separately and merged to demonstrate the population 
of endogenous and GFP expressing cells, respectively. 
5.3.11 Ovarian Single-Cell Isolation, Antibody Staining, and Flow Cytometry 
To characterize the cellular populations over time, whole ovaries were excised and placed 
in chilled L-15 medium. Insulin syringes were used to free the ovaries from the bursa. Ovaries 
were transferred into 500 µL of warmed 1X Hank’s Balanced Salt Solution (HBSS) where they 
were minced and placed into a 2 mL screw top tube. 50 µL of Liberase TM (13 Wünsch Units/mL) 
(Roche) was added to the tube and the minced ovaries were incubated in a water bath set to 37°C 
for 15 minutes. After incubation, 950 µL of FACS buffer was added to each tube to stop the 
enzymatic reaction and the tubes were then placed in a bead homogenizer then agitated for 30 
seconds at 2.10 m/s. Samples were filtered through a 100 µm cell strainer to prepare a single cell 
suspension and then cells were washed in 1X HBSS then pelleted in a centrifuge at 350 x g for 5 
minutes at 4°C. Cells were resuspended in 1 mL of 1X HBSS and 1 µL of BD Horizon Fixable 
Viability Stain 780 was added to cells and positive ArC Amine Compensation beads. Viability dye 
was incubated for 30 minutes at 4°C. Cells were washed twice with 2 mL of FACS buffer and 
supernatant was decanted. 2 µL of α-CD16/32 (Fc Block – Biolegend 101302) was added to each 
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sample and incubated from 10 minutes at room temperature. 1 mL of FACS buffer was added to 
each sample and spun down at 4°C. Supernatant was decanted from each sample and 2 µL of each 
extracellular antibody (Zp3, CD45, CD68, CD206, CD86) was added to the cells and allowed to 
incubate for 20 minutes at 4°C. AbC total antibody compensation tubes (Invitrogen) were stained 
with 1 uL of each corresponding antibody. Cells were washed twice with 2 mL of FACS buffer 
and supernatant decanted. Sample pellets were vortexed briefly to disrupt the cells, which were 
then fixed in 1 mL of 5% neutral buffered formalin and incubated from 40-60 minutes at 4°C 
protected from light. Cells were then permeabilized using 2 mL of 1X Permeabilization buffer 
(eBioscience) and spun at 400-600 x g for 5 minutes at 4°C. The supernatant was discarded and 
then permeabilization was repeated. The cell pellet was then resuspended in the residual volume 
(~100 µL after decanting) of 1X Permeabilization buffer. Without additional washes, 2 µL of 
intracellular markers (NOBOX, GFP, ki67, Caspase3) were added to the cells and incubated 
overnight at 4°C. For compensation, 1 µL of each intracellular antibody was added to AbC total 
compensation beads. After overnight incubation, 2 mL of 1X Permeabilization buffer was added 
to each tube and samples were centrifuged at 400-600 x g for 5 minutes at room temperature, 
supernatant discarded and wash repeated. Stained cells were resuspended in 200 µL and 
compensation beads in 500 µL of FACS buffer then analyzed by flow cytometry. First, we gated 
on non-debris (forward side scatter area vs side scatter area) and then on single cells (forward 
scatter area vs height plots) (Appendix Figure 39). From the population of single cells, we gated 
on total viable cells (viability dye). Out of the viable cells, we could then select the population of 
apoptotic (Caspase3) and proliferative (ki67) cells. From viable cells, we could also gate on 
CD45+ (immune cells) and CD45- (non-immune) cells. The CD45+ cell population would allow 
us to examine the population of resident macrophages (CD68) and macrophage phenotypes (CD86 
 120 
and CD206). The CD45- cell population would allow us to quantify oocyte-expressing cells (Zp3 
and NOBOX). In addition, cells expressing GFP would indicate cells that were donated from 
transgenic mice for follicle microinjection. 
5.3.12 Statistical Analysis 
All data were expressed as mean ± s.e.m and plotted using GraphPad Prism 7.02. In order 
to detect differences in follicle populations after chemotherapy, the individual means were 
compared using an unpaired, two-tailed, t-test. Exact P-values resulting from the statistical analysis 
are presented within each figure.    
5.4 Results and Discussion 
5.4.1 Alkylating Agents Significantly Reduce Endogenous Follicle Population 
After developing and characterizing the OECM hydrogel as a carrier for follicle injection, 
we created a clinically relevant ciPOF mouse model. We chose to induce POF using alkylating 
agents, busulfan and cyclophosphamide, due to their known cytotoxic effects on ovarian tissues 
and cells (162, 367, 387, 388). Briefly, a single intraperitoneal (IP) injection was given to 6-week 
old nude female mice. Dosing was titrated to determine an appropriate treatment that would 
significantly reduce the endogenous follicle pool to lower or eliminate the chances of fertility. The 
following doses were tested, abbreviated as busulfan-cyclophosphamide (mg/kg): (1) 12-100 (2) 
12-200 (3) 24-100 (4) 24-200.   
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At three weeks post-IP injection, histological staining with Weigert’s Hematoxylin-Picric 
Methyl Blue clearly illustrated the damaging effects of each chemotherapy regimen on the follicle 
population within the ovaries (Figure 31a-e). Dose dependent effects were observed with elevated 
levels of busulfan and cyclophosphamide reducing the follicle numbers (Figure 32a). Follicles 
were counted based upon developmental stage (Appendix Table 5 and Appendix Figure 33). 
Primordial and primary follicles were significantly reduced after exposure to all treatments in 
comparison to non-treated control mice (Figure 32b and Appendix Table 6). The outcomes of 
chemotherapy titration suggested that a range of doses could impair fertility outcomes or lead to 
ovarian insufficiency. Therefore, we determined that it was important to evaluate the efficacy of 
hydrogel-assisted follicle microinjection using female mice treated across each dosage of 
chemotherapy. We selected the 12-100, 12-200 and 24-100 doses of busulfan-cyclophosphamide 
to prepare our ciPOF mice for follicle transplantation because these doses caused significant 
follicle loss and the animals retained good overall health. Although the 24-200 treatment resulted 
in the greatest follicle reduction, we excluded this group from follicle transplantation due to the 







Figure 31 Effects of Chemotherapy Dosing on Ovarian Tissues 
Four doses of busulfan-cyclophosphamide a, 12-100 mg/kg b, 12-200 mg/kg c, 24-100 mg/kg d, 24-200 mg/kg e, 
non-injected (control) were administered via single IP injection. Ovaries were excised at 3 weeks post treatment and 




Figure 32 Endogenous Follicle Populations Post-Chemotherapy 
a, Follicles were manually counted, quantified and classified by developmental stage showing a steady decline of 
the total follicle number with increasing dose. Additionally, busulfan appeared to have an enhanced effect on follicle 
depletion in comparison to cyclophosphamide. b, Significant reduction of primordial follicles across all doses 
indicated a severe depletion of the ovarian reserve, decreasing potential fertility. 
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5.4.2 Enzymatic Follicle Isolation and Microinjection Provides an Efficient Transplant 
Procedure 
Follicle incubation time from isolation to transplant is a concern for cell therapy 
applications as it can directly impact viability (389). Therefore, we adapted an existing enzymatic 
isolation protocol (220) to reduce the time needed to obtain a large pool of immature follicles for 
transplant. To enable identification of transplanted versus endogenous follicles, we isolated 
follicles from transgenic mice exhibiting ubiquitous GFP under the chicken β-actin (CAG) 
promoter. We tested enzyme concentrations of 10% and 20% for both Liberase TM and DH (13 
Wünsch units/mL) to determine their effects on follicle disaggregation and quality. Briefly, 
Liberase TM or DH was added to the minced ovaries then two five-minute cycles of physical 
agitation at 37°C were performed with a minute of pipetting after each cycle. After assessing each 
sample, we determined that the best formulation was the 10% Liberase TM, which released a large 
population of morphologically normal GFP follicles during the 12-minute isolation procedure 
(Figure 33). In order to estimate the number of follicles isolated with this procedure, follicles were 
manually counted using a hemocytometer. There were approximately 1.5x103 total follicles 




Figure 33 Follicle Isolation and Quantification 
Intact GFP follicles were enzymatically isolated using Liberase TM and imaged under bright field (top) and 
fluorescence (bottom). Scale, 500 μm. Isolated follicles were quantified using a hemocytometer demostrating a 
predominantly primordial follicle population with approximately 1.0x103 follicles per intraovarian injection. 
 
Once we showed that it was feasible to efficiently obtain follicles, we wanted to test the 
efficacy of using microinjection to transplant follicles into the ovarian cortex of ciPOF mice. 
Immature follicles naturally reside within the ovarian cortex, as this region of the ovary has 
mechanically distinct properties that support maintenance of immature follicles (76, 390).  
Therefore, we wanted to precisely dispense follicles into or near the cortex. Previously, 
intragonadal cell delivery has been shown successfully using microinjection (224-226). So, we 
decided to implement this technique to facilitate intraovarian follicle transplant to establish an ISO. 
First, we tested the delivery of the OECM hydrogel alone via microinjection. A small volume of 
hydrogel was injected into the ovarian cortex, and the recipient animal was sacrificed to visualize 
the injection site (Figure 34i top). Bright field images clearly illustrated Trypan blue dye at the site 
of injection at the tissue surface (Figure 34i bottom). Furthermore, the use of a TRITC-labeled 
OECM hydrogel allowed us to identify the hydrogel at the ovarian surface post-injection (Figure 
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34j). These results confirmed this method as a suitable delivery mechanism for the viscous OECM 
within a specific anatomical location of the ovary. Finally, we performed the same experiment 
with the addition of isolated GFP follicles to determine if the gel and follicles could be delivered 
simultaneously, resulting in the formation of an ISO. Ovaries excised from the TRITC-OECM 
hydrogel and GFP follicle microinjection clearly indicated a co-localization of the OECM and 
follicles within the ovarian cortex (Figure 34k). 
 
 
Figure 34 Intraovarian Follicle Microinjection 
i, Brightfield images show the gross morphology of the ovary during microinjection (top) and magnified to show the 
injection site for follicle transplant (bottom). j, Pressurized microinjection was tested as a potential technique to 
deliver the OECM hydrogel (TRITC-labeled) and visualized under bright field (top) and fluorescence (bottom). 
Scale, 500 μm. k, Multiphoton images confirmed that intraovarian follicle microinjection of the isolated GFP 
follicles (green) and OECM (red) co-localized within the ovarian cortex to form an in situ ovary. The dotted line 
(white) indicates the outer surface of the ovarian epithelium. 
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5.4.3 Microinjected Follicles Give Rise to Multiple Generations of GFP Pups 
We used our ciPOF mice to investigate the therapeutic potential of an ISO to support 
follicle survival after intraovarian microinjection. Approximately 1.0x103 GFP+ follicles 
resuspended in 7 μL of OECM hydrogel were microinjected into the ovarian cortex of ciPOF nude 
female mice: 12-100 (n = 2), 12-200 (n = 2) and 24-100 (n = 2). Non-injected ciPOF nude female 
mice were used as controls: 12-100 (n = 3), 12-200 (n = 2) and 24-100 (n = 2). To reduce tissue 
damage due to needle puncture, only a single follicle injection was performed on each ovary. 
Freshly isolated GFP follicles from 6-14 day female (DBA-GFP/nu-) mice were used to ensure a 
predominantly immature follicle population at the time of injection.  
To determine the effects of follicle microinjection on fertility, follicle recipient and non-
injected control ciPOF nude female mice were mated with nude male mice for three breeding 
cycles (~100 days). The breeding strategy was designed to definitively distinguish between pups 
derived from transplanted or endogenous follicles (Appendix Table 7). Pups from endogenous 
follicles would be nude, lacking fur, whereas pups from transplanted GFP follicles would have fur 
with a 50% chance of glowing green (GFP/nu-). After three breeding cycles, ciPOF follicle 
transplant recipients produced a total of three GFP+/nu- pups within three separate litters 
(Appendix Table 8). The first breeding cycle yielded one GFP pup (GFP/nu-001) out of three 
healthy offspring followed by a single GFP pup (GFP/nu-002) with no littermates during the 
second cycle (Figure 35a,b). As a note, when litters were small, the pups were fostered into nude 
litters (as shown by the additional nude pups in Figure 35b). Each of the first two GFP pups were 
born from the same ciPOF mouse treated with a dose of 24-100 mg/kg. This observation 
demonstrates that intraovarian follicle transplant has the potential to lead to multiple births from a 
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single injection. During the third and final breeding cycle, one GFP pup (GFP/nu-003) was born 
out of five healthy offspring from a ciPOF mouse in the 12-100 mg/kg group (Figure 35c). This 
result suggests that transplanted follicles are viable for at least 90 days post-injection.  Overall, 
eight litters and a total of 35 pups were born from ciPOF mice that received a follicle transplant (n 
= 6). In comparison, seven litters with a total of 36 pups were born from non-injected ciPOF control 
mice (n = 7). A follow-up mating study was performed to test the reproductive health of the GFP 
pups generated from follicle transplantation. The GFP offspring resulting from follicle transplant 
(DBA-GFP+/nu-) were bred with DBA wild-type (GFP-/nu+) (Appendix Table 9) and inbred with 
each mating pair (Appendix Table 10) producing multiple large litters of hemizygous (GFP+/-) and 
homozygous (GFP+/+) genetic backgrounds (Figure 35d,e and Appendix Table 11). In each of the 
litters, GFP expression was clearly observed in the presence of a UV lamp and confirmed with 







Figure 35 Microinjected Follicles Give Rise to Multiple GFP Litters 
The efficacy of intraovarian follicle transplant for fertility preservation was tested by injecting a pool of isolated 
GFP follicles within an OECM hydrogel into a ciPOF nude female mice. The follicle recipient mice were then 
mated to male mice of the same genetic background (nu/nu) to distinguish between progeny derived from exogenous 
(GFP+) or endogenous (GFP-) follicles. a-b, Two GFP pups (GFP/nu-001 and GFP/nu-002) were born in 
consecutive liters from the same mother (24-100 mg/kg dose) as a direct result of the follicle transplantation. c, 
Another GFP pup (GFP/nu-003) was derived from a ciPOF female mouse (12-100 mg/kg dose) during the third 
mating cycle (>100 days post-transplant). This demonstrates that an ISO can support injected follicles in a dose-
independent manner and have long-term viability post-injection. Multiple litters of second generation pups were 
derived from both d, outbred (GFP/nu x DBA) and e, inbred (GFP/nu x GFP/nu) mice, which indicates that 




Figure 36 Genotyping of GFP Pups and Littermates 
Genotyping of the GFP pups and littermate controls was confirmed using standard PCR and gel electrophoresis. 
GFP bands only appeared within the GFP mouse samples and none within the littermate samples. β-actin was used 
as an internal control appearing in each of the samples tested. Gels were cropped and processed to highlight the 
bands of interest.  
 
5.4.4 Intraovarian Microinjection Supports Follicle Longevity Post-Transplant 
Finally, we wanted to determine the effects of this therapy on follicle longevity post-
transplant. To answer this question, we performed immunofluorescent labeling of ovaries excised 
from ciPOF nude female mice after three breeding cycles (~100 days). Comprehensive imaging 
demonstrated significant GFP expression throughout the transplanted tissues and suggests that 
multiple follicles remained viable post-transplantation (Figure 37a). Transplanted ovaries also 
retained growing endogenous follicles (Figure 37b).  Non-injected control tissues lacked GFP 
expression and endogenous follicles appeared to be reduced in comparison to ovaries from 
transplanted mice (Appendix Figure 36). However, we could not confirm any definitive 
differences between residual endogenous follicles based solely upon the immunofluorescence 
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images. Finally, we were able to identify follicles at various stages of development including 
primordial (Figure 37c), secondary (Figure 37d), antral (Figure 37e), and corpus luteum (Figure 




Figure 37 Survival of GFP+ Cells Post-Transplantation  
Ovarian tissues were excised from ciPOF follicle recipient mice after three breeding cycles (106 days on average). 
Immunofluorescence staining was performed using DAPI (endogenous cells) and GFP (transplanted cells) to 
evaluate follicle survival.  a, A representative image of a transplanted ovary suggests that GFP+ cells integrated 
within the tissues and were actively proliferating. Scale, 200 μm. b, Presence of an endogenous secondary follicle 
(GFP-), indicated by dotted line (white). Scale, 50 μm. Various stages of follicle development were also present 
among the transplanted tissues, including: c, Primordial (Scale, 50 μm) d, Secondary (Scale, 50 μm) e, Antral (Scale, 




In aim 2, the primary goal was to evaluate the efficacy of the OECM hydrogel to aid in the 
delivery, engraftment and survival of isolated ovarian follicles. In addition, we wanted to examine 
this approach in a clinically relevant chemotherapy treated mouse model. First, we assessed the 
effects of busulfan and cyclophosphamide dosing on ovarian follicle populations. Ovarian follicles 
were evaluated histologically, classified by developmental stage and quantified. Each dose of 
chemotherapy caused a significant reduction in total follicles in comparison to the non-treated 
control mice. The 24-200 dose resulted in the greatest depletion of endogenous follicles, however, 
this treatment group also resulted in small ovaries and poor overall health of the mice. Next, we 
showed the ability to efficiently isolate a predominantly immature follicle pool that could be for 
transplantation. Ovaries from transgenic DBA/GFP female mice were excised and follicles were 
isolated. Follicle quantification determined that a 7 µL injection would contain an estimated 
1.0x103 total follicles, 74% of which would be primordial follicles. Multi-photon imaging 
demonstrated feasibility of hydrogel-facilitated intraovarian follicle microinjection, showing a co-
localization of TRITC-labeled OECM hydrogel and GFP+ follicles with the ovarian cortex. 
Finally, chemotherapy treated female mice were given a single intraovarian follicle microinjection 
within each ovary facilitated by the OECM hydrogel to evaluate follicle engraftment and survival. 
Mating studies resulted in three healthy GFP+ pups in three separate litters over the span of three 
breeding cycles generated from mice treated with 12-100 and 24-100 mg/kg busulfan-
cyclophosphamide. Second generation breeding of GFP progeny derived from intraovarian follicle 
microinjection resulted in several large litters. In addition, immunofluorescence imaging of ovaries 
excised 100+ days post-follicle transplantation showed the presence of GFP+ cells, which were 
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integrated into follicle structures. These results demonstrate that hydrogel-facilitated intraovarian 
follicle microinjection can support follicle delivery, engraftment and long-term survival.       
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6.0 Discussion 
Women who cryopreserve oocytes or embryos prior to gonadotoxic treatments can use 
assisted-reproductive technologies (ART), such as IVF and embryo transfer to start a family (391, 
392). To preserve eggs or embryos, the patient must first undergo hormone stimulation to collect 
mature oocytes. Controlled ovarian stimulation requires two or more weeks and is not a viable 
option for patients who have not reached reproductive maturity or who cannot afford to postpone 
treatment (150, 151, 393). For these girls and women, cryopreservation of intact ovarian tissues 
prior to treatment is the only potential option to naturally restore endocrine function and fertility. 
The current gold standard for fertility preservation in patients in remission is the autologous 
surgical transplantation of cryopreserved ovarian cortical strips (152, 153, 172-175, 185, 374, 377, 
394). To date, there have been numerous successful procedures performed in humans, resulting in 
greater than 130 live-births; however, the efficiency of this method remains low, with live-birth 
rates ranging from 23-36% of patients achieving live-births (149, 395). Although ovarian tissue 
transplantation has shown promise, it is an invasive procedure and carries a potential risk of 
reintroducing malignant cells back into the body (396). To address these concerns, several pre-
clinical experimental approaches have been proposed, including in vitro follicle maturation (IVM), 







Table 2 Summary of Notable Pre-Clinical Fertility Preservation Studies 
Several therapeutic approaches have been explored to ameliorate the effects of infertility. In general, these can be divided into three main 
categories: (1) Ovarian engraftment (2) Biomaterial-facilitated and (3) Intraovarian transplantation methods. Ovarian engraftment can be equated 
to cortical strip autotransplantation, which is currently considered as the gold-standard in the field. Biomaterial-facilitated methods have recently 
progressed toward the development of a functional artificial ovary, which uses a scaffold or hydrogel to support follicle transplantation. 
Intraovarian transplantation has been primarily focused on the delivery of oogonial stem cells (OSCs). Each of the in vivo studies listed have used 
varied models of infertility, induced either by ovariectomy or chemotherapy, with a limited number showing the ability to produce pups 
(highlighted in green). However, the clinical translation of these approaches may be hindered by invasive surgical procedures and ex vivo follicle 
and stem cell manipulation. To overcome these barriers to the clinic, we have proposed a minimally invasive technique to facilitate the delivery 
















N/A In vivo 
Yes 
(Chemotherapy) 
Batchvarov et al. use a chemotherapy regimen of busulfan and 
cyclophosphamide to induce infertility. Grafted ovarian tissue was able to 
rescue host fertility although non-grafted hosts also gave rise to litters 200+ 








In vivo No 
Rios et al. examine the potential of immunoisolating and encapsulating 
ovarian follicles within alginate hydrogels for subcutaneous transplant. 
Hydrogels were retrieved and mature oocytes were collected then 







vitro/     
In vivo 
No 
Hassanpour et al. develop a decellularization protocol incorporating SLES 









Laronda et al. establish a bioprosthetic 3D printed ovary to restore ovarian 










Kim et al. implement a PEG-VS hydrogel to support the transplantation of 




Fibrin gel In vivo No 
Paulini et al. test an artificial ovary using a fibrin gel showing the efficacy 
of xenografting isolated preantral follicles within the peritoneum. Results 










Laronda et al. detail a procedure for the decellularization of both human and 
bovine ovaries. Primary ovarian cells seeded onto decellularized grafts were 












Kniazeva et al. test several biomaterial graft systems in an ovariectomized 





Fibrin gel In vivo 
Yes 
(Ovariectomy) 
Smith et al. characterize the use of a fibrin gel for the transplant of ovarian 
follicles. Early-stage follicles were enzymatically isolated, encapsulated 
within fibrin gels and transplanted into an ovariectomized mouse. Tissue 
explants were performed at 0, 3, 9 and 21 days with follicles populations 




Fibrin gel In vivo 
Yes 
(Ovariectomy) 
Luyckx et al. prepare an artificial ovary from fibrin gel that promotes 









Shikanov et al. introduce a combination system consisting of Fibrin gel 
supplemented with VEGF to stimulate angiogenesis and promote graft 
survival. Transplanted mouse ovarian tissues supported by the Fibrin/VEGF 
material improved follicle survival when compared to no biomaterial 








PBS In vivo 
Yes 
(Chemotherapy) 
Xiong et al. implement a stem cell therapy to reverse the effects observed 





PBS In vivo 
Yes 
(Chemotherapy) 
Park et al. show significant genetic changes within primordial follicle 
markers after exposure to chemotherapy. Intraovarian primordial follicle 
transplantation did not restore fertility. 
(379)  
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IVM consists of the isolation and culture of immature follicles to obtain meiotically-
competent oocytes for IVF. IVM approaches have predominantly shifted from two-dimensional 
culture toward three-dimensional hydrogel-based follicle encapsulation, which has improved 
follicle morphology and intercellular signaling (191).  The most commonly used hydrogel for IVM 
is alginate (190, 200, 375, 399-403); although, there are several other options that have been 
examined including, fibrin (209), fibrin-alginate (208, 215), and polyethylene glycol (PEG) (213, 
404). Each of these materials provide a unique set of physical and biochemical properties, which 
allows them to support the growth and maturation of follicles in vitro. Successful application of 
IVM has been shown in mice leading to live-births (190); however, the pre-clinical translation of 
this approach for human follicles has been limited (405). Recently, follicle maturation has been 
attempted in vivo through the heterotopic subcutaneous transplant of a retrievable hydrogel seeded 
with immature follicles (214). Antral follicles developed in the hydrogel and germinal vesicle stage 
oocytes could be extracted, matured to MII stage and fertilized, leading to the development of two 
and four cell embryos. However, embryos were not transferred in this study and pregnancies were 
not established. 
As IVM has proven to be a major challenge for human follicles, several groups have 
pursued the development of an artificial ovary. This concept involves the isolation and 
sequestering of immature follicles in a bio-supportive scaffold that can be transplanted to recover 
ovarian function. Similar to IVM, various biomaterials are being examined as options to support 
the delivery, survival and function of ovarian follicles in vivo. Recently, a fibrin gel supplemented 
with vascular endothelial growth factor (VEGF) was used to facilitate the transplantation of 
primordial follicles into the bursa of ovariectomized mice and gave rise to a healthy litter of pups 
(217). In another study, a 3D printed gelatin scaffolds were used to examine the effects of pore 
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geometry on follicle survival and achieved healthy pups through natural mating post-implantation 
in sterilized mice (221). Since each of these studies used ovariectomized mice as transplant 
recipients, they were unable to evaluate the suitability of the endogenous ovary as a transplant site 
or the impact that chemotherapy would have on transplant follicle engraftment, survival and 
development. 
The objective of the present study was to develop a method to transplant ovarian follicles 
into the endogenous ovary using a supportive OECM hydrogel. Our approach required minimal in 
vitro manipulation of follicles and short-term exposure to ex vivo conditions prior to intraovarian 
microinjection. This was accomplished by solubilizing acellular ovarian scaffolds to create a 
thermo-responsive, injectable material which was able to form in situ following injection under 
physiological conditions. In addition, we proposed an adapted method for efficiently isolating 
follicles to reduce the total time ex vivo prior to transplantation. To mimic ciPOF experienced in 
the clinic, a single intraperitoneal injection of busulfan and cyclophosphamide was used to 
significantly reduce the endogenous follicle population in female recipient mice. The OECM 
hydrogel combined with freshly isolated GFP+ ovarian follicles were successfully delivered into 
the ovarian cortex, forming an ISO. Intraovarian follicle transplant aided by the OECM hydrogel 
gave rise to multiple, consecutive litters containing at least one pup expressing GFP.  
This study demonstrates a potential strategy for restoring fertility after chemotherapy, but 
we acknowledge that there are several limitations. A major benefit of isolating follicles from the 
ovarian stroma is the potential to reduce malignant cells that could be introduced during 
transplantation and there have been reports suggesting that follicle isolation can significantly 
decrease cancer cells prior to implantation (217, 406). However, since our primary aim was to 
improve intraovarian follicle transplant and survival, we did not filter out stromal cells within our 
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follicle suspension after isolation. Therefore, it is possible that stromal cells or other cell types may 
have contributed to ovarian follicle survival within the ciPOF ovaries.  In addition, donor follicles 
were isolated from whole allogeneic ovaries rather than autologously sourced ovarian tissue. We 
also acknowledge that the wide age range (6-14 days) of mice used to collect donor follicles could 
yield drastically different follicle and stromal cell populations. In future experiments, it would be 
ideal to use donor mice from the same age to reduce variability. However, in order to increase the 
number of available donor follicles, isolated follicles were combined into a single batch and 
equally distributed for transplantation. One of the main goals of this therapy is to eventually restore 
fertility in human patients. However, as a first attempt, we were interested in examining the effects 
of this method on donor follicle survival after intraovarian microinjection. Although the ciPOF 
mice had a significantly reduced follicle number they were not infertile, as non-injected control 
mice had multiple litters. In addition, the presence of endogenous follicles could also aid 
exogenous follicle integration and survival within the ovarian niche. Another significant limitation 
of this study was the size of the mouse ovaries. The current animal model restricted the use of 
larger volumes of injected gel during a single treatment making it difficult to deliver a greater 
quantity of follicles. Theoretically, as the number of injected follicles increases it could also 
improve the potential fertility outcomes. In addition, the ratio of gel to follicles may also be a 
decisive factor in long-term follicle survival. For example, a higher follicle concentration could 
inhibit access to nutrients within the ISO triggering apoptosis or atresia. Finally, to improve the 
outcomes observed in this report, multiple hydrogels with varying compositions and mechanical 
properties will be tested to evaluate in situ follicle-hydrogel interactions over time.  To this end, a 
comprehensive follow up study will be conducted in a larger animal model using follicles isolated 
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from cryopreserved, autologous ovarian tissues to evaluate the therapeutic and translational 
potential of this approach.    
OECM hydrogels, paired with intraovarian microinjection created an environment that 
supported survival and development of transplanted follicles.  This therapeutic approach employs 
the innate remodeling capacity of the ECM to establish an ISO to facilitate follicle transplant. In 
the human clinic, this technique could be deployed using the same minimally-invasive ultrasound-
guided approach used to aspirate follicles from the ovary in IVF clinics. Instead of aspirating eggs, 
follicles could be injected directly into the ovarian cortex. Overall, the restorative reproductive 




7.0 Concluding Remarks 
7.1 Study Summary 
The overarching goal of this work was to improve upon the current therapies used to treat 
fertility preservation. Our hypothesis was that ovarian ECM hydrogels could facilitate the 
intraovarian delivery and engraftment of isolated follicles in chemotherapy-treated mice. To test 
this hypothesis, we developed a decellularization protocol to obtain ovarian-specific acellular 
tissues. We found that decellularized ovaries removed greater than 97% of dsDNA while retaining 
ECM components and hormones. Further, we found that decellularized ovarian tissues could be 
solubilized and formed into a hydrogel at physiological conditions. Hydrogel properties were 
examined at two different ECM concentrations using rheology, gelation kinetics and ultrastructure 
analyses. We found that increasing ECM concentration led to greater viscoelastic properties, while 
gelation times remained constant. Ovarian hydrogels were also tested as a candidate substrate for 
in vitro follicle culture. After 12 days in culture, pre-antral follicles transitioned into fully mature, 
fertilizable oocytes, which yielded a two-cell embryo.  
To create a clinically relevant chemotherapy model of premature ovarian failure, we treated 
young female mice with varying doses of busulfan and cyclophosphamide. Ovarian tissues were 
examined three weeks after injection to evaluate the effects of chemotherapy on follicle 
populations. Chemotherapy treatments resulted in a significant reduction in total follicles in 
comparison to untreated controls and indicated that primordial and primary follicles were the most 
sensitive to treatments. To assess the efficacy of intraovarian follicle microinjection, isolated 
follicles were resuspended in hydrogels then microinjected into the ovarian cortex. Confocal 
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microscopy showed that OECM hydrogels and follicles colocalized with the cortical region, 
establishing an in situ ovary. Finally, hydrogel-facilitated intraovarian follicle microinjection was 
tested using ciPOF mice to determine the impact on follicle survival. Transgenic (GFP+/DBA) 
female mice were used as follicle donors and nude ciPOF female mice were used as follicle 
transplant recipients. After three breeding cycles, with nude male mice, three litters contained three 
pups derived from donor follicle microinjection. Second generation breeding of the GFP+ progeny 
resulted in multiple healthy litters, indicating that follicle microinjection did not compromise their 
reproductive health. Additionally, histological analysis using immunofluorescence showed GFP+ 
cells within ciPOF treated tissues at greater than 100 days post-transplantation. These results 
suggest that hydrogel-facilitated follicle microinjection could promote the long-term survival of 
transplanted follicles.  
7.2 Limitations 
Although this study produced exciting results, there were several limitations that could 
have been improved. One of the major limitations of this work was the use of a mouse model. The 
size of the mouse ovary limited the total amount of hydrogel and follicles that could be injected. 
Theoretically, if a greater number of follicles are delivered into the ovary, the fertility potential 
would increase. Even though we only injected a small volume of gel, we were able to establish 
pregnancies from a small pool of transplanted follicles within each ovary. In addition, the 
transgenic backgrounds of the mice and breeding strategy could have been improved to yield 
offspring with only a single definitive trait (ie. GFP, hair/eye color, etc.). This would improve 
initial detection and differentiate between pups derived from transplanted follicles versus 
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endogenous follicles. It was also difficult to assess the variability in live-births between mice, 
which could have been attributed to uneven distribution of follicles and the efficiency of follicle 
injection. Methods for assessing donor follicle counts post-transplantation would have provided 
critical information to better evaluate breeding results within transplanted ciPOF mice.  
Another limitation of the study was that chemotherapy treated mice were not completely 
infertile making it difficult to assess whether supportive cells of the endogenous ovary played a 
role in facilitating donor follicle survival and development. To ensure infertility, follicle 
microinjections could have been delayed by eight weeks post-chemotherapy, which did not yield 
any litters during the third breeding cycle in higher doses of busulfan and cyclophosphamide. 
However, it is interesting that fertility was lost in ciPOF control animals shortly after the first two 
breeding cycles, which may be a sign there are residual effects of chemotherapy that may 
contribute to rapid follicle loss, rather than natural atresia. Therefore, it may suggest that the 
ovarian ECM hydrogel does have some chemoprotective properties that shield transplanted 
follicles from immediate apoptosis as they displayed GFP signals at 100 days post-transplantation. 
 Additionally, the follicle isolation procedure did not filter out loose stromal or somatic 
cells, which could have provided additional support for follicle survival and development. In order 
to accurately evaluate the effects of the ovarian hydrogel, a pure follicle population should be used. 
Further, for cancer patients with suspicious ovarian tissues that may contain malignant cells, it is 
important to develop and test an efficient protocol that completely eliminates the stromal cells 
from the follicle pool. 
Finally, the clinical translation of this type of procedure would need to be tested using 
minimally invasive methods such as intravaginal follicle injection under ultrasound guidance. At 
this initial stage development, this study was primarily focused on evaluating the efficacy of 
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hydrogel-facilitated microinjection and to determine if the hydrogel-follicle suspension 
colocalized within the ovarian cortex. To accommodate these initial tests, we performed an 
invasive surgical procedure to expose the ovaries and used a microinjection system to deliver the 
follicles. Therefore, we were unable to determine the feasibility of a minimally invasive 
application of this technique.  
7.3 Future Directions 
To improve upon the studies performed within the scope of the current dissertation, future 
experiments would be required to assess some of the outstanding questions regarding the effects 
of hydrogel-facilitated follicle microinjection. Ideally, this study should be performed in a higher 
order mammal, such as a non-human primate. Ovarian cortical strips should be collected and 
cryopreserved prior to chemotherapy, radiation or equivalent model to mimic the effects of 
iatrogenic infertility. After cytotoxic treatments are performed, donor follicles should be isolated 
from the same cryopreserved tissue to mimic the process of autologous follicle transplantation in 
humans. Further, methods should be developed to rapidly isolate a pure follicle pool, free from 
somatic and stromal cells. Multiple biomaterial compositions should be tested with varying 
viscoelastic properties along with sham controls. The mechanics of follicle delivery via 
microinjection should be characterized to evaluate the effects of shear stress and biomaterial 
viscosity on viability post-transplantation. Additionally, feasibility studies should be performed 
using transvaginal follicle delivery under ultrasound guidance. Finally, ovarian tissues should be 
explanted at both acute and long-term time points post-transplantation to determine the local and 
systemic effects using quantitative metrics, such as flow cytometry, Luminex assays and 
 143 
immunohistochemistry. Most importantly, the success of future experiments approach will be 
evaluated based upon the rate of healthy pregnancy and live-births, which demonstrate efficacy 
for a model of infertility.  
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Appendix A Decellularization Processing 
























Appendix Figure 4 Decellularized Porcine Ovaries 
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Appendix B Decellularization Mass Conservation 
Appendix Table 2 Effects of Decellularization on Tissue Mass 












































































Appendix Table 2 (continued) 


















































































Appendix Table 2 (continued) 
















































































Appendix Table 2 (continued) 

















































































Appendix Table 2 (continued) 








































































Total 473.377 473.377 339.881 27.59 4.641 159.571 9.653         
Overall 
Average 
4.734 94.675 67.976 5.518 0.9282 31.914 1.9306 83% 94% 0.0346 3.456% 
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Appendix C Ovarian Hydrogel Cytocompatibility 
 
Appendix Figure 5 Macrophage iNOS Expression 
 
 






Appendix Figure 7 Macrophage Phagocytosis 
 
 
Appendix Figure 8 Macrophage Nitric Oxide Production 
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Appendix D Detergent Concentration During Decellularization 
 
Appendix Figure 9 Effects of Washes on Detergent Concentrations 









0 Before Detergents 
1 After 3% Triton 
2 After dIH20 
3 After Type I H20 
4 After 1X PBS 
5 After Type I H20 
6 After 4% SDC 
7 After dIH20 
8 After Type I H20 
9 After 1X PBS 
10 After Type I H20 
11 After PAA/EtOH 
12 Final Type I H20 
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Appendix E DNA Fragmentation Post-Decellularization 
 
Appendix Figure 10 Agarose Gel Electrophoresis 
A 2.5% agarose gel was used to characterize the presence of DNA within ovarian tissues post-decellularization. No 
visible bands were observed within the decellularized ovarian tissues (D1-D5). Native ovarian tissues (N1-N5) were 
used as a positive control. Each lane represents an individual sample of DNA. 
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Appendix F Ovarian Tissue Immunohistochemistry  
 
Appendix Figure 11 IHC Ovarian ECM Proteins 
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Appendix G Effect of Ovarian Tissue Processing on Hormones and Growth Factors 
 
Appendix Figure 12  Retention of Ovarian-specific Hormones and Growth Factors 
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Appendix H Ovarian Hydrogel Optimization 
 
Appendix Figure 13 Effects of Pepsin on Gelation Kinetics 






Appendix I Ovarian Hydrogel Mechanical Characterization 
 
Appendix Figure 14 Ultrasound Elastography 
Ultrasound elastography was tested as potential alternative technique to directly measure bulk mechanical properties 
















Appendix Figure 16 OECM Soluble/Insoluble Fraction 
 
 
Appendix Figure 17 Protein Gel Soluble vs Insoluble Fraction 
Urea extraction was used to enrich soluble fraction of the OECM components. 
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Appendix J In Vitro Newborn Mouse Ovary Culture 
 








Waymouth’s MB 7521 Medium DMEM/F-12 Medium 
10% FBS 0.1% Albumax 
50 U Penicillin/Streptomycin 50 U Penicillin/Streptomycin 
0.23 mM Pyruvic Acid 1X Glutamax 
 27.5 µg/mL Transferrin 
 0.05 mg/mL L-ascorbic Acid 
 1 µg/mL Insulin 
 0.1% Bovine Serum Albumin (BSA) 
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Appendix Figure 21 Viscoelastic Properties of OECM Hydrogel for Ovary Culture  
The initial protocol used to decellularize ovarian tissues resulted in residual detergents within the scaffold and 
negatively impacted the viscoelastic properties (shown here). The revised protocol, which added wash steps, 
significantly improved the mechanical stiffness of the OECM hydrogels. 
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Appendix K In Vitro Mouse Follicle Cultures 
 
Appendix Figure 22 Mechanical Follicle Isolation for IVM 
 
 
Appendix Figure 23 IVM Trial 1 – Isolated Follicles 
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Appendix Figure 24 OECM-IVM Trial 1 - Single Follicle – Day 1 
 
 




Appendix Figure 26 OECM-IVM Trial 1 – Grouped Follicles - Day 1 
 
 
Appendix Figure 27 OECM-IVM Trial 1 – Grouped Follicles – Day 6 
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Appendix Figure 29 OECM Hydrogel Droplets 
 
 




Appendix Figure 31 New OECM-IVM Trial 2 – Follicle Morphology 
 
 




Appendix Table 4 In Vitro Follicle Culture Media 











0.5% Pen/Strep 0.5% Pen/Strep 
 


































Appendix L Ovarian Follicle Stage Determination 
 
Appendix Figure 33 Morphological Characterization of Follicle Stage 
Follicles were quantified and developmental stage was determined by their morphology a, Primordial follicles were 
recognized by a central oocyte surrounded by a single layer of squamous granulosa cells. Scale, 50 μm. b, Primary 
follicles were counted if they contained a single oocyte with a layer of cuboidal granulosa cells. Scale, 50 μm. c, 
Secondary follicles contained an oocyte with 2-4 layers of cuboidal granulosa cells. Scale, 50 μm. d, Antral follicles 
were distinguished by an oocyte with several layers of cuboidal granulosa cells containing pockets of antral fluid. 
Scale, 100 μm. Red arrows indicate counted follicles. 
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Appendix M Follicle Quantification Post-Chemotherapy 
Appendix Table 5 Follicle Counts Post-Chemotherapy 
The table (below) lists the means (bold) and standard deviations (SD) of quantified follicles at each of the tested 
dosages (busulfan-cyclophosphamide mg/kg). Total and primordial follicle reductions were calculated as a 
percentage of the follicles present within healthy control mice. 
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Appendix N Statistical Differences Comparing Chemotherapy Dose 
Appendix Table 6 Dose-Dependent Statistical Differences in Follicle Counts 
The table (below) displays statistical differences between follicle counts based upon chemotherapy treatment. One-
way ANOVA with Tukey's multiple comparisons showed significant differences (highlighted in green) within each 
follicle stage and total follicles. 
Follicle Stage Group Comparison Significant? Summary P-Value 
Primordial 
Control vs. 12-100 Yes **** <0.0001 
Control vs. 24-100 Yes **** <0.0001 
Control vs. 12-200 Yes **** <0.0001 
Control vs. 24-200 Yes **** <0.0001 
12-100 vs. 24-100 No ns 0.0955 
12-100 vs. 12-200 No ns 0.3891 
12-100 vs. 24-200 Yes * 0.0352 
24-100 vs. 12-200 No ns 0.8517 
24-100 vs. 24-200 No ns 0.9846 
12-200 vs. 24-200 No ns 0.5538 
Primary 
Control vs. 12-100 Yes ** 0.0013 
Control vs. 24-100 Yes *** 0.0002 
Control vs. 12-200 Yes ** 0.0011 
Control vs. 24-200 Yes **** <0.0001 
12-100 vs. 24-100 No ns 0.5468 
12-100 vs. 12-200 No ns >0.9999 
12-100 vs. 24-200 No ns 0.1333 
24-100 vs. 12-200 No ns 0.6133 
24-100 vs. 24-200 No ns 0.8779 
12-200 vs. 24-200 No ns 0.1611 
Secondary 
Control vs. 12-100 No ns 0.2642 
Control vs. 24-100 Yes ** 0.0086 
Control vs. 12-200 Yes * 0.03 
Control vs. 24-200 Yes ** 0.0048 
12-100 vs. 24-100 No ns 0.1349 
12-100 vs. 12-200 No ns 0.4933 
12-100 vs. 24-200 No ns 0.0679 
24-100 vs. 12-200 No ns 0.859 
24-100 vs. 24-200 No ns 0.9957 
12-200 vs. 24-200 No ns 0.6543 
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Appendix Table 6 (continued) 
Follicle Stage Group Comparison Significant? Summary P-Value 
Antral 
Control vs. 12-100 No ns 0.9899 
Control vs. 24-100 No ns 0.7998 
Control vs. 12-200 No ns 0.8471 
Control vs. 24-200 No ns 0.4231 
12-100 vs. 24-100 No ns 0.9076 
12-100 vs. 12-200 No ns 0.9465 
12-100 vs. 24-200 No ns 0.4535 
24-100 vs. 12-200 No ns 0.9998 
24-100 vs. 24-200 No ns 0.9222 
12-200 vs. 24-200 No ns 0.8377 
Total 
Control vs. 12-100 Yes **** <0.0001 
Control vs. 24-100 Yes **** <0.0001 
Control vs. 12-200 Yes **** <0.0001 
Control vs. 24-200 Yes **** <0.0001 
12-100 vs. 24-100 Yes * 0.0278 
12-100 vs. 12-200 No ns 0.3087 
12-100 vs. 24-200 Yes ** 0.0045 
24-100 vs. 12-200 No ns 0.5743 
24-100 vs. 24-200 No ns 0.8932 
12-200 vs. 24-200 No ns 0.1547 
 
 179 
Appendix O Transgenic GFP Mouse Ovary 
 





Appendix P Fluorescently Labeled Ovarian ECM Hydrogel 
 
Appendix Figure 35 TRITC-labeled Ovarian Hydrogel 
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Appendix Q Breeding Strategy and Outcomes Following Follicle Microinjection 
Appendix Table 7 Breeding Strategy for Follicle Recipients 
The table represents the potential breeding outcomes expected after intraovarian follicle microinjection. Genetic 
backgrounds may be derived from both endogenous and transplanted follicles. Pups born from the transplanted 
follicles were distinguished by GFP expression and/or fur with dark eyes. 
 
 
Appendix Table 8 Breeding Outcomes of ciPOF Female Mice 
Three cycles of breeding occurred with the tranplanted ciPOF nude (nu-/nu-) female mice mated to nude (nu-/nu-) 
male mice. Three GFP pups were born as a result of the follicle transplation. Non-injected control ciPOF mice are 





Appendix Table 9 Outbreeding Strategy of GFP Progeny 




Appendix Table 10 Inbreeding Strategy of GFP Progeny 











Appendix Table 11 Second Generation Breeding Outcomes 













Appendix R Control Non-Injected ciPOF Ovaries 
 
Appendix Figure 36 Immunofluorescence of Control ciPOF Ovaries 
Merged DAPI and FITC immunofluorescence images of control ovaries (Animal ID: 6240 and 6241) Scale, 200 μm. 
Non-injected control tissues showed endogenous follicle growth, but appeared to have a reduced population of 
immature follicles in comparison to ovaries that received follicle transplant. As expected, no cells within the control 
tissues expressed GFP. 
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Appendix S Two-Photon Imaging 
 
Appendix Figure 37 Two-Photon Filter Cube Design 
A future direction for the characterization of the ovarian microenvironment post-follicle microinjection would be to 
use tissue clearing with two-photon microscopy. Methods were being developed to establish a custom filter cube for 




Appendix Figure 38 Two-Photon Excitation and Emission Wavelengths/Filters 
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Appendix T Ovarian Flow Cytometry 




Appendix Figure 39 Ovarian Flow Gating Strategy 
A flow panel and intracellular staining protocol was established to detect changes within the ovary post-follicle 





























Appendix Figure 42 Percentage of Macrophage Populations (CD206+ and CD86+ Cells) 
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